

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Inhaler technique education in elderly patients with Asthma or COPD: impact on disease exacerbations – a protocol for a single-blinded randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022685
Article Type:	Protocol
Date Submitted by the Author:	01-Mar-2018
Complete List of Authors:	Maricoto, Tiago; Aveiro-Aradas Family Health Unit, ACeS Baixo Vouga; Faculty of Health Sciences, University of Beira Interior Correia-de-Sousa, Jaime; Life and Health Sciences Research Institute (ICVS)/3B's – PT Government Associate Laboratory, University of Minho; Horizonte Family Health Unit, Taborda-Barata, Luís; CICS - Health Sciences Research Centre; NuESA – Environment & Health Study Group, Faculty of Health Sciences, University of Beira Interior; Department of Allergy & Clinical Immunology, Cova da Beira University Hospital Centre
Keywords:	Chronic Obstructive Pulmonary Disease, Asthma < THORACIC MEDICINE, Nebulizers and Vaporizers

SCHOLARONE™
Manuscripts

Inhaler technique education in elderly patients with Asthma or COPD: impact on disease exacerbations – a protocol for a single-blinded randomised controlled trial

AUTHORS

Tiago Maricoto^{1,2}; Jaime Correia-de-Sousa^{3,4}; Luís Taborda-Barata^{5,6}

(1) Aveiro-Aradas Family Health Unit; Aveiro Health Centre; Portugal

(2) Faculty of Health Sciences; University of Beira Interior, Covilhã, Portugal

(3) Life and Health Sciences Research Institute (ICVS)/3B's — PT Government Associate Laboratory, University of Minho, Braga, Portugal

(4) Horizonte Family Health Unit, Matosinhos, Portugal.

(5) CICS - Health Sciences Research Centre & NuESA – Environment & Health Study Group, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal

(6) Department of Allergy & Clinical Immunology, Cova da Beira University Hospital Centre, Covilhã, Portugal

CORRESPONDING AUTHOR

- Tiago Maricoto, MD
Family Doctor
USF Aveiro-Aradas; Praceta Rainha D. Leonor; 3800; Aveiro; Portugal
Tel: +351 234 891 213
PhD Student; Faculty of Health Sciences; University of Beira Interior
tiago.maricoto@gmail.com

WORD COUNT

3186 words

REGISTRY

This RCT protocol is registered in clinicaltrials.gov, with the number NCT03449316.

PROTOCOL VERSION

This is the first version of this RCT protocol.

ABSTRACT

Introduction

COPD and Asthma affect more than 10% of the population. Most patients use their inhaler incorrectly, mainly the elderly, thereby becoming more susceptible to poor clinical control and exacerbations. Placebo device training is regarded as one of the best teaching methods, but there is scarce evidence to support it as the most effective one to improve major clinical outcomes. Our objective is to perform a single-blinded RCT to assess the impact of this education tool in these patients.

Methods and Analysis

A multicentre single-blinded RCT will be set, comparing a placebo-device training programme versus usual care, with a one-year follow-up, in elderly patients with Asthma or COPD. Intervention will be provided at baseline, and after 3 and 6 months, with interim analysis at an intermediate time point. Exacerbation rates were set as primary outcomes, and quality of life, adherence rates, clinical control and respiratory function were chosen as secondary outcomes. A sample size of 146 participants (73 in each arm) was estimated as adequate to detect a 50% reduction in event rates. Two-sample proportions Chi-squared test will be used to study primary outcome and subgroup analysis will be carried out according to major baseline characteristics.

Discussion

This will be the first study to test if inhaler performance education significantly reduces exacerbation rate and improves clinical and functional control.

Ethics and dissemination:

Every participant will sign a consent form. A Data Safety Monitoring Board will be set up to evaluate data throughout the study and to monitor stop earlier criteria. Identity of all participants will be protected. Results will be presented in scientific meeting and published in peer-reviewed journals.

KEYWORDS

Chronic Obstructive Pulmonary Disease; Asthma; Nebulizers and Vaporizers

STRENGTHS AND LIMITATIONS OF THIS STUDY

- Elderly patients with COPD or Asthma use their inhaler incorrectly, thus being more susceptible to exacerbations.
- No previous study has addressed specific teaching methods in these patients.
- This is the first study to address, in an isolated manner, a specific placebo device education programme in this subgroup of elderly patients.
- We expect to confirm the hypothesis that the intervention group will have a significant reduction on exacerbation rate and an improvement in clinical and functional parameters during the follow-up.

INTRODUCTION

Epidemiology

Asthma and COPD affect about 10% of the population, but many patients have their symptoms uncontrolled [1]. In Asthma, particularly, it should be highlighted that only 57% of all patients were shown to have their symptoms controlled [2 3], and the elderly population is particularly vulnerable to this condition [3]. In fact, late onset asthma may be frequently misdiagnosed and mistreated, and the risk of drug interactions also requires close monitoring [4]. Hospitalization rates due to Asthma and COPD are reported to reach 27% among non-adherent patients, and could be up to 53% in community treated cases, and this may be even more apparent in elderly patients. It should also be stressed that good adherence to inhaler treatment may, in contrast, be associated with a lower rate of severe exacerbations, with reductions achieving half of the cases [5-7].

Inhaler technique

Inhaled therapy is the most widely used way to treat this patients [8], but up to 90% of them do not use their inhalers correctly [9 10]. Several inhaler devices are available in the market and it seems that differences either in device type or in patient characteristics may significantly influence performance [11]. However, all inhalers, when properly used, show no significant differences in terms of treatment efficacy [12], but it is well established that poor inhaler technique leads to poor clinical control [13 14] and also to an increased health costs [15].

Patients in controlled trials receive more training in inhaler performance and more counselling on adherence than patients who are seen as part of routine clinical practice, but few studies have addressed these variables as separate outcomes [16]. Some studies show that teaching of inhaler technique may lower the risk of exacerbations and death [6 17 18]. However, its impact is quickly lost as time elapses, suggesting this is a practice that should be rechecked and regularly applied in patients [19 20]. Significant evidence has shown that inhaler technique performance is regarded as particularly complex by older patients [21 22]. Furthermore, they also present lower adhesion rates [9] and are more resistant to correct performance [23 24]. However, the significance of these observations still has to be fully ascertained since elderly patients are frequently excluded from major clinical trials.

Inhaler technique may be taught using many tools, such as step-by-step flyer schemes, video demonstrations or even using web-based platforms, but there is insufficient evidence about which is the best education method to improve inhaler performance or its impact upon major outcomes [25]. Nevertheless, some studies suggest that the most efficient method seems to be using a teach-to-goal approach with placebo device demonstration and training provided in person [26-28]. This study will focus upon elderly patients and aims at testing the effect of a structured and regular placebo device training approach upon exacerbation rates.

SPECIFIC AIMS AND HYPOTHESES

The research question of this work is whether an inhaler technique education programme in elderly patients with Asthma or COPD reduces the risk of disease exacerbations. The main hypothesis is that an established programme of regular education of inhaler technique using a placebo device-based training approach in elderly patients can reduce the exacerbation risk by 50%.

RESEARCH DESIGN AND METHODOLOGY

Study Design

Two arms single blinded randomised controlled trial with a 1 year follow up (fig.1). Participants will be allocated to each group on a random basis, which is defined by a computerized generator and is independent of the control of the principal investigator. The allocation sequence of the 146 participants will be defined through a computer generator prior to the start of the study. After the generation of this sequence, 146 envelopes will be created, numbered in the appropriate order, and will contain the result of the allocation. The order of the envelopes' number will define the order of participants' enrolment. The principal investigator will not be aware of the information contained within the envelopes, thus maintaining a minimization randomization process. To ensure the accuracy of the use of the envelopes, the documents inside the envelope will be signed by the Data Safety Monitoring Board and must be returned by the researchers after the allocation of the participants.

Sample size calculation

Sample size was estimated using the *Chi square independent group proportions* approach of *STATA Statistical Package*®, considering the event proportion in control group of 50% (0.5 annual rate) as reported in bibliographic findings [17 18 29] and estimating a reduction of event rate in the intervention group to 25% (0.25 annual rate) as reported in similar studies. A 95% confidence interval, with β value (power) of 80%, an alpha level of 5% and a ratio of cases/controls of 1:1 were established. At last, the sample size was upward readjusted, considering an estimated proportion of full compliance of the study of 80% (20% losses). The estimated sample size was 116, readjusted to a total of 146 individuals (73 in each arm).

Inclusion Criteria

Patients with a diagnosis of COPD or Asthma, medicated with any kind of inhaler device (pressurized Metered Dose Inhaler (pMDI) with or without Spacer, Dry Powder Inhaler (DPI) or Soft Mist), aged ≥ 65 years and being a regular user of primary health care services (defined as having at least one consultation performed in the last two years with his/her own Family Doctor). In order to minimize diagnostic inaccuracy, Asthma and COPD diagnosis will be reviewed in every participant at baseline prior to enrolment and according to GINA and GOLD strategies [30 31].

Exclusion Criteria

Severe or acute illness (such as unstable cardiovascular status, unstable angina, recent myocardial infarction (within one month) or pulmonary embolism, haemoptysis of unknown origin, recent pneumothorax (within one month), recent thoracic, abdominal or eye surgery (within one month), acute nausea or vomiting, severe respiratory distress, dementia).

We will exclude patients with intermittent asthma, as well as COPD patients with mild obstruction (GOLD class I), since these patients do not need to take inhaler medication on a daily basis, and tend to have a low frequency of disease exacerbations.

Predictors/Intervention

Intervention Group – This group will receive a structured and regular follow-up plan, with education on inhaler technique. Patients will be trained by a Family Doctor (the primary investigator) in terms of the inhaler technique using placebo devices similar to their own devices. A teach-to-goal approach will be used, repeating all correct steps as many times as needed in order for patients to perform them correctly at each evaluation. There will be visits at baseline and after 3, 6 and 12 months to assess outcomes. In each visit, and prior to the main intervention with the primary investigator, assessment of

the inhaler technique and application of all questionnaires (clinical control, treatment adherence and quality of life) will be performed by a secondary blinded investigator.

Control Group – This group will receive usual care from their own Family doctors, with no specific intervention. Each doctor will perform the necessary consultations according to his real life judgment. Besides this, this group will perform visits at baseline and after 3, 6 and 12 months to assess secondary outcomes. At each visit, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adherence and quality of life) will be performed by a secondary blinded investigator. At any appointment, if the patient asks for or if the clinician decides to teach inhaler technique, that will be recorded.

If any adjustments are made in drug classes or device types in every participants, this information will be recorded.

Outcomes of interest

Primary Outcome: Adverse events (continuous, time to event).

For Asthma, an event will be defined as increased respiratory clinical symptoms leading the patient to search for medical care, and resulting in any of the following:

- Need for increased inhaled corticosteroid dose of at least 4x the regular dose
- Need for increase of short-acting β_2 agonists on a daily basis
- Need for oral corticosteroids
- Need for oral antibiotics
- Hospitalization or Emergency Room (ER) visit with increased respiratory clinical symptoms.

For COPD, an event will be defined as increased respiratory clinical symptoms inducing the patient to search for medical care, and resulting in any of the following:

- Need for increase of long-acting β_2 agonists on a daily basis
- Need for oral corticosteroids
- Need for oral antibiotics
- Hospitalization or ER visit with increased respiratory clinical symptoms.

Respiratory-related mortality and all-cause mortality will also be considered an adverse event.

All adverse events and mortality causes will be carefully analysed in order to assess their eligibility by two independent and external investigators, who will constitute a Data Safety Monitoring Board. This will be performed using different platforms of clinical records, from the ER of the regional reference hospital, from the Primary Health Care facilities (such as PEM© for prescribed drugs, SCLINICO© for clinical records and PDS© for ER records) and even by asking the participant for additional information. After any event, and if necessary for ethical reasons, inhaler technique and adherence improvement will be addressed by the primary investigator regardless of the participant allocation, and according to the recommendation of the Data Safety Monitoring Board.

Secondary Outcomes:

- Clinical assessment using COPD Assessment Tools (CAT) and modified Medical Research Council (mMRC) for COPD; Control of Allergic Rhinitis and Asthma Test (CARAT) [32] and Asthma Control Test (ACT) for Asthma [33].
- Quality of Life using St. George's Respiratory Questionnaire [34] and Clinical COPD Questionnaire (CCQ) [35] for COPD and Asthma Quality of Life Questionnaire (AQLQ) [36].
- Functional control using Forced Expiratory Volume in 1st second (FEV1), Forced Vital Capacity (FVC), Peak Expiratory Flow (PEF) and Maximum Expiratory Flows of 25-75% of FVC (MEF25-75) as a % of predicted value; and FEV1/FVC ratio.

- Adherence rate using the Brief Medication Questionnaire (this will also evaluate the frequency of using the devices) [37].
- Number of errors in inhaler technique (that will be standardized to a score up to 100% scale) [To evaluate inhaler technique performance with each device, the Aerosol Drug Management Improvement Team (ADMIT) protocols and guidelines will be used [38], evaluating all the recommended steps for inhaler use on each one of them (pMDI with or without chamber, Qvar Autohaler, Turbohaler, Diskus, Aerolizer, Handihaler, Breezhaler, Novolizer, Genuair, Twisthaler and Easyhaler). For those devices that do not have any protocol from the ADMIT group we will use the recommendations from the manufacture's Summary of Product Characteristics (Soft Mist Inhaler, Budesonide from *Farmoz*[®], Ellipta, Spiromax and Forspiro)].

All questionnaires will be used in validated Portuguese versions [32-37 39 40]. All participants will perform spirometry with bronchodilation test at baseline visit for diagnostic confirmation, as well as a baseline spirometry without bronchodilation for functional control at subsequent visits. A certified provider will perform spirometry.

Other variables collected at baseline

- Demographics (Body Mass Index, Age, Sex)
- Classification of clinical status, according to:
 - Exacerbation history.
 - Years of diagnosis.
 - Asthma classification/stage according to GINA guidelines (clinically as well controlled, partially controlled or uncontrolled; and therapeutically as in STEP 1, 2, 3, 4 or 5)[30]
 - COPD stage according to 2017 GOLD guidelines (combined assessment stages A,B,C and D; and severity of airflow limitation GOLD 1, 2, 3 and 4)[31].
- Social class according to Graffar classification (Portuguese version)[41].
- Co-morbidities (such as concomitant allergic rhinitis, cancer, cardiac heart failure, alcohol or drug abuse, current smoking and smoking pack years, diabetes mellitus, previous stroke or acute myocardial infarction, thoracic, abdominal or cerebral aneurysms, severe osteoarthritis in hands and upper limbs).
- Depression using Geriatric Depression Scale in Portuguese[42].
- Frailty state in elderly, using a self-reported instrument in Portuguese [43].
- Cognitive function using Montreal Cognitive Assessment (MOCA)in Portuguese [44]
- Influenza and pneumococcal vaccination status
- Previous teaching of inhaler technique with a placebo device approach.

The principal investigator will collect all baseline data prior to allocation and randomization, and this will be recorded in a proper form.

Statistical Analysis

The hypothesis testing approach will be the following:

H0: Teaching inhaler technique performance with a placebo device approach reduces the exacerbation risk in elderly patients with Asthma or COPD.

HA: Teaching inhalation technique performance with a placebo device approach does not reduce the exacerbation risk in elderly patients with Asthma or COPD.

Dichotomous Predictor: Usual Care VS Regular teach-to-goal education with placebo device.

Dichotomous Outcome: Exacerbation Yes/No

1
2
3 Test statistic: Two-sample proportions Chi-square test

4 Data will be analysed using the *STATA Statistical Package*[®] software.

5 The primary outcome will be analysed using a two-sample proportions Chi-square test and a COX
6 proportional hazard time-to-event analysis, and comparing groups using the measures of association:
7 risk ratio; risk difference; hazard ratio and Number Needed to Treat (NNT) analyses. In case of cohort
8 losses above 20%, comparative analysis for intention to treat, per-protocol and a multidata imputation
9 will be carried out. Secondary outcomes will be analysed using parametric tests, such as T test for
10 comparison of mean values and Chi-square test for association of qualitative variables. A subgroup
11 analysis will be performed according to secondary variables, such as age, sex, years of diagnosis,
12 disease classification/stage, previous teaching of inhaler technique and device type. This will be
13 performed using regression models to multivariate analyses.

14 Missing data will be treated as missing completely at random. In order to test differences between
15 groups in the mean values of continuous analysis, mixed effects models for repeated measures will be
16 used. For binary outcomes, linear regression models with group-time interactions will also be adapted,
17 and generalized linear models (such as Poisson regression) will be applied for exacerbations, as
18 recommended in the literature [45].

19 An interim analysis will be performed midway through the follow-up, namely at 6 months, defining a
20 significance level adjusted by the Bonferroni technique of 0.025 [46].
21
22
23

24 **Study Setting**

25 The study will be conducted in a multicentre network that will include two or three primary care
26 centres, which will be coordinated by a team of experts in the field. All of them will be in urban or
27 suburban areas. A Portuguese primary care centre usually accounts approximately for more than
28 10,000 patients, and about 30% of them are aged above 65 years. Considering an approximate
29 prevalence of Asthma and COPD of 8% among this population, there is a potential target population
30 of almost 250 patients in each health care facility. Recruiting patients at more than one site will
31 improve the feasibility, reproducibility and credibility of the study, but will increase all the logistic
32 issues.
33

34 All invited participants will have a first contact with the primary investigator to confirm the diagnosis
35 and all the eligibility criteria, and to carefully explain all the study procedures before their inclusion
36 and the subsequent randomisation. Diagnosis will be confirmed according to state of art and the
37 previously mentioned updated guidelines, and with an actual spirometry. The number of patients
38 screened and deemed ineligible as well as the number of patients who are considered eligible but
39 decline participation will be also recorded.
40
41

42 **Timeline**

43 Study protocol final version: August 2017

44 Ethics consent and scientific academic authorization: December 2017

45 Clinical administrative authorizations: first semester of 2018

46 Multicentre team gathering: first semester of 2018

47 Beginning of recruitment: second semester of 2018

48 End of recruitment: second semester of 2019

49 Data analysis and dissemination: during 2020
50
51
52
53

54 **DISCUSSION**

55
56
57
58
59
60

1
2
3 This is the first study designed to test a specific intervention on inhaler education in elderly patients,
4 and it was designed to detect a significant reduction on exacerbation rate. It is expected to observe
5 approximately 55 adverse events, 18 in the intervention group and 37 in the control group. In addition,
6 it is expected to find a more significant improvement in all clinical and functional parameters during
7 the follow-up in the intervention group.

8 This study has some limitations, mainly in selection bias due to the risk of missing data and follow-up
9 losses. To overcome this problem, different strategies will be applied, such as an increase in estimated
10 sample size, readjusted for an estimation of 20% losses; and sending a reminder prior to each visit
11 using SMS/Email/Call to contact the participant.

12
13 Another aspect that could bias our study is the Hawthorne effect throughout the study (ie. the
14 behaviour change in participants due to their involvement in the study). However, we believe that by
15 establishing a cohort time of one year this effect will not be sustained. On the other hand, the control
16 group will maintain their usual care in their own family doctors, who are completely free from any
17 influence of the study design. For this reason, control group participants will not receive any
18 intervention from the primary investigator, but only with the secondary one, who is completely
19 blinded to randomization. With this approach, the Hawthorne effect will not contaminate the control
20 group, and it will represent a real life usual care. On the other hand, the Data Safety Monitoring Board
21 will be composed of two external investigators, who will be blinded to the endpoints and outcomes
22 (PROBE setting).

23
24 The standardization of the protocol intervention is another issue to be considered. In order to
25 overcome different approaches among different investigators from different multicentre sites, a
26 protocol with detailed instructions will be created to guide them during the intervention (investigators)
27 and assessment visits (secondary investigators). This protocol will explain all the steps and procedures
28 for training inhaler technique as well as for assessing it, and all the procedures to follow in each visit
29 for assessing the outcomes.

30
31 Primary investigators will be trained in communication techniques related to inhaler education of
32 different devices and all of them will have a kit of placebo devices for use with participants. Such
33 training will allow the standardization of all procedures of intervention and it will be provided ahead
34 by the coordination team of the study.

35 36 37 38 **ETHICS AND DISSEMINATION**

39
40 The study protocol has already been analysed by the local Ethics Committee of University of Beira
41 Interior, with the reference number CE-UBI-Pj-2017-025, and was approved on 22th, November 2017.
42 Every participant will sign a consent form (Appendix I). A Data Safety Monitoring Board will be set
43 up, composed of two external investigators with a board expertise in this clinical field and in academic
44 and scientific activities, to evaluate data obtained throughout the study. Evaluations will occur every 6
45 months, whatever the number of participants enrolled or the follow-up time achieved at that time. The
46 stop earlier criteria will be defined as any moment on follow-up in which the collected data show
47 statistically significant differences in the primary outcomes. The study may be suspended earlier if
48 sufficient data are obtained for at least 6 months of follow-up, or if significant evidence of intervention
49 effectiveness is obtained, providing that statistical significance values are met by the Bonferroni
50 adaptation.

51
52 Invited participants who refuse to participate will be evaluated at baseline, according to previously
53 mentioned characteristics, in order to compare them with the included cohort. They also will be
54 invited to sign a proper informed consent that will allow investigators to collect such data. The
55 documents used to collect the data of the participants will contain only an identification code of each
56
57

1
2
3 participant, in order to protect their identity. The code of each participant must be composed of the
4 initials of the first two names, followed by the last two digits of the National Health Care Service
5 Number (eg. *Name FirstSurname SecondSurname*, 123456789 -----> code "NF89").

6 The number of participants considered ineligible will be recorded, as well as the number of eligible
7 participants who refuse to participate in the study.

8 The results obtained from this study will be presented to publish in peer-reviewed journals and
9 presented in scientific meetings of primary health care and respiratory fields. All data recorded during
10 the study will be stored for a period of 5 years, according to the Portuguese Clinical Research Law, in
11 a safe and proper place in the primary investigator's health centre. After this period, all data that
12 contain participants' codes will be destroyed.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AUTHORS' CONTRIBUTIONS

All authors have equally contributed to the elaboration of this protocol in every stage of its design and writing.

COMPETING INTERESTS STATEMENT

Dr. Correia-de-Sousa reports other from Harvard Medical School, during the conduct of the study. Also other from Boheringer Ingelheim, other from AstraZeneca, other from Boheringer Ingelheim, outside the submitted work; all these fees were received by a non-profit organisation to be used in CME and research. The remaining authors declare only from Harvard Medical School, during the conduct of the study.

FUNDING

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

This work was developed without any funding support or financial source. The academic affiliation of this protocol is the Life and Health Sciences Research Institute (ICVS)/3B's at University of Minho and the Faculty of Health Sciences at the University of Beira Interior in Portugal.

This work was prepared with scientific support from Harvard Medical School, in accordance with the Portuguese Clinical Scholarship Research Training Program.

ACKNOWLEDGMENTS

The authors endorse acknowledgment to Prof. Jonh Groarke, from the Harvard Medical School, for his important scientific support and input in reviewing the final version of this manuscript.

DATA ACCESS

All data from the trial will be kept in a safe place of the principal investigator's institutional facilities and by the Data Safety Monitoring Board, in accordance with the national and international clinical research policies.

FIGURE LEGENDS

Figure 1 – Study design diagram.

REFERENCES

1. World Health Organization. The global burden of disease: 2004 update. Available from: <http://www.who.int>, 2008:160.
2. Sa-Sousa A, Morais-Almeida M, Azevedo LF, et al. Prevalence of asthma in Portugal - The Portuguese National Asthma Survey. *Clinical and translational allergy* 2012;**2**(1):15 doi: 10.1186/2045-7022-2-15[published Online First: Epub Date].
3. de Sousa JC, Santo ME, Colaço T, et al. Asthma in an Urban Population in Portugal: A prevalence study. *BMC Public Health* 2011;**11**:347-47 doi: 10.1186/1471-2458-11-347[published Online First: Epub Date].
4. Reddel H, Battersman E, Becker A, et al. Global Strategy for Asthma Management and Prevention. Available from: <http://www.ginasthma.org>: Global initiative for asthma, 2015 update:149.
5. van Boven JF, Tommelein E, Boussery K, et al. Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. *Respiratory research* 2014;**15**:66 doi: 10.1186/1465-9921-15-66[published Online First: Epub Date].
6. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. *Thorax* 2009;**64**(11):939-43 doi: 10.1136/thx.2009.113662[published Online First: Epub Date].
7. Engelkes M, Janssens HM, de Jongste JC, et al. Medication adherence and the risk of severe asthma exacerbations: a systematic review. *The European respiratory journal* 2015;**45**(2):396-407 doi: 10.1183/09031936.00075614[published Online First: Epub Date].
8. Rees J. Methods of delivering drugs. *BMJ : British Medical Journal* 2005;**331**(7515):504-06
9. Cochrane MG, Bala MV, Downs KE, et al. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. *Chest* 2000;**117**(2):542-50
10. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. *Respiratory medicine* 2008;**102**(4):593-604 doi: 10.1016/j.rmed.2007.11.003[published Online First: Epub Date].
11. Broeders ME, Molema J, Hop WC, et al. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. *Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine* 2003;**16**(2):131-41 doi: 10.1089/089426803321919898[published Online First: Epub Date].
12. Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. *Health technology assessment (Winchester, England)* 2001;**5**(26):1-149
13. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. *The European respiratory journal* 2002;**19**(2):246-51
14. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. *Respiratory medicine* 2011;**105**(6):930-8 doi: 10.1016/j.rmed.2011.01.005[published Online First: Epub Date].
15. Roggeri A, Micheletto C, Roggeri DP. Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues. *International journal of chronic obstructive pulmonary disease* 2016;**11**:597-602 doi: 10.2147/copd.s103335[published Online First: Epub Date].
16. Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. *The European respiratory journal* 2011;**37**(6):1308-31 doi: 10.1183/09031936.00166410[published Online First: Epub Date].
17. Tommelein E, Mehuys E, Van Hees T, et al. Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. *British journal*

of clinical pharmacology 2014;**77**(5):756-66 doi: 10.1111/bcp.12242[published Online First: Epub Date].

18. Takemura M, Mitsui K, Ido M, et al. Effect of a network system for providing proper inhalation technique by community pharmacists on clinical outcomes in COPD patients. *International journal of chronic obstructive pulmonary disease* 2013;**8**:239-44 doi: 10.2147/copd.s44022[published Online First: Epub Date].

19. Broeders ME, Sanchis J, Levy ML, et al. The ADMIT series--issues in inhalation therapy. 2. Improving technique and clinical effectiveness. *Primary care respiratory journal : journal of the General Practice Airways Group* 2009;**18**(2):76-82 doi: 10.4104/pcrj.2009.00025[published Online First: Epub Date].

20. Crompton GK, Barnes PJ, Broeders M, et al. The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. *Respiratory medicine* 2006;**100**(9):1479-94 doi: 10.1016/j.rmed.2006.01.008[published Online First: Epub Date].

21. Allen SC, Jain M, Ragab S, et al. Acquisition and short-term retention of inhaler techniques require intact executive function in elderly subjects. *Age and ageing* 2003;**32**(3):299-302

22. Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. *American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists* 2011;**68**(13):1221-32 doi: 10.2146/ajhp100452[published Online First: Epub Date].

23. Quinet P, Young CA, Heritier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. *Annals of physical and rehabilitation medicine* 2010;**53**(2):69-76 doi: 10.1016/j.rehab.2009.11.001[published Online First: Epub Date].

24. Allen SC, Warwick-Sanders M, Baxter M. A comparison of four tests of cognition as predictors of inability to learn to use a metered dose inhaler in old age. *Int J Clin Pract* 2009;**63**(8):1150-3 doi: 10.1111/j.1742-1241.2009.02060.x[published Online First: Epub Date].

25. Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for people with asthma. *The Cochrane database of systematic reviews* 2017;**3**:CD012286 doi: 10.1002/14651858.CD012286.pub2[published Online First: Epub Date].

26. Bosnic-Anticevich SZ, Sinha H, So S, et al. Metered-dose inhaler technique: the effect of two educational interventions delivered in community pharmacy over time. *The Journal of asthma : official journal of the Association for the Care of Asthma* 2010;**47**(3):251-6 doi: 10.3109/02770900903580843[published Online First: Epub Date].

27. Crane MA, Jenkins CR, Goeman DP, et al. Inhaler device technique can be improved in older adults through tailored education: findings from a randomised controlled trial. *NPJ primary care respiratory medicine* 2014;**24**:14034 doi: 10.1038/npjpcrm.2014.34[published Online First: Epub Date].

28. Lavorini F, Levy ML, Corrigan C, et al. The ADMIT series - issues in inhalation therapy. 6) Training tools for inhalation devices. *Primary care respiratory journal : journal of the General Practice Airways Group* 2010;**19**(4):335-41 doi: 10.4104/pcrj.2010.00065[published Online First: Epub Date].

29. Goris S, Tasci S, Elmali F. The effects of training on inhaler technique and quality of life in patients with COPD. *Journal of aerosol medicine and pulmonary drug delivery* 2013;**26**(6):336-44 doi: 10.1089/jamp.2012.1017[published Online First: Epub Date].

30. GINA. Pocket Guide for Asthma Management and Prevention. Available in: <http://ginasthma.org>, Updated 2015:32.

31. GOLD. Pocket Guide to COPD Diagnosis, Management, and Prevention - A Guide for Health Care Professionals. Available in: <http://www.goldcopd.org>, 2017 report:42.

32. Fonseca JA, Nogueira-Silva L, Morais-Almeida M, et al. Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthma. *Allergy* 2010;**65**(8):1042-8 doi: 10.1111/j.1398-9995.2009.02310.x[published Online First: Epub Date].
33. Roxo JP, Ponte EV, Ramos DC, et al. [Portuguese-language version of the Asthma Control Test]. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisiologia* 2010;**36**(2):159-66
34. Camelier A, Rosa FW, Salim C, et al. Using the Saint George's Respiratory Questionnaire to evaluate quality of life in patients with chronic obstructive pulmonary disease: validating a new version for use in Brazil. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisiologia* 2006;**32**(2):114-22
35. Faria da Silva LS. Validação do Questionário Clínico para a Doença Pulmonar Obstrutiva Crônica (CCQ) para a Língua Portuguesa [Master Thesis]. Escola Superior de Enfermagem do Porto, 2012.
36. Ferreira J, Silveira P, Figueiredo MM, et al. Validation of the Portuguese version of the Asthma Quality of Life Questionnaire [AQLQ-M] by Marks. *Revista portuguesa de pneumologia* 2005;**11**(4):351-66
37. Ben AJ, Neumann CR, Mengue SS. The Brief Medication Questionnaire and Morisky-Green test to evaluate medication adherence. *Revista de saude publica* 2012;**46**(2):279-89
38. (ADMIT) TADMIT. Inhalation Protocols. Secondary Inhalation Protocols 2017.
39. Silva GP, Morano MT, Viana CM, et al. Portuguese-language version of the COPD Assessment Test: validation for use in Brazil. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisiologia* 2013;**39**(4):402-8 doi: 10.1590/s1806-37132013000400002[published Online First: Epub Date].
40. Kovelis D, Segretti NO, Probst VS, et al. Validation of the Modified Pulmonary Functional Status and Dyspnea Questionnaire and the Medical Research Council scale for use in Brazilian patients with chronic obstructive pulmonary disease. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisiologia* 2008;**34**(12):1008-18
41. Amaro F. Escala de Graffar, 1990.
42. Apóstolo JLA, Loureiro LMdJ, Reis IACd, et al. Contribuição para a adaptação da Geriatric Depression Scale -15 para a língua portuguesa. *Revista de Enfermagem Referência* 2014;**serIV**:65-73
43. Nunes DP, Duarte YAdO, Santos JLF, et al. Screening for frailty in older adults using a self-reported instrument. *Revista de saude publica* 2015;**49**:2 doi: 10.1590/S0034-8910.2015049005516[published Online First: Epub Date].
44. Freitas Sandra SMR, Martins Cristina, Vilar Manuela, Santana Isabel. . Estudos de adaptação do Montreal Cognitive Assessment (MoCA) para a população portuguesa. *Aval. psicol.* [online]. 2010;**9**(3):345-57
45. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2006;**173**(8):842-6 doi: 10.1164/rccm.200508-1338PP[published Online First: Epub Date].
46. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. *BMJ* 1995;**310**(6973):170 doi: 10.1136/bmj.310.6973.170[published Online First: Epub Date].

APPENDIX I - Informed consent form, according to Portuguese Directorate-General of Health.

Consentimento Informado nos termos da Norma nº 015/2013 da DGS

Estudo “Ensino da técnica inalatória em idosos com Asma e DPOC: impacto nas exacerbações”

A sua unidade de saúde convida-o a participar no estudo “Ensino da técnica inalatória em idosos com Asma e DPOC: impacto nas exacerbações”. Foi convidado para participar neste estudo porque se trata de um doente com uma doença respiratória crónica (como Asma ou DPOC) e está a ser medicado com um dispositivo inalatório diariamente.

Os objetivos deste estudo são:

- Verificar se utiliza corretamente o seu dispositivo inalatório
- Testar se o ensino regular do uso do inalador melhora o controlo da sua doença.
- Testar se o mesmo ensino regular diminui a probabilidade de ter alguma crise de agudização/exacerbação pela sua doença, e que pode ser potencialmente fatal.

Para verificar estes objetivos iremos dividir, de forma aleatória, os utentes convidados a participar em dois grupos diferentes. Ambos os grupos irão ser avaliados regularmente sobre o controlo da sua doença, quer quando aos sintomas, qualidade de vida e quanto à sua capacidade pulmonar/respiratória. Isto será feito através da aplicação de questionários bem como da realização de um exame complementar simples e não invasivo, a espirometria.

A principal diferença entre os dois grupos, é que, um deles irá receber adicionalmente de um investigador, um ensino e treino regular sobre o uso correto dos dispositivos inalatórios, enquanto o outro grupo irá apenas receber os cuidados médicos regulares que necessitar pelo seu próprio Medico de Família.

A sua participação no estudo irá durar 12 meses. Ao aceitar participar neste estudo, será sorteado para um dos dois grupos, e após isso irá ser avaliado nesta Unidade de Saúde passados 3, 6 e 12 meses pelos investigadores. Não irá saber em nenhum momento (nem o seu Medico de Família) a qual dos grupos pertence, pois, o objetivo do estudo é não influenciar a forma como os dois grupos se comportam. Todas as consultas realizadas no âmbito deste estudo serão gratuitas para si, bem como a realização das avaliações pelos investigadores.

O estudo será coordenado pelo Dr. Tiago Maricoto, da USF Aveiro-Aradas, que é o investigador principal. A sua participação no estudo é voluntária. Poderá decidir não participar no estudo a qualquer momento sem prejuízo dos seus cuidados médicos. Todos os dados recolhidos neste estudo permanecerão confidenciais. O seu Medico de Família terá acesso no final do estudo aos resultados dos seus exames e avaliações.

O potencial benefício para a sua Saúde ao participar neste estudo é melhorar o controlo clínico da sua doença respiratória, melhorar a capacidade respiratória dos seus pulmões e diminuir o risco de crises de agudização graves e potencialmente fatais. Não existem riscos significativos para a sua saúde. Ao não participar neste estudo perde ainda a oportunidade de poder melhorar a forma como usa os seus dispositivos inalatórios, o que pode comprometer o bom controlo da sua doença a longo prazo.

[Parte declarativa do profissional]

Confirmo que expliquei à pessoa abaixo indicada, de forma adequada e inteligível, os procedimentos necessários ao ato referido neste documento. Respondi a todas as questões que me foram colocadas e assegurei-me de que houve um período de reflexão suficiente para a tomada da decisão. Também garanti que, em caso de recusa, serão assegurados os melhores cuidados possíveis nesse contexto, no respeito pelos seus direitos.

Nome legível do profissional de saúde: | _____ |

Assinatura, nº de cédula profissional/mecanográfico:

Unidade de Saúde: _____

Contato institucional do profissional de saúde: _____

À Pessoa/representante

Por favor, leia com atenção todo o conteúdo deste documento. Não hesite em solicitar mais informações se não estiver completamente esclarecido/a. Verifique se todas as informações estão corretas. Se tudo estiver conforme, então assine este documento.

[Parte declarativa da pessoa que consente]

Declaro ter compreendido os objetivos de quanto me foi proposto e explicado pelo profissional de saúde que assina este documento, ter-me sido dada oportunidade de fazer todas as perguntas sobre o assunto e para todas elas ter obtido resposta esclarecedora, ter-me sido garantido que não haverá prejuízo para os meus direitos assistenciais se eu recusar esta solicitação, e ter-me sido dado tempo suficiente para refletir sobre esta proposta. Autorizo/Não autorizo (~~riscar o que não interessa~~) o ato indicado, bem como os procedimentos diretamente relacionados que sejam necessários no meu próprio interesse e justificados por razões clínicas fundamentadas.

NOME: | _____ |

Assinatura /...../..... (data)

SE NÃO FOR O PRÓPRIO A ASSINAR POR IDADE OU INCAPACIDADE

(se o menor tiver discernimento deve também assinar em cima)

NOME:

DOC. IDENTIFICAÇÃO N.º DATA OU VALIDADE /..... /.....

GRAU DE PARENTESCO OU TIPO DE REPRESENTAÇÃO:

ASSINATURA.....

O presente documento é emitido em duplicado, ficando um na posse do participante, e outro arquivado pelos investigadores em local próprio na unidade de saúde.




Figure 1 - Study Design Diagram

446x297mm (96 x 96 DPI)

Reporting checklist for protocol of a clinical trial (SPIRIT).

Instructions to authors

Upload this checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	1
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	1
Protocol version	#3	Date and version identifier	1
Funding	#4	Sources and types of financial, material, and other support	9
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	9
Roles and responsibilities: sponsor contact information	#5b	Name and contact information for the trial sponsor	NA
Roles and responsibilities: sponsor and funder	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have	NA

ultimate authority over any of these activities

1				
2				
3	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	8
4	responsibilities:		centre, steering committee, endpoint adjudication	
5	committees		committee, data management team, and other individuals or	
6			groups overseeing the trial, if applicable (see Item 21a for	
7			data monitoring committee)	
8				
9				
10				
11	Background and	#6a	Description of research question and justification for	3
12	rationale		undertaking the trial, including summary of relevant studies	
13			(published and unpublished) examining benefits and harms	
14			for each intervention	
15				
16				
17	Background and	#6b	Explanation for choice of comparators	3
18	rationale: choice of			
19	comparators			
20				
21				
22				
23	Objectives	#7	Specific objectives or hypotheses	3
24				
25	Trial design	#8	Description of trial design including type of trial (eg, parallel	4
26			group, crossover, factorial, single group), allocation ratio,	
27			and framework (eg, superiority, equivalence, non-inferiority,	
28			exploratory)	
29				
30				
31				
32	Study setting	#9	Description of study settings (eg, community clinic,	4
33			academic hospital) and list of countries where data will be	
34			collected. Reference to where list of study sites can be	
35			obtained	
36				
37				
38				
39	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	4
40			eligibility criteria for study centres and individuals who will	
41			perform the interventions (eg, surgeons, psychotherapists)	
42				
43				
44	Interventions:	#11a	Interventions for each group with sufficient detail to allow	4
45	description		replication, including how and when they will be	
46			administered	
47				
48				
49	Interventions:	#11b	Criteria for discontinuing or modifying allocated	4
50	modifications		interventions for a given trial participant (eg, drug dose	
51			change in response to harms, participant request, or	
52			improving / worsening disease)	
53				
54				
55				
56	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	4
57	adherence		and any procedures for monitoring adherence (eg, drug	
58				
59				
60				

tablet return; laboratory tests)

1				
2				
3	Interventions:	#11d	Relevant concomitant care and interventions that are	4
4	concomitant care		permitted or prohibited during the trial	
5				
6	Outcomes	#12	Primary, secondary, and other outcomes, including the	5
7			specific measurement variable (eg, systolic blood pressure),	
8			analysis metric (eg, change from baseline, final value, time	
9			to event), method of aggregation (eg, median, proportion),	
10			and time point for each outcome. Explanation of the clinical	
11			relevance of chosen efficacy and harm outcomes is strongly	
12			recommended	
13				
14				
15				
16				
17	Participant timeline	#13	Time schedule of enrolment, interventions (including any	5
18			run-ins and washouts), assessments, and visits for	
19			participants. A schematic diagram is highly recommended	
20			(see Figure)	
21				
22				
23				
24	Sample size	#14	Estimated number of participants needed to achieve study	4-5
25			objectives and how it was determined, including clinical and	
26			statistical assumptions supporting any sample size	
27			calculations	
28				
29				
30				
31	Recruitment	#15	Strategies for achieving adequate participant enrolment to	4-5
32			reach target sample size	
33				
34				
35	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	7
36	generation		computer-generated random numbers), and list of any	
37			factors for stratification. To reduce predictability of a random	
38			sequence, details of any planned restriction (eg, blocking)	
39			should be provided in a separate document that is	
40			unavailable to those who enrol participants or assign	
41			interventions	
42				
43				
44				
45				
46	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	7
47	concealment		central telephone; sequentially numbered, opaque, sealed	
48	mechanism		envelopes), describing any steps to conceal the sequence	
49			until interventions are assigned	
50				
51				
52				
53	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	7
54	implementation		participants, and who will assign participants to	
55			interventions	
56				
57				
58	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	7
59				
60				

1		trial participants, care providers, outcome assessors, data	
2		analysts), and how	
3			
4	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is
5	emergency		permissible, and procedure for revealing a participant's
6	unblinding		allocated intervention during the trial
7			7
8			
9	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,
10			and other trial data, including any related processes to
11			promote data quality (eg, duplicate measurements, training
12			of assessors) and a description of study instruments (eg,
13			questionnaires, laboratory tests) along with their reliability
14			and validity, if known. Reference to where data collection
15			forms can be found, if not in the protocol
16			6-7
17			
18	Data collection plan:	#18b	Plans to promote participant retention and complete follow-
19	retention		up, including list of any outcome data to be collected for
20			participants who discontinue or deviate from intervention
21			protocols
22			6-7
23			
24	Data management	#19	Plans for data entry, coding, security, and storage, including
25			any related processes to promote data quality (eg, double
26			data entry; range checks for data values). Reference to
27			where details of data management procedures can be
28			found, if not in the protocol
29			6-7
30			
31	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary
32			outcomes. Reference to where other details of the statistical
33			analysis plan can be found, if not in the protocol
34			6-7
35			
36	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and
37	analyses		adjusted analyses)
38			6-7
39			
40	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-
41	population and		adherence (eg, as randomised analysis), and any statistical
42	missing data		methods to handle missing data (eg, multiple imputation)
43			6-7
44			
45	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary
46	formal committee		of its role and reporting structure; statement of whether it is
47			independent from the sponsor and competing interests; and
48			reference to where further details about its charter can be
49			found, if not in the protocol. Alternatively, an explanation of
50			why a DMC is not needed
51			7-8
52			
53			
54			
55			
56			
57			
58			
59			
60			

1	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	7-8
2	interim analysis		including who will have access to these interim results and	
3			make the final decision to terminate the trial	
4				
5				
6	Harms	#22	Plans for collecting, assessing, reporting, and managing	7-8
7			solicited and spontaneously reported adverse events and	
8			other unintended effects of trial interventions or trial conduct	
9				
10				
11	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	7-8
12			and whether the process will be independent from	
13			investigators and the sponsor	
14				
15				
16				
17	Research ethics	#24	Plans for seeking research ethics committee / institutional	8
18	approval		review board (REC / IRB) approval	
19				
20				
21	Protocol	#25	Plans for communicating important protocol modifications	8
22	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
23			relevant parties (eg, investigators, REC / IRBs, trial	
24			participants, trial registries, journals, regulators)	
25				
26				
27	Consent or assent	#26a	Who will obtain informed consent or assent from potential	8
28			trial participants or authorised surrogates, and how (see	
29			Item 32)	
30				
31				
32				
33	Consent or assent:	#26b	Additional consent provisions for collection and use of	8
34	ancillary studies		participant data and biological specimens in ancillary	
35			studies, if applicable	
36				
37				
38	Confidentiality	#27	How personal information about potential and enrolled	8
39			participants will be collected, shared, and maintained in	
40			order to protect confidentiality before, during, and after the	
41			trial	
42				
43				
44				
45	Declaration of	#28	Financial and other competing interests for principal	9
46	interests		investigators for the overall trial and each study site	
47				
48				
49	Data access	#29	Statement of who will have access to the final trial dataset,	9
50			and disclosure of contractual agreements that limit such	
51			access for investigators	
52				
53				
54	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for	9
55	trial care		compensation to those who suffer harm from trial	
56			participation	
57				
58				
59				
60				

1	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	8
2	trial results		results to participants, healthcare professionals, the public,	
3			and other relevant groups (eg, via publication, reporting in	
4			results databases, or other data sharing arrangements),	
5			including any publication restrictions	
6				
7				
8				
9	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use of	8
10	authorship		professional writers	
11				
12				
13	Dissemination policy:	#31c	Plans, if any, for granting public access to the full protocol,	8
14	reproducible		participant-level dataset, and statistical code	
15	research			
16				
17				
18	Informed consent	#32	Model consent form and other related documentation given	13
19	materials		to participants and authorised surrogates	
20				
21				
22	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of	NA
23			biological specimens for genetic or molecular analysis in the	
24			current trial and for future use in ancillary studies, if	
25			applicable	
26				
27				
28				

29 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 30 BY-ND 3.0. This checklist was completed on 05. February 2018 using <http://www.goodreports.org/>, a
 31 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Inhaler technique education in elderly patients with Asthma or COPD: impact on disease exacerbations – a protocol for a single-blinded randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022685.R1
Article Type:	Protocol
Date Submitted by the Author:	09-May-2018
Complete List of Authors:	Maricoto, Tiago; Aveiro-Aradas Family Health Unit, ACeS Baixo Vouga; Faculty of Health Sciences, University of Beira Interior Correia-de-Sousa, Jaime; Life and Health Sciences Research Institute (ICVS)/3B's – PT Government Associate Laboratory, University of Minho; Horizonte Family Health Unit, Taborda-Barata, Luís; CICS - Health Sciences Research Centre; NuESA – Environment & Health Study Group, Faculty of Health Sciences, University of Beira Interior; Department of Allergy & Clinical Immunology, Cova da Beira University Hospital Centre
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	General practice / Family practice
Keywords:	Chronic Obstructive Pulmonary Disease, Asthma < THORACIC MEDICINE, Nebulizers and Vaporizers

SCHOLARONE™
Manuscripts

Inhaler technique education in elderly patients with Asthma or COPD: impact on disease exacerbations – a protocol for a single-blinded randomised controlled trial

AUTHORS

Tiago Maricoto^{1,2}; Jaime Correia-de-Sousa^{3,4}; Luís Taborda-Barata^{5,6}

(1) Aveiro-Aradas Family Health Unit; Aveiro Health Centre; Portugal

(2) Faculty of Health Sciences; University of Beira Interior, Covilhã, Portugal

(3) Life and Health Sciences Research Institute (ICVS)/3B's — PT Government Associate Laboratory, University of Minho, Braga, Portugal

(4) Horizonte Family Health Unit, Matosinhos, Portugal.

(5) CICS - Health Sciences Research Centre & NuESA – Environment & Health Study Group, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal

(6) Department of Allergy & Clinical Immunology, Cova da Beira University Hospital Centre, Covilhã, Portugal

CORRESPONDING AUTHOR

- Tiago Maricoto, MD
Family Doctor
USF Aveiro-Aradas; Praceta Rainha D. Leonor; 3800; Aveiro; Portugal
Tel: +351 234 891 213
PhD Student; Faculty of Health Sciences; University of Beira Interior
tiago.maricoto@gmail.com

WORD COUNT

3186 words

PROTOCOL VERSION

This is the second version of this RCT protocol.

ABSTRACT

Introduction

COPD and Asthma affect more than 10% of the population. Most patients use their inhaler incorrectly, mainly the elderly, thereby becoming more susceptible to poor clinical control and exacerbations. Placebo device training is regarded as one of the best teaching methods, but there is scarce evidence to support it as the most effective one to improve major clinical outcomes. Our objective is to perform a single-blinded RCT to assess the impact of this education tool in these patients.

Methods and Analysis

A multicentre single-blinded RCT will be set up, comparing a placebo-device training programme with usual care, with a one-year follow-up, in elderly patients with Asthma or COPD. Intervention will be provided at baseline, and after 3 and 6 months, with interim analysis at an intermediate time point. Exacerbation rates were set as primary outcomes, and quality of life, adherence rates, clinical control and respiratory function were chosen as secondary outcomes. A sample size of 146 participants (73 in each arm) was estimated as adequate to detect a 50% reduction in event rates. Two-sample proportions Chi-squared test will be used to study primary outcome and subgroup analysis will be carried out according to major baseline characteristics.

Ethics and dissemination:

Every participant will sign a written consent form. A Data Safety Monitoring Board will be set up to evaluate data throughout the study and to monitor early stopping criteria. Identity of all participants will be protected. This protocol was approved on the 22th November 2017 by the local Ethics Committee of University of Beira Interior, with the reference number CE-UBI-Pj-2017-025. Results will be presented in scientific meeting and published in peer-reviewed journals.

KEYWORDS

Chronic Obstructive Pulmonary Disease; Asthma; Nebulizers and Vaporizers

REGISTRY

This RCT protocol is registered in clinicaltrials.gov, with the number NCT03449316.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This is the first study to address, in an isolated manner, a specific placebo device education programme in elderly patients with Asthma or COPD.
- No previous study has addressed this teaching method in these patients, as it seems to be the most efficient one.
- Our study has a randomised design, which has been a major limitation in previous studies.
- The one-year follow up period, with two interim evaluations, allow this study to comprehensively address the real impact of a regular education programme.
- The main limitation of this study is the single blinded design, due to the nature of intervention itself, which may introduce some performance bias.

INTRODUCTION

Epidemiology

Asthma and COPD affect about 10% of the population, but many patients have uncontrolled symptoms [1]. In Asthma, in particular, it should be highlighted that only 57% of all patients were shown to have their symptoms controlled [2 3], and the elderly population is particularly vulnerable to this condition [3]. In fact, late onset asthma may be frequently misdiagnosed and mistreated, and the risk of drug interactions also requires close monitoring [4]. Hospitalisation rates due to Asthma and COPD are reported to reach 27% among non-adherent patients, and could be up to 53% in community treated cases, and this may be even more apparent in elderly patients. It should also be stressed that good adherence to inhaler treatment may, in contrast, be associated with a lower rate of severe exacerbations, with reductions observed in up to half of the cases [5-7].

Inhaler technique

Inhaled therapy is the most widely used way to treat asthma and COPD patients [8], but up to 90% of them do not use their inhalers correctly [9 10]. Performance errors have been described with almost every type of device, and over the past decades this problem has not improved, which highlights the need to better understand on the specificities of different inhaler use as well as the impact of different inhaler teaching methods [11]. Several inhaler devices are available on the market and it seems that differences either in device type or in patient characteristics may significantly influence performance [12]. However, all inhalers, when properly used, show no significant differences in terms of treatment efficacy [13 14], but it is well established that poor inhaler technique leads to poor clinical control [15 16] and also to an increased health costs [17]. In addition, some type of specific errors seem to have a higher impact on clinical control, but there is no consensus yet on which errors are critical and non-critical [18 19].

Patients in controlled trials receive more training in inhaler performance and more counselling on adherence than patients who are seen as part of routine clinical practice, but few studies have addressed these variables as separate outcomes [20]. Some studies show that teaching inhaler technique may lower the risk of exacerbations and death [6 21 22]. However, its impact is quickly lost as time elapses, suggesting this is a practice that should be rechecked and regularly applied to patients [23 24]. Nevertheless, how often the review should be carried out has not been established yet, since most studies have not addressed this issue in an isolated manner.

Significant evidence has shown that inhaler technique performance is regarded as particularly complex by older patients [25 26]. These patients also present lower adherence rates [9] and are more resistant to correct performance [27 28]. Furthermore, other major characteristics may influence inhaler use, such as educational level, previous teaching, or even age itself (i.e. age above 75 years) [29]. However, the significance of these observations still has to be fully ascertained since elderly patients are frequently excluded from major clinical trials. Randomised studies with elderly patients are scarce, and most of them did not address these aspects. Some of these studies have shown significant reductions in exacerbation risk with inhaler education programmes, but none has yet addressed inhaler review alone or in a regular education programme [21 30-33].

Inhaler technique may be taught using many tools, such as step-by-step flyer schemes, video demonstrations, videoconferencing and face-to-face demonstrations or even using web-based platforms, but there is insufficient evidence about which is the best education method to improve inhaler performance or its impact upon major outcomes [34 35]. Nevertheless, some studies suggest that the most efficient method seems to be using a teach-to-goal approach with placebo device demonstration and training provided in person [36-38]. In addition, manufacturers' recommendations often differ from clinical guidelines, which makes it difficult for patients to fully understand all the

necessary steps of inhaler use [39]. This highlights the importance of watching patients using their inhalers, which can be achieved with a placebo device training set.

This study will focus upon elderly patients and aims at testing the effect of a structured and regular placebo device training approach upon disease exacerbation rates.

SPECIFIC AIMS AND HYPOTHESES

Our objective is to test the impact of an inhaler technique education programme on the risk of exacerbations in elderly patients with Asthma or COPD..

The main hypothesis is that regular education of inhaler technique using a placebo device-based approach in elderly patients can reduce the exacerbation risk by 50%.

RESEARCH DESIGN AND METHODOLOGY

Study Design

Two arms single blinded randomised controlled trial with a 1 year follow up (fig.1). Participants will be allocated to each group on a random basis, which is defined by a computerised generator and is independent of the control of the principal investigator. The allocation sequence of the 146 participants will be defined through a computer generator prior to the start of the study. After the generation of this sequence, 146 envelopes will be created, numbered in the appropriate order, and will contain the result of the allocation. The order of the envelopes' number will define the order of participants' enrolment. The principal investigator will not be aware of the information contained within the envelopes, thereby maintaining a minimisation randomisation process. To ensure the accuracy of the use of the envelopes, the documents inside the envelope will be signed by the Data Safety Monitoring Board and must be returned by the researchers after the allocation of the participants.

Sample size calculation

Sample size was estimated using the *Chi square independent group proportions* approach of *STATA Statistical Package*®, considering the event proportion in control group of 50% (0.5 annual rate) as reported in other previous studies [21 22 40] and estimating a reduction of event rate in the intervention group to 25% (0.25 annual rate) as reported in similar studies. A 95% confidence interval, with β value (power) of 80%, an alpha level of 5% and a ratio of cases/controls of 1:1 were established. Finally, the sample size was readjusted upward, considering an estimated proportion of full compliance of the study of 80% (20% losses). The estimated sample size was 116, readjusted to a total of 146 individuals (73 in each arm).

Inclusion Criteria

Patients with a diagnosis of COPD or Asthma, prescribed any kind of inhaler device (pressurised Metered Dose Inhaler (pMDI) with or without Spacer, Dry Powder Inhaler (DPI) or Soft Mist), aged ≥ 65 years and being a regular user of primary health care services (defined as having had at least one appointment in the last two years with his/her own Family Doctor). In order to minimise diagnostic inaccuracy, Asthma and COPD diagnosis will be reviewed in every participant at baseline prior to enrolment and in accordance with GINA and GOLD strategies [41 42].

Exclusion Criteria

Severe or acute illness (such as unstable cardiovascular status, unstable angina, recent myocardial infarction (within one month) or pulmonary embolism, haemoptysis of unknown origin, recent pneumothorax (within one month), recent thoracic, abdominal or eye surgery (within one month), acute nausea or vomiting, severe respiratory distress, dementia).

We will exclude patients who do not need inhaler medication on a daily basis, since these patients are less susceptible to the full impact of the intervention. In addition, these are mostly patients with intermittent asthma, as well as COPD patients with mild obstruction (GOLD stage I), and tend to have a low frequency of disease exacerbations, which would hamper our ability to detect a true outcome effect.

Predictors/Intervention

Intervention Group – This group will receive a structured and regular follow-up plan, with education on inhaler technique. Patients will be trained by a Family Doctor (the primary investigator) in terms of the inhaler technique using placebo devices similar to their own devices. A teach-to-goal approach will be used, repeating all correct steps as many times as needed in order for patients to perform them correctly at each evaluation. There will be visits at baseline and after 3, 6 and 12 months to assess outcomes. In each visit, and prior to the main intervention with the primary investigator, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adherence and quality of life) will be performed by a secondary blinded investigator.

Control Group – This group will receive usual care from their own Family doctors, with no specific intervention. Each doctor will perform the necessary clinical appointments according to his/her real life judgment. Besides this, this group will have visits at baseline and after 3, 6 and 12 months to assess secondary outcomes. At each visit, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adherence and quality of life) will be performed by a secondary blinded investigator. At any appointment, if the patient asks for or if the clinician decides to teach inhaler technique, that will be recorded.

If any adjustments are made in drug classes or device types in any participant, this information will be recorded.

Outcomes of interest

Primary Outcome: Adverse events (continuous, time to event).

For Asthma, an event will be defined as increased respiratory clinical symptoms leading the patient to search for medical care, and resulting in any of the following:

- Need for increased inhaled corticosteroid dose of at least 4x the regular dose
- Need for increase of short-acting β_2 agonists on a daily basis
- Need for oral corticosteroids
- Need for oral antibiotics
- Hospitalisation or Emergency Room (ER) visit with increased respiratory clinical symptoms.

For COPD, an event will be defined as increased respiratory clinical symptoms prompting the patient to search for medical care, and resulting in any of the following:

- Need for increase of long-acting β_2 agonists on a daily basis
- Need for oral corticosteroids
- Need for oral antibiotics
- Hospitalisation or ER visit with increased respiratory clinical symptoms.

Respiratory-related mortality and all-cause mortality will also be considered an adverse event.

All adverse events and mortality causes will be carefully analysed in order to assess their eligibility by two independent and external investigators, who will constitute a Data Safety Monitoring Board. This will be performed using different platforms of clinical records, from the ER of the regional reference hospital, from the Primary Health Care facilities (such as PEM© for prescribed drugs, SCLINICO© for clinical records and PDS© for ER records) and even by asking the participant for additional information. After any event, and if necessary for ethical reasons, inhaler technique and adherence improvement will be addressed by the primary investigator regardless of the participant allocation, and in accordance with the recommendation of the Data Safety Monitoring Board.

Secondary Outcomes:

- Clinical assessment using COPD Assessment Tools (CAT) and modified Medical Research Council (mMRC) for COPD; Control of Allergic Rhinitis and Asthma Test (CARAT) [43] and Asthma Control Test (ACT) for Asthma [44].
- Quality of Life using St. George's Respiratory Questionnaire [45] and Clinical COPD Questionnaire (CCQ) [46] for COPD and Asthma Quality of Life Questionnaire (AQLQ) [47].
- Functional control using Forced Expiratory Volume in 1st second (FEV1), Forced Vital Capacity (FVC), Peak Expiratory Flow (PEF) and Maximum Expiratory Flows of 25-75% of FVC (MEF25-75) as a % of predicted value; and FEV1/FVC ratio.
- Adherence rate using the Brief Medication Questionnaire (this will also evaluate the frequency of using the devices) [48].
- Number of errors in inhaler technique (that will be standardised to a score up to 100% scale) [To evaluate inhaler technique performance with each device, the Aerosol Drug Management Improvement Team (ADMIT) protocols and guidelines will be used [49], evaluating all the recommended steps for inhaler use in each one of them (pMDI with or without chamber, Qvar Autohaler, Turbohaler, Diskus, Aerolizer, Handihaler, Breezhaler, Novolizer, Genuair, Twisthaler and Easyhaler). For those devices that do not have any protocol from the ADMIT group we will use the recommendations from the manufacture's Summary of Product Characteristics (Soft Mist Inhaler, Budesonide from *Farmoz*[®], Ellipta, Spiromax and Forspiro)].

All questionnaires will be used in validated Portuguese versions [43-48 50 51]. All participants will perform spirometry with bronchodilation test at baseline visit for diagnostic confirmation, as well as a baseline spirometry without bronchodilation for functional control at subsequent visits. A certified provider will perform spirometry.

Other variables collected at baseline

- Demographics (Body Mass Index, Age, Sex)
- Classification of clinical status, according to:
 - Exacerbation history.
 - Years of diagnosis.
 - Asthma classification/stage according to GINA guidelines (clinically as well controlled, partially controlled or uncontrolled; and therapeutically as in STEP 1, 2, 3, 4 or 5)[41]
 - COPD stage according to 2017 GOLD guidelines (combined assessment stages A,B,C and D; and severity of airflow limitation GOLD 1, 2, 3 and 4)[42].
- Social class according to Graffar classification (Portuguese version)[52].
- Co-morbidities (such as concomitant allergic rhinitis, cancer, cardiac heart failure, alcohol or drug abuse, current smoking and smoking pack years, diabetes mellitus, previous stroke or

acute myocardial infarction, thoracic, abdominal or cerebral aneurysms, severe osteoarthritis in hands and upper limbs).

- Depression using Geriatric Depression Scale in Portuguese[53].
- Frailty state in elderly, using a self-reported instrument in Portuguese [54].
- Cognitive function using Montreal Cognitive Assessment (MOCA)in Portuguese [55]
- Influenza and pneumococcal vaccination status
- Previous teaching of inhaler technique, specifying the education type (placebo device, video, leaflet, multimedia, etc.)..
- Years of use with current device.

The principal investigator will collect all baseline data prior to allocation and randomisation, and this will be recorded in a proper form.

Statistical Analysis

The hypothesis testing approach will be the following:

H0: Teaching inhalation technique performance with a placebo device approach does not reduce the exacerbation risk in elderly patients with Asthma or COPD.

HA: Teaching inhaler technique performance with a placebo device approach reduces the exacerbation risk in elderly patients with Asthma or COPD Dichotomous Predictor: Usual Care VS Regular teach-to-goal education with placebo device.

Dichotomous Outcome: Exacerbation Yes/No

Test statistic: Two-sample proportions Chi-square test

Data will be analysed using the *STATA Statistical Package*® software.

The primary outcome will be analysed using a two-sample proportions Chi-square test and a COX proportional hazard time-to-event analysis, and comparing groups using the measures of association: risk ratio; risk difference; hazard ratio and Number Needed to Treat (NNT) analyses. In case of cohort losses above 20%, comparative analysis for intention to treat, per-protocol and a multidata imputation will be carried out. Secondary outcomes will be analysed using parametric tests, such as T test for comparison of mean values and Chi-square test for association of qualitative variables. Subgroup analysis will be performed according to secondary variables, such as diagnosis, age (including stratification into the following categories: 65-75, 75-85, and >85 years), sex, years of diagnosis, disease classification/stage, comorbidities, educational level, previous teaching of inhaler technique, device type, as well as the specific types of detected errors (in order to identify the most critical ones). This will be performed using regression models to multivariate analyses.

Missing data will be treated as missing completely at random. In order to test differences between groups in the mean values of continuous analysis, mixed effects models for repeated measures will be used. For binary outcomes, linear regression models with group-time interactions will also be adapted, and generalised linear models (such as Poisson regression) will be applied for exacerbations, as recommended in the literature [56]. As an alternative approach, generalised estimating equation models will be used to handle unmeasured dependence between outcomes.

An interim analysis will be performed midway through the follow-up, namely at 6 months, defining a significance level adjusted by the Bonferroni technique of 0.025 [57].

Study Setting

The study will be conducted in a multicentre network that will include two or three primary care centres, which will be coordinated by a team of experts in the field. All of them will be in urban or suburban areas. A Portuguese primary care centre usually accounts approximately for more than 10,000 patients, and about 30% of them are aged above 65 years. Considering an approximate

1
2
3 prevalence of Asthma and COPD of 8% in this population, there is a potential target population of
4 almost 250 patients in each health care facility. Recruiting patients at more than one site will improve
5 the feasibility, reproducibility and credibility of the study, but will increase all the logistic issues.

6 All invited participants will have a first contact with the primary investigator to confirm the diagnosis
7 and all the eligibility criteria, and to carefully explain all the study procedures before their inclusion
8 and subsequent randomisation. Diagnosis will be confirmed according to state of the art and the
9 previously mentioned updated guidelines, and with spirometry. The number of patients screened and
10 deemed ineligible as well as the number of patients who are considered eligible but decline
11 participation will be also recorded.
12

13 14 **Timeline**

15 Study protocol final version: August 2017

16 Ethics consent and scientific academic authorisation: December 2017

17 Clinical administrative authorisations: first semester of 2018

18 Multicentre team gathering: first semester of 2018

19 Beginning of recruitment: second semester of 2018

20 End of recruitment: second semester of 2019

21 Data analysis and dissemination: during 2020
22
23

24 **Patient and Public Involvement**

25 No patient or public were involved in the design of this protocol, or in the establishment of the
26 intervention and the outcome measures. Results from all participants will be given to their own family
27 doctors in order to be used if deemed necessary to clinical practice.
28
29
30
31

32 **DISCUSSION**

33
34 This is the first study designed to test this specific intervention in inhaler performance in elderly
35 patients with a regular education programme, and it was designed to detect a significant reduction on
36 disease exacerbation rate. It is expected to detect approximately 55 adverse events, 18 in the
37 intervention group and 37 in the control group. In addition, it is expected to find a more significant
38 improvement in the intervention group, in all clinical and functional parameters during the follow-up.

39 This study has some limitations, mainly in selection bias due to the risk of missing data and follow-up
40 losses. To overcome this problem, different strategies will be applied, such as an increase in estimated
41 sample size, readjusted for an estimation of 20% losses; and sending a reminder prior to each visit
42 using SMS/Email/Call to contact the participant.
43

44 Another aspect that could bias our study is the Hawthorne effect throughout the study (ie. behaviour
45 change in participants due to their involvement in the study). However, we believe that by establishing
46 a cohort time of one year this effect will not be sustained. On the other hand, the control group (“usual
47 care”) will maintain their usual care at their own family doctors, who are completely free from any
48 influence of the study design. For this reason, the control group (“usual care”) participants will not
49 receive any intervention from the primary investigator. They will only contact with the secondary
50 investigator in order to collect endpoints and outcome data, and the latter is completely blinded to
51 randomisation. With this approach, the Hawthorne effect will not contaminate the control group, and
52 will represent a real life usual care. On the other hand, the Data Safety Monitoring Board will be
53 composed of two external investigators, who will, together with the statistician, be blinded to the
54 endpoints and outcomes (PROBE setting).
55
56
57

Another possible limitation of our study is that we will not use electronic measures of adherence and inhalation techniques. These are a very useful approach to monitoring real world adherence to inhaler therapy. In fact, these electronic measures overcome the bias seen with self-report and other problems observed with objective medication checks such as prescription refill rates. However, most electronic measures of adherence do not measure timing of device activation but rather the overall number of activations performed, and, in addition, this measure does not mean that medication was taken on a regular basis (patients may just activate the inhaler several times, prior to handing over the device). It is not until recently that a new device has been studied, which seems to overcome this problem, and which also analyses inhaler technique, but it is not widely available – INCA device[58]. Nevertheless, these devices are expensive and their use could not be implemented in our study. We therefore decided to use the adherence questionnaire (BMQ), which is a well-validated tool in several languages worldwide, and also in Portuguese [48]. Furthermore, it is a very simple and easy method to detect non-adherence, which also allows separating sub-domains of adherence. Thus, it is a good tool for assessing adherence in our study involving the general population of asthma and COPD patients. Regarding inhalation technique, we decided to use regular checklists, since they are the most widely method used in other studies, thereby allowing further comparisons. They are also easy to use and allow detection of critical errors in each device.

The standardisation of the protocol intervention is another issue to be considered. In order to overcome different approaches among different investigators from different multicentre sites, a protocol with detailed instructions will be created to guide them during the intervention (investigators) and assessment visits (secondary investigators). This protocol will explain all the steps and procedures for training inhaler technique as well as for assessing it, and all the procedures to follow in each visit for assessing the outcomes.

Primary investigators will be trained in communication techniques related to inhaler education of different devices and all of them will have a kit of placebo devices for use with participants. Such training will allow the standardization of all procedures of intervention and it will be provided ahead by the coordination team of the study.

ETHICS AND DISSEMINATION

The study protocol has already been analysed by the local Ethics Committee of University of Beira Interior, with the reference number CE-UBI-Pj-2017-025, and was approved on 22th, November 2017. Every participant will sign a written consent form (Appendix I). A Data Safety Monitoring Board will be set up, composed of two external investigators with a board expertise in this clinical field and in academic and scientific activities, to evaluate data obtained throughout the study. Evaluations will occur every 6 months, whatever the number of participants enrolled or the follow-up time reached at that point. The stop earlier criteria will be defined as any moment on follow-up in which the collected data show statistically significant differences in the primary outcomes. The study may be suspended earlier if sufficient data are obtained for at least 6 months of follow-up, or if significant evidence of intervention effectiveness is obtained, providing that statistical significance values are met by the Bonferroni adaptation.

Invited participants who refuse to participate will be evaluated at baseline, according to previously mentioned characteristics, in order to compare them with the included cohort. They will also be

1
2
3 invited to sign a written informed consent form that will allow investigators to collect such data. The
4 documents used to collect the data of the participants will contain only an identification code of each
5 participant, in order to protect their identity. The code of each participant must be composed of the
6 initials of the first two names, followed by the last two digits of the National Health Care Service
7 Number (eg. *Name FirstSurname SecondSurname*, 123456789 -----> code "NF89").

8 The number of participants considered ineligible will be recorded, as well as the number of eligible
9 participants who refuse to participate in the study.

10 The results obtained from this study will be published in peer-reviewed journals and presented at
11 scientific meetings of primary health care and respiratory fields. All data recorded during the study
12 will be stored for a period of 5 years, in accordance with the Portuguese Clinical Research Law, in a
13 safe and proper place in the primary investigator's health centre. After this period, all data that contain
14 participants' codes will be destroyed.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AUTHORS' CONTRIBUTIONS

All authors have equally contributed to the elaboration of this protocol in every stage of its design and writing. TM elaborated the first draft of the study, JCS and LTB gave inputs to all necessary design adjustments, and all authors have carried out final revisions of the manuscript.

COMPETING INTERESTS STATEMENT

Dr. Correia-de-Sousa reports competing interests from Harvard Medical School, during the conduct of the study, as scientific support. He also reports from Boheringer Ingelheim and from AstraZeneca outside the submitted work, and all these fees were received by a non-profit organisation to be used in CME and research.

The remaining authors declare only from Harvard Medical School, during the conduct of the study, as scientific support.

FUNDING

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

This work was developed without any funding support or financial source. The academic affiliation of this protocol is the Life and Health Sciences Research Institute (ICVS)/3B's at University of Minho and the Faculty of Health Sciences at the University of Beira Interior in Portugal.

This work was prepared with scientific support from Harvard Medical School, in accordance with the Portuguese Clinical Scholarship Research Training Program.

ACKNOWLEDGMENTS

The authors endorse acknowledgment to Prof. Jonh Groarke, from the Harvard Medical School, for his important scientific support and input in reviewing the final version of this manuscript.

DATA ACCESS

All data from the trial will be kept in a safe place of the principal investigator's institutional facilities and by the Data Safety Monitoring Board, in accordance with the national and international clinical research policies.

FIGURE LEGENDS

Figure 1 – Study design diagram.

REFERENCES

1. World Health Organization. The global burden of disease: 2004 update. Available from: <http://www.who.int>, 2008:160.
2. Sa-Sousa A, Morais-Almeida M, Azevedo LF, et al. Prevalence of asthma in Portugal - The Portuguese National Asthma Survey. *Clinical and translational allergy* 2012;**2**(1):15 doi: 10.1186/2045-7022-2-15[published Online First: Epub Date]].
3. de Sousa JC, Santo ME, Colaço T, et al. Asthma in an Urban Population in Portugal: A prevalence study. *BMC Public Health* 2011;**11**:347-47 doi: 10.1186/1471-2458-11-347[published Online First: Epub Date]].
4. Reddel H, Battersman E, Becker A, et al. Global Strategy for Asthma Management and Prevention. Available from: <http://www.ginasthma.org>: Global initiative for asthma, 2015 update:149.
5. van Boven JF, Tommelein E, Boussery K, et al. Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. *Respiratory research* 2014;**15**:66 doi: 10.1186/1465-9921-15-66[published Online First: Epub Date]].
6. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. *Thorax* 2009;**64**(11):939-43 doi: 10.1136/thx.2009.113662[published Online First: Epub Date]].
7. Engelkes M, Janssens HM, de Jongste JC, et al. Medication adherence and the risk of severe asthma exacerbations: a systematic review. *The European respiratory journal* 2015;**45**(2):396-407 doi: 10.1183/09031936.00075614[published Online First: Epub Date]].
8. Rees J. Methods of delivering drugs. *BMJ : British Medical Journal* 2005;**331**(7515):504-06
9. Cochrane MG, Bala MV, Downs KE, et al. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. *Chest* 2000;**117**(2):542-50
10. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. *Respiratory medicine* 2008;**102**(4):593-604 doi: 10.1016/j.rmed.2007.11.003[published Online First: Epub Date]].
11. Sanchis J, Gich I, Pedersen S. Systematic Review of Errors in Inhaler Use. *Chest* 2016;**150**(2):394-406 doi: 10.1016/j.chest.2016.03.041[published Online First: Epub Date]].
12. Broeders ME, Molema J, Hop WC, et al. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. *Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine* 2003;**16**(2):131-41 doi: 10.1089/089426803321919898[published Online First: Epub Date]].
13. Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. *Health technology assessment (Winchester, England)* 2001;**5**(26):1-149
14. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest* 2005;**127**(1):335-71 doi: 10.1378/chest.127.1.335[published Online First: Epub Date]].
15. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. *The European respiratory journal* 2002;**19**(2):246-51
16. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. *Respiratory medicine* 2011;**105**(6):930-8 doi: 10.1016/j.rmed.2011.01.005[published Online First: Epub Date]].
17. Roggeri A, Micheletto C, Roggeri DP. Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues. *International journal of chronic obstructive pulmonary disease* 2016;**11**:597-602 doi: 10.2147/copd.s103335[published Online First: Epub Date]].
18. Price DB, Román-Rodríguez M, McQueen RB, et al. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. *The Journal of Allergy and Clinical*

- 1
2
3 Immunology: In Practice 2017 doi: <http://dx.doi.org/10.1016/j.iaip.2017.01.004>[published
4 Online First: Epub Date]].
- 5 19. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic
6 review of impact on health outcomes. *Respiratory research* 2018;**19**(1):10 doi:
7 10.1186/s12931-017-0710-y[published Online First: Epub Date]].
- 8 20. Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the
9 new inhalation therapies. *The European respiratory journal* 2011;**37**(6):1308-31 doi:
10 10.1183/09031936.00166410[published Online First: Epub Date]].
- 11 21. Tommelein E, Mehuys E, Van Hees T, et al. Effectiveness of pharmaceutical care for patients with
12 chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. *British
13 journal of clinical pharmacology* 2014;**77**(5):756-66 doi: 10.1111/bcp.12242[published Online
14 First: Epub Date]].
- 15 22. Takemura M, Mitsui K, Ido M, et al. Effect of a network system for providing proper inhalation
16 technique by community pharmacists on clinical outcomes in COPD patients. *International
17 journal of chronic obstructive pulmonary disease* 2013;**8**:239-44 doi:
18 10.2147/copd.s44022[published Online First: Epub Date]].
- 19 23. Broeders ME, Sanchis J, Levy ML, et al. The ADMIT series--issues in inhalation therapy. 2.
20 Improving technique and clinical effectiveness. *Primary care respiratory journal : journal of
21 the General Practice Airways Group* 2009;**18**(2):76-82 doi:
22 10.4104/pcrj.2009.00025[published Online First: Epub Date]].
- 23 24. Crompton GK, Barnes PJ, Broeders M, et al. The need to improve inhalation technique in Europe:
24 a report from the Aerosol Drug Management Improvement Team. *Respiratory medicine*
25 2006;**100**(9):1479-94 doi: 10.1016/j.rmed.2006.01.008[published Online First: Epub Date]].
- 26 25. Allen SC, Jain M, Ragab S, et al. Acquisition and short-term retention of inhaler techniques
27 require intact executive function in elderly subjects. *Age and ageing* 2003;**32**(3):299-302
- 28 26. Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients
29 with chronic obstructive pulmonary disease. *American journal of health-system pharmacy :
30 AJHP : official journal of the American Society of Health-System Pharmacists* :
31 2011;**68**(13):1221-32 doi: 10.2146/ajhp100452[published Online First: Epub Date]].
- 32 27. Quinet P, Young CA, Heritier F. The use of dry powder inhaler devices by elderly patients suffering
33 from chronic obstructive pulmonary disease. *Annals of physical and rehabilitation medicine*
34 2010;**53**(2):69-76 doi: 10.1016/j.rehab.2009.11.001[published Online First: Epub Date]].
- 35 28. Allen SC, Warwick-Sanders M, Baxter M. A comparison of four tests of cognition as predictors of
36 inability to learn to use a metered dose inhaler in old age. *Int J Clin Pract* 2009;**63**(8):1150-3
37 doi: 10.1111/j.1742-1241.2009.02060.x[published Online First: Epub Date]].
- 38 29. Blasi F, Canonica GW, Centanni S, et al. Genuair(R) Usability Test: Results of a National Public
39 Survey of the Elderly. *Copd* 2016;**13**(3):367-71 doi:
40 10.3109/15412555.2015.1067675[published Online First: Epub Date]].
- 41 30. Rootmensen GN, van Keimpema AR, Looyen EE, et al. The effects of additional care by a
42 pulmonary nurse for asthma and COPD patients at a respiratory outpatient clinic: results
43 from a double blind, randomized clinical trial. *Patient education and counseling*
44 2008;**70**(2):179-86 doi: 10.1016/j.pec.2007.09.021[published Online First: Epub Date]].
- 45 31. Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic
46 obstructive pulmonary disease: a disease-specific self-management intervention. *Arch Intern
47 Med* 2003;**163**(5):585-91
- 48 32. Khmour MR, Kidney JC, Smyth BM, et al. Clinical pharmacy-led disease and medicine management
49 programme for patients with COPD. *British journal of clinical pharmacology* 2009;**68**(4):588-
50 98 doi: 10.1111/j.1365-2125.2009.03493.x[published Online First: Epub Date]].
- 51 33. Strayhorn-Smith V, Tolley E, Demirkan K, et al. Metered dose inhaler - spacer technique in
52 hospitalized geriatric patients: Effect of patient education by a pharmacist. *Hosp
53 Pharm*;**35**:162-64
- 54
55
56
57
58
59
60

- 1
- 2
- 3 34. Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for people
4 with asthma. The Cochrane database of systematic reviews 2017;**3**:CD012286 doi:
5 10.1002/14651858.CD012286.pub2[published Online First: Epub Date]].
- 6 35. Thomas RM, Locke ER, Woo DM, et al. Inhaler Training Delivered by Internet-Based Home
7 Videoconferencing Improves Technique and Quality of Life. *Respiratory care*
8 2017;**62**(11):1412
- 9 36. Bosnic-Anticevich SZ, Sinha H, So S, et al. Metered-dose inhaler technique: the effect of two
10 educational interventions delivered in community pharmacy over time. *The Journal of*
11 *asthma : official journal of the Association for the Care of Asthma* 2010;**47**(3):251-6 doi:
12 10.3109/02770900903580843[published Online First: Epub Date]].
- 13 37. Crane MA, Jenkins CR, Goeman DP, et al. Inhaler device technique can be improved in older
14 adults through tailored education: findings from a randomised controlled trial. *NPJ primary*
15 *care respiratory medicine* 2014;**24**:14034 doi: 10.1038/nppjprm.2014.34[published Online
16 First: Epub Date]].
- 17 38. Lavorini F, Levy ML, Corrigan C, et al. The ADMIT series - issues in inhalation therapy. 6) Training
18 tools for inhalation devices. *Primary care respiratory journal : journal of the General Practice*
19 *Airways Group* 2010;**19**(4):335-41 doi: 10.4104/pcrj.2010.00065[published Online First: Epub
20 Date]].
- 21 39. Self TH, Hoth LM, Bolin JM, et al. Metered-dose inhaler technique per the Global Initiative for
22 Asthma and Expert Panel Report 3. *Annals of Allergy, Asthma & Immunology*
23 2016;**117**(1):101-02 doi: 10.1016/j.anai.2016.05.002[published Online First: Epub Date]].
- 24 40. Goris S, Tasci S, Elmali F. The effects of training on inhaler technique and quality of life in patients
25 with COPD. *Journal of aerosol medicine and pulmonary drug delivery* 2013;**26**(6):336-44 doi:
26 10.1089/jamp.2012.1017[published Online First: Epub Date]].
- 27 41. GINA. Pocket Guide for Asthma Management and Prevention. Available in: <http://ginasthma.org>,
28 Updated 2015:32.
- 29 42. GOLD. Pocket Guide to COPD Diagnosis, Management, and Prevention - A Guide for Health Care
30 Professionals. Available in: <http://www.goldcopd.org>, 2017 report:42.
- 31 43. Fonseca JA, Nogueira-Silva L, Morais-Almeida M, et al. Validation of a questionnaire (CARAT10) to
32 assess rhinitis and asthma in patients with asthma. *Allergy* 2010;**65**(8):1042-8 doi:
33 10.1111/j.1398-9995.2009.02310.x[published Online First: Epub Date]].
- 34 44. Roxo JP, Ponte EV, Ramos DC, et al. [Portuguese-language version of the Asthma Control Test].
35 *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia*
36 *e Tisiologia* 2010;**36**(2):159-66
- 37 45. Camelier A, Rosa FW, Salim C, et al. Using the Saint George's Respiratory Questionnaire to
38 evaluate quality of life in patients with chronic obstructive pulmonary disease: validating a
39 new version for use in Brazil. *Jornal brasileiro de pneumologia : publicacao oficial da*
40 *Sociedade Brasileira de Pneumologia e Tisiologia* 2006;**32**(2):114-22
- 41 46. Faria da Silva LS. Validação do Questionário Clínico para a Doença Pulmonar Obstrutiva Crónica
42 (CCQ) para a Língua Portuguesa [Master Thesis]. Escola Superior de Enfermagem do Porto,
43 2012.
- 44 47. Ferreira J, Silveira P, Figueiredo MM, et al. Validation of the Portuguese version of the Asthma
45 Quality of Life Questionnaire [AQLQ-M] by Marks. *Revista portuguesa de pneumologia*
46 2005;**11**(4):351-66
- 47 48. Ben AJ, Neumann CR, Mengue SS. The Brief Medication Questionnaire and Morisky-Green test to
48 evaluate medication adherence. *Revista de saude publica* 2012;**46**(2):279-89
- 49 49. (ADMIT) TADMIT. Inhalation Protocols. Secondary Inhalation Protocols 2017.
- 50 50. Silva GP, Morano MT, Viana CM, et al. Portuguese-language version of the COPD Assessment
51 Test: validation for use in Brazil. *Jornal brasileiro de pneumologia : publicacao oficial da*
52 *Sociedade Brasileira de Pneumologia e Tisiologia* 2013;**39**(4):402-8 doi: 10.1590/s1806-
53 37132013000400002[published Online First: Epub Date]].
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 51. Kovelis D, Segretti NO, Probst VS, et al. Validation of the Modified Pulmonary Functional Status
4 and Dyspnea Questionnaire and the Medical Research Council scale for use in Brazilian
5 patients with chronic obstructive pulmonary disease. *Jornal brasileiro de pneumologia :
6 publicacao oficial da Sociedade Brasileira de Pneumologia e Tisiologia* 2008;**34**(12):1008-18
7
8 52. Amaro F. Escala de Graffar, 1990.
9
10 53. Apóstolo JLA, Loureiro LMdJ, Reis IACd, et al. Contribuição para a adaptação da Geriatric
11 Depression Scale -15 para a língua portuguesa. *Revista de Enfermagem Referência*
12 2014;**serIV**:65-73
13
14 54. Nunes DP, Duarte YAdO, Santos JLF, et al. Screening for frailty in older adults using a self-reported
15 instrument. *Revista de saude publica* 2015;**49**:2 doi: 10.1590/S0034-
16 8910.2015049005516[published Online First: Epub Date] |
17
18 55. Freitas Sandra SMR, Martins Cristina, Vilar Manuela, Santana Isabel. . Estudos de adaptação do
19 Montreal Cognitive Assessment (MoCA) para a população portuguesa. *Aval. psicol.* [online].
20 2010;**9**(3):345-57
21
22 56. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive
23 pulmonary disease. *Am J Respir Crit Care Med* 2006;**173**(8):842-6 doi: 10.1164/rccm.200508-
24 1338PP[published Online First: Epub Date] |
25
26 57. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. *BMJ*
27 1995;**310**(6973):170 doi: 10.1136/bmj.310.6973.170[published Online First: Epub Date] |
28
29 58. Moran C, Doyle F, Sulaiman I, et al. The INCA(TM) (Inhaler Compliance Assessment(TM)): A
30 comparison with established measures of adherence. *Psychology & health* 2017;**32**(10):1266-
31 87 doi: 10.1080/08870446.2017.1290243[published Online First: Epub Date] |
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 - Study Design Diagram

APPENDIX I - Informed consent form, according to Portuguese Directorate-General of Health.

Consentimento Informado nos termos da Norma nº 015/2013 da DGS

Estudo “Ensino da técnica inalatória em idosos com Asma e DPOC: impacto nas exacerbações”

A sua unidade de saúde convida-o a participar no estudo “Ensino da técnica inalatória em idosos com Asma e DPOC: impacto nas exacerbações”. Foi convidado para participar neste estudo porque se trata de um doente com uma doença respiratória crónica (como Asma ou DPOC) e está a ser medicado com um dispositivo inalatório diariamente.

Os objetivos deste estudo são:

- Verificar se utiliza corretamente o seu dispositivo inalatório
- Testar se o ensino regular do uso do inalador melhora o controlo da sua doença.
- Testar se o mesmo ensino regular diminui a probabilidade de ter alguma crise de agudização/exacerbação pela sua doença, e que pode ser potencialmente fatal.

Para verificar estes objetivos iremos dividir, de forma aleatória, os utentes convidados a participar em dois grupos diferentes. Ambos os grupos irão ser avaliados regularmente sobre o controlo da sua doença, quer quando aos sintomas, qualidade de vida e quanto à sua capacidade pulmonar/respiratória. Isto será feito através da aplicação de questionários bem como da realização de um exame complementar simples e não invasivo, a espirometria.

A principal diferença entre os dois grupos, é que, um deles irá receber adicionalmente de um investigador, um ensino e treino regular sobre o uso correto dos dispositivos inalatórios, enquanto o outro grupo irá apenas receber os cuidados médicos regulares que necessitar pelo seu próprio Medico de Família.

A sua participação no estudo irá durar 12 meses. Ao aceitar participar neste estudo, será sorteado para um dos dois grupos, e após isso irá ser avaliado nesta Unidade de Saúde passados 3, 6 e 12 meses pelos investigadores. Não irá saber em nenhum momento (nem o seu Medico de Família) a qual dos grupos pertence, pois, o objetivo do estudo é não influenciar a forma como os dois grupos se comportam. Todas as consultas realizadas no âmbito deste estudo serão gratuitas para si, bem como a realização das avaliações pelos investigadores.

O estudo será coordenado pelo Dr. Tiago Maricoto, da USF Aveiro-Aradas, que é o investigador principal. A sua participação no estudo é voluntária. Poderá decidir não participar no estudo a qualquer momento sem prejuízo dos seus cuidados médicos. Todos os dados recolhidos neste estudo permanecerão confidenciais. O seu Medico de Família terá acesso no final do estudo aos resultados dos seus exames e avaliações.

O potencial benefício para a sua Saúde ao participar neste estudo é melhorar o controlo clínico da sua doença respiratória, melhorar a capacidade respiratória dos seus pulmões e diminuir o risco de crises de agudização graves e potencialmente fatais. Não existem riscos significativos para a sua saúde. Ao não participar neste estudo perde ainda a oportunidade de poder melhorar a forma como usa os seus dispositivos inalatórios, o que pode comprometer o bom controlo da sua doença a longo prazo.

[Parte declarativa do profissional]

Confirmo que expliquei à pessoa abaixo indicada, de forma adequada e inteligível, os procedimentos necessários ao ato referido neste documento. Respondi a todas as questões que me foram colocadas e assegurei-me de que houve um período de reflexão suficiente para a tomada da decisão. Também garanti que, em caso de recusa, serão assegurados os melhores cuidados possíveis nesse contexto, no respeito pelos seus direitos.

Nome legível do profissional de saúde: _____

Assinatura, nº de cédula profissional/mecanográfico:

Unidade de Saúde: _____

Contato institucional do profissional de saúde: _____

À Pessoa/representante

Por favor, leia com atenção todo o conteúdo deste documento. Não hesite em solicitar mais informações se não estiver completamente esclarecido/a. Verifique se todas as informações estão corretas. Se tudo estiver conforme, então assine este documento.

[Parte declarativa da pessoa que consente]

*Declaro ter compreendido os objetivos de quanto me foi proposto e explicado pelo profissional de saúde que assina este documento, ter-me sido dada oportunidade de fazer todas as perguntas sobre o assunto e para todas elas ter obtido resposta esclarecedora, ter-me sido garantido que não haverá prejuízo para os meus direitos assistenciais se eu recusar esta solicitação, e ter-me sido dado tempo suficiente para refletir sobre esta proposta. Autorizo/Não autorizo (**riscar o que não interessa**) o ato indicado, bem como os procedimentos diretamente relacionados que sejam necessários no meu próprio interesse e justificados por razões clínicas fundamentadas.*

NOME: _____

Assinatura /...../..... (data)

SE NÃO FOR O PRÓPRIO A ASSINAR POR IDADE OU INCAPACIDADE

(se o menor tiver discernimento deve também assinar em cima)

NOME:

DOC. IDENTIFICAÇÃO N.º DATA OU VALIDADE /..... /.....

GRAU DE PARENTESCO OU TIPO DE REPRESENTAÇÃO:

ASSINATURA.....

O presente documento é emitido em duplicado, ficando um na posse do participante, e outro arquivado pelos investigadores em local próprio

Reporting checklist for protocol of a clinical trial (SPIRIT).

Instructions to authors

Upload this checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	#3	Date and version identifier	1
Funding	#4	Sources and types of financial, material, and other support	12
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	12
Roles and responsibilities: sponsor contact information	#5b	Name and contact information for the trial sponsor	NA
Roles and responsibilities: sponsor and funder	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have	NA

		ultimate authority over any of these activities	
1			
2			
3	Roles and	#5d	10
4	responsibilities:	Composition, roles, and responsibilities of the coordinating	
5	committees	centre, steering committee, endpoint adjudication	
6		committee, data management team, and other individuals or	
7		groups overseeing the trial, if applicable (see Item 21a for	
8		data monitoring committee)	
9			
10			
11	Background and	#6a	4
12	rationale	Description of research question and justification for	
13		undertaking the trial, including summary of relevant studies	
14		(published and unpublished) examining benefits and harms	
15		for each intervention	
16			
17	Background and	#6b	4
18	rationale: choice of	Explanation for choice of comparators	
19	comparators		
20			
21			
22			
23	Objectives	#7	5
24		Specific objectives or hypotheses	
25			
26	Trial design	#8	5
27		Description of trial design including type of trial (eg, parallel	
28		group, crossover, factorial, single group), allocation ratio,	
29		and framework (eg, superiority, equivalence, non-inferiority,	
30		exploratory)	
31			
32	Study setting	#9	8
33		Description of study settings (eg, community clinic,	
34		academic hospital) and list of countries where data will be	
35		collected. Reference to where list of study sites can be	
36		obtained	
37			
38			
39	Eligibility criteria	#10	5
40		Inclusion and exclusion criteria for participants. If applicable,	
41		eligibility criteria for study centres and individuals who will	
42		perform the interventions (eg, surgeons, psychotherapists)	
43			
44	Interventions:	#11a	6
45	description	Interventions for each group with sufficient detail to allow	
46		replication, including how and when they will be	
47		administered	
48			
49	Interventions:	#11b	6
50	modifications	Criteria for discontinuing or modifying allocated	
51		interventions for a given trial participant (eg, drug dose	
52		change in response to harms, participant request, or	
53		improving / worsening disease)	
54			
55			
56	Interventions:	#11c	9
57	adherence	Strategies to improve adherence to intervention protocols,	
58		and any procedures for monitoring adherence (eg, drug	
59			
60			

tablet return; laboratory tests)

1				
2				
3	Interventions:	#11d	Relevant concomitant care and interventions that are	6
4	concomitant care		permitted or prohibited during the trial	
5				
6	Outcomes	#12	Primary, secondary, and other outcomes, including the	6
7			specific measurement variable (eg, systolic blood pressure),	
8			analysis metric (eg, change from baseline, final value, time	
9			to event), method of aggregation (eg, median, proportion),	
10			and time point for each outcome. Explanation of the clinical	
11			relevance of chosen efficacy and harm outcomes is strongly	
12			recommended	
13				
14				
15				
16				
17	Participant timeline	#13	Time schedule of enrolment, interventions (including any	6
18			run-ins and washouts), assessments, and visits for	
19			participants. A schematic diagram is highly recommended	
20			(see Figure)	
21				
22				
23				
24	Sample size	#14	Estimated number of participants needed to achieve study	5
25			objectives and how it was determined, including clinical and	
26			statistical assumptions supporting any sample size	
27			calculations	
28				
29				
30				
31	Recruitment	#15	Strategies for achieving adequate participant enrolment to	5,9
32			reach target sample size	
33				
34				
35	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	5,8
36	generation		computer-generated random numbers), and list of any	
37			factors for stratification. To reduce predictability of a random	
38			sequence, details of any planned restriction (eg, blocking)	
39			should be provided in a separate document that is	
40			unavailable to those who enrol participants or assign	
41			interventions	
42				
43				
44				
45				
46	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	5,8
47	concealment		central telephone; sequentially numbered, opaque, sealed	
48	mechanism		envelopes), describing any steps to conceal the sequence	
49			until interventions are assigned	
50				
51				
52				
53	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	5,8
54	implementation		participants, and who will assign participants to	
55			interventions	
56				
57				
58	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	6,9
59				
60				

1			trial participants, care providers, outcome assessors, data	
2			analysts), and how	
3				
4	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	6,9
5	emergency		permissible, and procedure for revealing a participant's	
6	unblinding		allocated intervention during the trial	
7				
8				
9	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	7,8
10			and other trial data, including any related processes to	
11			promote data quality (eg, duplicate measurements, training	
12			of assessors) and a description of study instruments (eg,	
13			questionnaires, laboratory tests) along with their reliability	
14			and validity, if known. Reference to where data collection	
15			forms can be found, if not in the protocol	
16				
17				
18				
19				
20	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	7,8
21	retention		up, including list of any outcome data to be collected for	
22			participants who discontinue or deviate from intervention	
23			protocols	
24				
25				
26				
27	Data management	#19	Plans for data entry, coding, security, and storage, including	7,8
28			any related processes to promote data quality (eg, double	
29			data entry; range checks for data values). Reference to	
30			where details of data management procedures can be	
31			found, if not in the protocol	
32				
33				
34				
35				
36	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	8
37			outcomes. Reference to where other details of the statistical	
38			analysis plan can be found, if not in the protocol	
39				
40				
41	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	8
42	analyses		adjusted analyses)	
43				
44				
45	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	8
46	population and		adherence (eg, as randomised analysis), and any statistical	
47	missing data		methods to handle missing data (eg, multiple imputation)	
48				
49				
50	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	10
51	formal committee		of its role and reporting structure; statement of whether it is	
52			independent from the sponsor and competing interests; and	
53			reference to where further details about its charter can be	
54			found, if not in the protocol. Alternatively, an explanation of	
55			why a DMC is not needed	
56				
57				
58				
59				
60				

1	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	10
2	interim analysis		including who will have access to these interim results and	
3			make the final decision to terminate the trial	
4				
5				
6	Harms	#22	Plans for collecting, assessing, reporting, and managing	10
7			solicited and spontaneously reported adverse events and	
8			other unintended effects of trial interventions or trial conduct	
9				
10				
11	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	10
12			and whether the process will be independent from	
13			investigators and the sponsor	
14				
15				
16				
17	Research ethics	#24	Plans for seeking research ethics committee / institutional	10
18	approval		review board (REC / IRB) approval	
19				
20				
21	Protocol	#25	Plans for communicating important protocol modifications	10
22	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
23			relevant parties (eg, investigators, REC / IRBs, trial	
24			participants, trial registries, journals, regulators)	
25				
26				
27	Consent or assent	#26a	Who will obtain informed consent or assent from potential	10
28			trial participants or authorised surrogates, and how (see	
29			Item 32)	
30				
31				
32				
33	Consent or assent:	#26b	Additional consent provisions for collection and use of	10
34	ancillary studies		participant data and biological specimens in ancillary	
35			studies, if applicable	
36				
37				
38	Confidentiality	#27	How personal information about potential and enrolled	10
39			participants will be collected, shared, and maintained in	
40			order to protect confidentiality before, during, and after the	
41			trial	
42				
43				
44				
45	Declaration of	#28	Financial and other competing interests for principal	12
46	interests		investigators for the overall trial and each study site	
47				
48				
49	Data access	#29	Statement of who will have access to the final trial dataset,	12
50			and disclosure of contractual agreements that limit such	
51			access for investigators	
52				
53				
54	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for	12
55	trial care		compensation to those who suffer harm from trial	
56			participation	
57				
58				
59				
60				

1	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	10,11
2	trial results		results to participants, healthcare professionals, the public,	
3			and other relevant groups (eg, via publication, reporting in	
4			results databases, or other data sharing arrangements),	
5			including any publication restrictions	
6				
7				
8				
9	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use of	10,11
10	authorship		professional writers	
11				
12				
13	Dissemination policy:	#31c	Plans, if any, for granting public access to the full protocol,	10,11
14	reproducible		participant-level dataset, and statistical code	
15	research			
16				
17				
18	Informed consent	#32	Model consent form and other related documentation given	Apx.
19	materials		to participants and authorised surrogates	
20				
21				
22	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of	NA
23			biological specimens for genetic or molecular analysis in the	
24			current trial and for future use in ancillary studies, if	
25			applicable	
26				
27				
28				

29 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 30 BY-ND 3.0. This checklist was completed on 05. February 2018 using <http://www.goodreports.org/>, a
 31 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Inhaler technique education in elderly patients with Asthma or COPD: impact on disease exacerbations – a protocol for a single-blinded randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022685.R2
Article Type:	Protocol
Date Submitted by the Author:	29-Jun-2018
Complete List of Authors:	Maricoto, Tiago; Aveiro-Aradas Family Health Unit, ACeS Baixo Vouga; Faculty of Health Sciences, University of Beira Interior Correia-de-Sousa, Jaime; Life and Health Sciences Research Institute (ICVS)/3B's – PT Government Associate Laboratory, University of Minho; Horizonte Family Health Unit, Taborda-Barata, Luís; CICS - Health Sciences Research Centre; NuESA – Environment & Health Study Group, Faculty of Health Sciences, University of Beira Interior; Department of Allergy & Clinical Immunology, Cova da Beira University Hospital Centre
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	General practice / Family practice
Keywords:	Chronic Obstructive Pulmonary Disease, Asthma < THORACIC MEDICINE, Nebulizers and Vaporizers

SCHOLARONE™
Manuscripts

Inhaler technique education in elderly patients with Asthma or COPD: impact on disease exacerbations – a protocol for a single-blinded randomised controlled trial

AUTHORS

Tiago Maricoto^{1,2}; Jaime Correia-de-Sousa^{3,4}; Luís Taborda-Barata^{5,6}

(1) Aveiro-Aradas Family Health Unit; Aveiro Health Centre; Portugal

(2) Faculty of Health Sciences; University of Beira Interior, Covilhã, Portugal

(3) Life and Health Sciences Research Institute (ICVS)/3B's — PT Government Associate Laboratory, University of Minho, Braga, Portugal

(4) Horizonte Family Health Unit, Matosinhos, Portugal.

(5) CICS - Health Sciences Research Centre & NuESA – Environment & Health Study Group, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal

(6) Department of Allergy & Clinical Immunology, Cova da Beira University Hospital Centre, Covilhã, Portugal

CORRESPONDING AUTHOR

- Tiago Maricoto, MD
Family Doctor
USF Aveiro-Aradas; Praceta Rainha D. Leonor; 3800; Aveiro; Portugal
Tel: +351 234 891 213
PhD Student; Faculty of Health Sciences; University of Beira Interior
tiago.maricoto@gmail.com

WORD COUNT

3186 words

PROTOCOL VERSION

This is the second version of this RCT protocol.

ABSTRACT

Introduction

COPD and Asthma affect more than 10% of the population. Most patients use their inhaler incorrectly, mainly the elderly, thereby becoming more susceptible to poor clinical control and exacerbations. Placebo device training is regarded as one of the best teaching methods, but there is scarce evidence to support it as the most effective one to improve major clinical outcomes. Our objective is to perform a single-blinded RCT to assess the impact of this education tool in these patients.

Methods and Analysis

A multicentre single-blinded RCT will be set up, comparing an inhaler education programme with placebo-device training versus usual care, with a one-year follow-up, in elderly patients with Asthma or COPD. Intervention will be provided at baseline, and after 3 and 6 months, with interim analysis at an intermediate time point. Exacerbation rates were set as primary outcomes, and quality of life, adherence rates, clinical control and respiratory function were chosen as secondary outcomes. A sample size of 146 participants (73 in each arm) was estimated as adequate to detect a 50% reduction in event rates. Two-sample proportions Chi-squared test will be used to study primary outcome and subgroup analysis will be carried out according to major baseline characteristics.

Ethics and dissemination:

Every participant will sign a written consent form. A Data Safety Monitoring Board will be set up to evaluate data throughout the study and to monitor early stopping criteria. Identity of all participants will be protected. This protocol was approved on the 22th November 2017 by the local Ethics Committee of University of Beira Interior, with the reference number CE-UBI-Pj-2017-025. Results will be presented in scientific meeting and published in peer-reviewed journals.

KEYWORDS

Chronic Obstructive Pulmonary Disease; Asthma; Nebulizers and Vaporizers

REGISTRY

This RCT protocol is registered in clinicaltrials.gov, with the number NCT03449316.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This is the first study to address a specific placebo device education programme alone, without any other aspects, in elderly patients with Asthma or COPD.
- No previous study has addressed this teaching method in these patients, as it seems to be the most efficient one.
- Our study has a randomised design, which has been a major limitation in previous studies.
- The one-year follow up period, with two interim evaluations, allow this study to comprehensively address the real impact of a regular education programme.
- The main limitation of this study is the single blinded design, due to the nature of intervention itself, which may introduce some performance bias.

INTRODUCTION

Epidemiology

Asthma and COPD affect about 10% of the population, but many patients have uncontrolled symptoms [1]. In Asthma, in particular, it should be highlighted that only 57% of all patients were shown to have their symptoms controlled [2 3], and the elderly population is particularly vulnerable to this condition [3]. In fact, late onset asthma may be frequently misdiagnosed and mistreated, and the risk of drug interactions also requires close monitoring [4]. Hospitalisation rates due to Asthma and COPD are reported to reach 27% among non-adherent patients, and could be up to 53% in community treated cases, and this may be even more apparent in elderly patients. It should also be stressed that good adherence to inhaler treatment may, in contrast, be associated with a lower rate of severe exacerbations, with reductions observed in up to half of the cases [5-7].

Inhaler technique

Inhaled therapy is the most widely used way to treat asthma and COPD patients [8], but up to 90% of them do not use their inhalers correctly [9 10]. Performance errors have been described with almost every type of device, and over the past decades this problem has not improved, which highlights the need to better understand on the specificities of different inhaler use as well as the impact of different inhaler teaching methods [11]. Several inhaler devices are available on the market and it seems that differences either in device type or in patient characteristics may significantly influence performance [12]. However, all inhalers, when properly used, show no significant differences in terms of treatment efficacy [13 14], but it is well established that poor inhaler technique leads to poor clinical control [15 16] and also to an increased health costs [17]. In addition, some type of specific errors seem to have a higher impact on clinical control, but there is no consensus yet on which errors are critical and non-critical [18 19].

Patients in controlled trials receive more training in inhaler performance and more counselling on adherence than patients who are seen as part of routine clinical practice, but few studies have addressed these variables as separate outcomes [20]. Some studies show that teaching inhaler technique may lower the risk of exacerbations and death [6 21 22]. However, its impact is quickly lost as time elapses, suggesting this is a practice that should be rechecked and regularly applied to patients [23 24]. Nevertheless, how often the review should be carried out has not been established yet, since most studies have not addressed this issue in an isolated manner.

Significant evidence has shown that inhaler technique performance is regarded as particularly complex by older patients [25 26]. These patients also present lower adherence rates [9] and are more resistant to correct performance [27 28]. Furthermore, other major characteristics may influence inhaler use, such as educational level, previous teaching, or even age itself (i.e. age above 75 years) [29]. However, the significance of these observations still has to be fully ascertained since elderly patients are frequently excluded from major clinical trials. Randomised studies with elderly patients are scarce, and most of them did not address these aspects. Some of these studies have shown significant reductions in exacerbation risk with inhaler education programmes, but most of them addressed several aspects of intervention besides inhaler technique education itself, namely self-management plans, disease knowledge, management of exacerbations and their triggers. None has yet addressed inhaler review alone or in a regular education programme [21 30-33].

Inhaler technique may be taught using many tools, such as step-by-step flyer schemes, video demonstrations, videoconferencing and face-to-face demonstrations or even using web-based platforms, but there is insufficient evidence about which is the best education method to improve inhaler performance or its impact upon major outcomes [34-37]. Nevertheless, some studies including adult patients as well, suggest that the most efficient method seems to be using a teach-to-goal

1
2
3 approach with placebo device demonstration and training provided in person [38-42]. In addition,
4 manufacturers' recommendations often differ from clinical guidelines, which makes it difficult for
5 patients to fully understand all the necessary steps of inhaler use [43]. This highlights the importance
6 of watching patients using their inhalers, which can be achieved with a placebo device training set.
7 This study will focus upon elderly patients and aims at testing the effect of a structured and regular
8 placebo device training approach upon disease exacerbation rates.
9

10 11 12 **SPECIFIC AIMS AND HYPOTHESES**

13
14 Our objective is to test the impact of an inhaler technique education programme on the risk of
15 exacerbations in elderly patients with Asthma or COPD.

16 The main hypothesis is that regular education of inhaler technique using a placebo device-based
17 approach in elderly patients can reduce the exacerbation risk by 50% after a one-year follow-up.
18
19
20
21
22

23 **RESEARCH DESIGN AND METHODOLOGY**

24 25 **Study Design**

26 Two arms single blinded randomised controlled trial with a 1 year follow up (fig.1). Participants will
27 be allocated to each group on a random basis, which is defined by a computerised generator and is
28 independent of the control of the principal investigator. The allocation sequence of the 146
29 participants will be defined through a computer generator prior to the start of the study. After the
30 generation of this sequence, 146 envelopes will be created, numbered in the appropriate order, and will
31 contain the result of the allocation. The order of the envelopes' number will define the order of
32 participants' enrolment. The principal investigator will not be aware of the information contained
33 within the envelopes, thereby maintaining a minimisation randomisation process. To ensure the
34 accuracy of the use of the envelopes, the documents inside the envelope will be signed by the Data
35 Safety Monitoring Board and must be returned by the researchers after the allocation of the
36 participants.
37
38
39

40 **Sample size calculation**

41 Sample size was estimated using the *Chi square independent group proportions* approach of *STATA*
42 *Statistical Package*®, considering the event proportion in control group of 50% (0.5 annual rate) as
43 reported in other previous studies [21 22 44] and estimating a reduction of event rate in the
44 intervention group to 25% (0.25 annual rate) as reported in similar studies. A 95% confidence interval,
45 with β value (power) of 80%, an alpha level of 5% and a ratio of cases/controls of 1:1 were
46 established. Finally, the sample size was readjusted upward, considering an estimated proportion of
47 full compliance of the study of 80% (20% losses). The estimated sample size was 116, readjusted to a
48 total of 146 individuals (73 in each arm).
49
50
51

52 **Inclusion Criteria**

53 Patients with a diagnosis of COPD or Asthma, prescribed any kind of inhaler device (pressurised
54 Metered Dose Inhaler (pMDI) with or without Spacer, Dry Powder Inhaler (DPI) or Soft Mist), aged
55 ≥ 65 years and being a regular user of primary health care services (defined as having had at least one
56 appointment in the last two years with his/her own Family Doctor). In order to minimise diagnostic
57
58
59

1
2
3 inaccuracy, Asthma and COPD diagnosis will be reviewed in every participant at baseline prior to
4 enrolment and in accordance with GINA and GOLD strategies [45 46].
5

6 **Exclusion Criteria**

7 Severe or acute illness (such as unstable cardiovascular status, unstable angina, recent myocardial
8 infarction (within one month) or pulmonary embolism, haemoptysis of unknown origin, recent
9 pneumothorax (within one month), recent thoracic, abdominal or eye surgery (within one month),
10 acute nausea or vomiting, severe respiratory distress, dementia).
11

12 We will exclude patients who do not need inhaler medication on a daily basis, since these patients are
13 less susceptible to the full impact of the intervention. In addition, these are mostly patients with
14 intermittent asthma, as well as COPD patients with mild obstruction (GOLD stage I), and tend to have
15 a low frequency of disease exacerbations, which would hamper our ability to detect a true outcome
16 effect.
17

18 **Predictors/Intervention**

19 Intervention Group – This group will receive a structured and regular follow-up plan, with education
20 on inhaler technique. Patients will be trained by a Family Doctor (the primary investigator) in terms of
21 the inhaler technique using placebo devices similar to their own devices. We will start by evaluating
22 their baseline technique, and then, a teach-to-goal approach will be used, repeating all correct steps as
23 many times as needed in order for patients to perform them correctly. This will be performed at each
24 follow-up evaluation. There will be visits at baseline and after 3, 6 and 12 months to assess outcomes,
25 since there is dissenting evidence about the best timeline to achieve significant exacerbation risk
26 reductions [21 30 32]. In each visit, and prior to the main intervention with the primary investigator,
27 assessment of the inhaler technique and application of all questionnaires (clinical control, treatment
28 adherence and quality of life) will be performed by a secondary blinded investigator.
29

30 Control Group – This group will receive usual care from their own Family doctors, with no specific
31 intervention. Each doctor will perform the necessary clinical appointments according to his/her real
32 life judgment. Besides this, this group will have visits at baseline and after 3, 6 and 12 months to
33 assess secondary outcomes. At each visit, assessment of the inhaler technique and application of all
34 questionnaires (clinical control, treatment adherence and quality of life) will be performed by a
35 secondary blinded investigator. At any appointment, if the patient asks for or if the clinician decides to
36 teach inhaler technique, that will be recorded.
37

38 If any adjustments are made in drug classes or device types in any participant, this information will be
39 recorded.
40
41

42 **Outcomes of interest**

43 Primary Outcome: Adverse events (continuous, time to event).
44

45 For Asthma, an event will be defined as increased respiratory clinical symptoms leading the patient to
46 search for medical care, and resulting in any of the following:

- 47 • Need for increased inhaled corticosteroid dose of at least 4x the regular dose
- 48 • Need for increase of short-acting β_2 agonists on a daily basis
- 49 • Need for oral corticosteroids
- 50 • Need for oral antibiotics
- 51 • Hospitalisation or Emergency Room (ER) visit with increased respiratory clinical symptoms.

52 For COPD, an event will be defined as increased respiratory clinical symptoms prompting the patient
53 to search for medical care, and resulting in any of the following:

- 54 • Need for increase of long-acting β_2 agonists on a daily basis
- 55
56
57
58
59
60

- Need for oral corticosteroids
- Need for oral antibiotics
- Hospitalisation or ER visit with increased respiratory clinical symptoms.

Respiratory-related mortality and all-cause mortality will also be considered an adverse event.

All adverse events and mortality causes will be carefully analysed in order to assess their eligibility by two independent and external investigators, who will constitute a Data Safety Monitoring Board. This will be performed using different platforms of clinical records, from the ER of the regional reference hospital, from the Primary Health Care facilities (such as PEM© for prescribed drugs, SCLINICO© for clinical records and PDS© for ER records) and even by asking the participant for additional information. After any event, and if necessary for ethical reasons, inhaler technique and adherence improvement will be addressed by the primary investigator regardless of the participant allocation, and in accordance with the recommendation of the Data Safety Monitoring Board.

Secondary Outcomes:

- Clinical assessment using COPD Assessment Tools (CAT) and modified Medical Research Council (mMRC) for COPD; Control of Allergic Rhinitis and Asthma Test (CARAT) [47] and Asthma Control Test (ACT) for Asthma [48].
- Quality of Life using St. George's Respiratory Questionnaire [49] and Clinical COPD Questionnaire (CCQ) [50] for COPD and Asthma Quality of Life Questionnaire (AQLQ) [51].
- Functional control using Forced Expiratory Volume in 1st second (FEV₁), Forced Vital Capacity (FVC), Peak Expiratory Flow (PEF) and Maximum Expiratory Flows of 25-75% of FVC (MEF₂₅₋₇₅) as a % of predicted value; and FEV₁/FVC ratio.
- Adherence rate using the Brief Medication Questionnaire (this will also evaluate the frequency of using the devices) [52].
- Number of errors in inhaler technique (that will be standardised to a score up to 100% scale) [To evaluate inhaler technique performance with each device, the Aerosol Drug Management Improvement Team (ADMIT) protocols and guidelines will be used [53], evaluating all the recommended steps for inhaler use in each one of them (pMDI with or without chamber, Qvar Autohaler, Turbohaler, Diskus, Aerolizer, Handihaler, Breezhaler, Novolizer, Genuair, Twisthaler and Easyhaler). For those devices that do not have any protocol from the ADMIT group we will use the recommendations from the manufacture's Summary of Product Characteristics (Soft Mist Inhaler, Budesonide from *Farmoz*[®], Ellipta, Spiromax and Forspiro)].

All questionnaires will be used in validated Portuguese versions [47-52 54 55]. All participants will perform spirometry with bronchodilation test at baseline visit for diagnostic confirmation, as well as a baseline spirometry without bronchodilation for functional control at subsequent visits. A certified provider will perform spirometry.

Other variables collected at baseline

- Demographics (Body Mass Index, Age, Sex)
- Classification of clinical status, according to:
 - Exacerbation history.
 - Years of diagnosis.
 - Asthma classification/stage according to GINA guidelines (clinically as well controlled, partially controlled or uncontrolled; and therapeutically as in STEP 1, 2, 3, 4 or 5)[45]

- COPD stage according to 2017 GOLD guidelines (combined assessment stages A,B,C and D; and severity of airflow limitation GOLD 1, 2, 3 and 4)[46].
- Social class according to Graffar classification (Portuguese version)[56].
- Co-morbidities (such as concomitant allergic rhinitis, cancer, cardiac heart failure, alcohol or drug abuse, current smoking and smoking pack years, diabetes mellitus, previous stroke or acute myocardial infarction, thoracic, abdominal or cerebral aneurysms, severe osteoarthritis in hands and upper limbs).
- Depression using Geriatric Depression Scale in Portuguese[57].
- Frailty state in elderly, using a self-reported instrument in Portuguese [58].
- Cognitive function using Montreal Cognitive Assessment (MOCA)in Portuguese [59]
- Influenza and pneumococcal vaccination status
- Previous teaching of inhaler technique, specifying the education type (placebo device, video, leaflet, multimedia, etc.)..
- Years of use with current device.

The principal investigator will collect all baseline data prior to allocation and randomisation, and this will be recorded in a proper form.

Statistical Analysis

The hypothesis testing approach will be the following:

Null hypothesis: Teaching inhalation technique performance with a placebo device approach does not reduce the exacerbation risk in elderly patients with Asthma or COPD after a one-year follow-up.

Alternative hypothesis: Teaching inhaler technique performance with a placebo device approach reduces the exacerbation risk in elderly patients with Asthma or COPD after a one-year follow-up.

Dichotomous Predictor: Usual Care VS Regular teach-to-goal education with placebo device.

Dichotomous Outcome: Exacerbation Yes/No

Data will be analysed using the *STATA Statistical Package*® software.

Test statistic for primary outcome: Dichotomous data will be analysed with a two-sample proportions Chi-square test and a COX proportional hazard time-to-event analysis, and both arms will be compared using the measures of association: risk ratio; risk difference; hazard ratio and Number Needed to Treat (NNT) analyses.

Test statistic for secondary outcomes: Continuous data will be analysed using parametric tests, such as T test for comparison of mean values and dichotomous data will be analysed using Chi-square test. In order to test differences between groups in the mean values of continuous analysis, mixed effects models for repeated measures will be used. For binary outcomes, linear regression models with group-time interactions will also be adapted, and generalised linear models (such as Poisson regression) will be applied for exacerbations, as recommended in the literature [60]. As an alternative approach, generalised estimating equation models will be used to handle unmeasured dependence between outcomes.

In case of cohort losses above 20%, comparative analysis for intention to treat, per-protocol and a multidata imputation will be carried out. Missing data will be treated as missing completely at random. Subgroup analysis will be performed according to secondary variables, such as diagnosis, age (including stratification into the following categories: 65-75, 75-85, and >85 years), sex, years of diagnosis, disease classification/stage, comorbidities, educational level, previous teaching of inhaler technique, device type, as well as the specific types of detected errors (in order to identify the most critical ones). This will be performed using regression models to multivariate analyses.

1
2
3 An interim analysis will be performed midway through the follow-up, namely at 6 months, defining a
4 significance level adjusted by the Bonferroni technique of 0.025 [61].
5

6 **Study Setting**

7 The study will be conducted in a multicentre network that will include two or three primary care
8 centres, which will be coordinated by a team of experts in the field. All of them will be in urban or
9 suburban areas. A Portuguese primary care centre usually accounts approximately for more than
10 10,000 patients, and about 30% of them are aged above 65 years. Considering an approximate
11 prevalence of Asthma and COPD of 8% in this population, there is a potential target population of
12 almost 250 patients in each health care facility. Recruiting patients at more than one site will improve
13 the feasibility, reproducibility and credibility of the study, but will increase all the logistic issues.

14 All invited participants will have a first contact with the primary investigator to confirm the diagnosis
15 and all the eligibility criteria, and to carefully explain all the study procedures before their inclusion
16 and subsequent randomisation. Diagnosis will be confirmed according to state of the art and the
17 previously mentioned updated guidelines, and with spirometry. The number of patients screened and
18 deemed ineligible as well as the number of patients who are considered eligible but decline
19 participation will be also recorded.
20
21
22

23 **Timeline**

24 Study protocol final version: August 2017

25 Ethics consent and scientific academic authorisation: December 2017

26 Clinical administrative authorisations: first semester of 2018

27 Multicentre team gathering: first semester of 2018

28 Beginning of recruitment: second semester of 2018

29 End of recruitment: second semester of 2019

30 Data analysis and dissemination: during 2020
31
32

33 **Patient and Public Involvement**

34 No patient or public were involved in the design of this protocol, or in the establishment of the
35 intervention and the outcome measures. Results from all participants will be given to their own family
36 doctors in order to be used if deemed necessary to clinical practice.
37
38
39
40

41 **DISCUSSION**

42
43 This is the first study designed to test this specific intervention in inhaler performance in elderly
44 patients with a regular education programme, and it was designed to detect a significant reduction on
45 disease exacerbation rate. It is expected to detect approximately 55 adverse events, 18 in the
46 intervention group and 37 in the control group. In addition, it is expected to find a more significant
47 improvement in the intervention group, in all clinical and functional parameters during the follow-up.

48 This study has some limitations, mainly in selection bias due to the risk of missing data and follow-up
49 losses. To overcome this problem, different strategies will be applied, such as an increase in estimated
50 sample size, readjusted for an estimation of 20% losses; and sending a reminder prior to each visit
51 using SMS/Email/Call to contact the participant.
52

53 Another aspect that could bias our study is the Hawthorne effect throughout the study (ie. behaviour
54 change in participants due to their involvement in the study). However, we believe that by establishing
55 a cohort time of one year this effect will not be sustained. On the other hand, the control group (“usual
56
57
58

1
2
3 care”) will maintain their usual care at their own family doctors, who are completely free from any
4 influence of the study design. For this reason, the control group (“usual care”) participants will not
5 receive any intervention from the primary investigator. They will only contact with the secondary
6 investigator in order to collect endpoints and outcome data, and the latter is completely blinded to
7 randomisation. With this approach, the Hawthorne effect will not contaminate the control group, and
8 will represent a real life usual care. On the other hand, the Data Safety Monitoring Board will be
9 composed of two external investigators, who will, together with the statistician, be blinded to the
10 endpoints and outcomes (PROBE setting).

11
12 Another possible limitation of our study is that we will not use electronic measures of adherence and
13 inhalation techniques. These are a very useful approach to monitoring real world adherence to inhaler
14 therapy. In fact, these electronic measures overcome the bias seen with self-report and other problems
15 observed with objective medication checks such as prescription refill rates. However, most electronic
16 measures of adherence do not measure timing of device activation but rather the overall number of
17 activations performed, and, in addition, this measure does not mean that medication was taken on a
18 regular basis (patients may just activate the inhaler several times, prior to handing over the device). It
19 is not until recently that a new device has been studied, which seems to overcome this problem, and
20 which also analyses inhaler technique, but it is not widely available – INCA device[62]. Nevertheless,
21 these devices are expensive and their use could not be implemented in our study. We therefore decided
22 to use the adherence questionnaire (BMQ), which is a well-validated tool in several languages
23 worldwide, and also in Portuguese [52]. Furthermore, it is a very simple and easy method to detect
24 non-adherence, which also allows separating sub-domains of adherence. Thus, it is a good tool for
25 assessing adherence in our study involving the general population of asthma and COPD patients.
26 Regarding inhalation technique, we decided to use regular checklists, since they are the most widely
27 method used in other studies, thereby allowing further comparisons. They are also easy to use and
28 allow detection of critical errors in each device.

29
30
31 The standardisation of the protocol intervention is another issue to be considered. In order to overcome
32 different approaches among different investigators from different multicentre sites, a protocol with
33 detailed instructions will be created to guide them during the intervention (investigators) and
34 assessment visits (secondary investigators). This protocol will explain all the steps and procedures for
35 training inhaler technique as well as for assessing it, and all the procedures to follow in each visit for
36 assessing the outcomes.

37
38 Primary investigators will be trained in communication techniques related to inhaler education of
39 different devices and all of them will have a kit of placebo devices for use with participants. Such
40 training will allow the standardization of all procedures of intervention and it will be provided ahead
41 by the coordination team of the study.
42
43
44

45 **ETHICS AND DISSEMINATION**

46
47 The study protocol has already been analysed by the local Ethics Committee of University of Beira
48 Interior, with the reference number CE-UBI-Pj-2017-025, and was approved on 22th, November 2017.
49 Every participant will sign a written consent form (Appendix I). We decided to use “usual care” as the
50 main comparator instead of another intervention method, since all methods have shown some degree
51 of efficacy in clinically relevant outcomes, as previously mentioned. Using other education methods
52 would minimise the effect detection of our intervention. Moreover, all of the randomised studies
53 performed in elderly patients also used “usual care”, which will be important when comparing them
54 with our results.
55
56
57
58
59
60

1
2
3 A Data Safety Monitoring Board will be set up, composed of two external investigators with a board
4 expertise in this clinical field and in academic and scientific activities, to evaluate data obtained
5 throughout the study. Evaluations will occur every 6 months, whatever the number of participants
6 enrolled or the follow-up time reached at that point. The stop earlier criteria will be defined as any
7 moment on follow-up in which the collected data show statistically significant differences in the
8 primary outcomes. The study may be suspended earlier if sufficient data are obtained for at least 6
9 months of follow-up, or if significant evidence of intervention effectiveness is obtained, providing that
10 statistical significance values are met by the Bonferroni adaptation.

11 Invited participants who refuse to participate will be evaluated at baseline, according to previously
12 mentioned characteristics, in order to compare them with the included cohort. They will also be
13 invited to sign a written informed consent form that will allow investigators to collect such data. The
14 documents used to collect the data of the participants will contain only an identification code of each
15 participant, in order to protect their identity. The code of each participant must be composed of the
16 initials of the first two names, followed by the last two digits of the National Health Care Service
17 Number (eg. *Name FirstSurname SecondSurname*, 123456789 -----> code "NF89").

18
19 The number of participants considered ineligible will be recorded, as well as the number of eligible
20 participants who refuse to participate in the study.

21 The results obtained from this study will be published in peer-reviewed journals and presented at
22 scientific meetings of primary health care and respiratory fields. All data recorded during the study
23 will be stored for a period of 5 years, in accordance with the Portuguese Clinical Research Law, in a
24 safe and proper place in the primary investigator's health centre. After this period, all data that contain
25 participants' codes will be destroyed.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AUTHORS' CONTRIBUTIONS

All authors have equally contributed to the elaboration of this protocol in every stage of its design and writing. TM elaborated the first draft of the study, JCS and LTB gave inputs to all necessary design adjustments, and all authors have carried out final revisions of the manuscript.

COMPETING INTERESTS STATEMENT

Dr. Correia-de-Sousa reports competing interests from Harvard Medical School, during the conduct of the study, as scientific support. He also reports from Boheringer Ingelheim and from AstraZeneca outside the submitted work, and all these fees were received by a non-profit organisation to be used in CME and research.

The remaining authors declare only from Harvard Medical School, during the conduct of the study, as scientific support.

FUNDING

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

This work was developed without any funding support or financial source. The academic affiliation of this protocol is the Life and Health Sciences Research Institute (ICVS)/3B's at University of Minho and the Faculty of Health Sciences at the University of Beira Interior in Portugal.

This work was prepared with scientific support from Harvard Medical School, in accordance with the Portuguese Clinical Scholarship Research Training Program.

ACKNOWLEDGMENTS

The authors endorse acknowledgment to Prof. Jonh Groarke, from the Harvard Medical School, for his important scientific support and input in reviewing the final version of this manuscript.

DATA ACCESS

All data from the trial will be kept in a safe place of the principal investigator's institutional facilities and by the Data Safety Monitoring Board, in accordance with the national and international clinical research policies.

FIGURE LEGENDS

Figure 1 – Study design diagram.

REFERENCES

1. World Health Organization. The global burden of disease: 2004 update. Available from: <http://www.who.int>, 2008:160.
2. Sa-Sousa A, Morais-Almeida M, Azevedo LF, et al. Prevalence of asthma in Portugal - The Portuguese National Asthma Survey. *Clinical and translational allergy* 2012;**2**(1):15 doi: 10.1186/2045-7022-2-15[published Online First: Epub Date].
3. de Sousa JC, Santo ME, Colaço T, et al. Asthma in an Urban Population in Portugal: A prevalence study. *BMC Public Health* 2011;**11**:347-47 doi: 10.1186/1471-2458-11-347[published Online First: Epub Date].
4. Reddel H, Battersman E, Becker A, et al. Global Strategy for Asthma Management and Prevention. Available from: <http://www.ginasthma.org>: Global initiative for asthma, 2015 update:149.
5. van Boven JF, Tommelein E, Boussery K, et al. Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. *Respiratory research* 2014;**15**:66 doi: 10.1186/1465-9921-15-66[published Online First: Epub Date].
6. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. *Thorax* 2009;**64**(11):939-43 doi: 10.1136/thx.2009.113662[published Online First: Epub Date].
7. Engelkes M, Janssens HM, de Jongste JC, et al. Medication adherence and the risk of severe asthma exacerbations: a systematic review. *The European respiratory journal* 2015;**45**(2):396-407 doi: 10.1183/09031936.00075614[published Online First: Epub Date].
8. Rees J. Methods of delivering drugs. *BMJ : British Medical Journal* 2005;**331**(7515):504-06
9. Cochrane MG, Bala MV, Downs KE, et al. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. *Chest* 2000;**117**(2):542-50
10. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. *Respiratory medicine* 2008;**102**(4):593-604 doi: 10.1016/j.rmed.2007.11.003[published Online First: Epub Date].
11. Sanchis J, Gich I, Pedersen S. Systematic Review of Errors in Inhaler Use. *Chest* 2016;**150**(2):394-406 doi: 10.1016/j.chest.2016.03.041[published Online First: Epub Date].
12. Broeders ME, Molema J, Hop WC, et al. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. *Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine* 2003;**16**(2):131-41 doi: 10.1089/089426803321919898[published Online First: Epub Date].
13. Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. *Health technology assessment (Winchester, England)* 2001;**5**(26):1-149
14. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest* 2005;**127**(1):335-71 doi: 10.1378/chest.127.1.335[published Online First: Epub Date].
15. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. *The European respiratory journal* 2002;**19**(2):246-51
16. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. *Respiratory medicine* 2011;**105**(6):930-8 doi: 10.1016/j.rmed.2011.01.005[published Online First: Epub Date].
17. Roggeri A, Micheletto C, Roggeri DP. Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues. *International journal of chronic obstructive pulmonary disease* 2016;**11**:597-602 doi: 10.2147/copd.s103335[published Online First: Epub Date].
18. Price DB, Román-Rodríguez M, McQueen RB, et al. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. *The Journal of Allergy and Clinical Immunology: In Practice* 2017 doi: <http://dx.doi.org/10.1016/j.jaip.2017.01.004>[published Online First: Epub Date].

19. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. *Respiratory research* 2018;**19**(1):10 doi: 10.1186/s12931-017-0710-y[published Online First: Epub Date].
20. Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. *The European respiratory journal* 2011;**37**(6):1308-31 doi: 10.1183/09031936.00166410[published Online First: Epub Date].
21. Tommelein E, Mehuys E, Van Hees T, et al. Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. *British journal of clinical pharmacology* 2014;**77**(5):756-66 doi: 10.1111/bcp.12242[published Online First: Epub Date].
22. Takemura M, Mitsui K, Ido M, et al. Effect of a network system for providing proper inhalation technique by community pharmacists on clinical outcomes in COPD patients. *International journal of chronic obstructive pulmonary disease* 2013;**8**:239-44 doi: 10.2147/copd.s44022[published Online First: Epub Date].
23. Broeders ME, Sanchis J, Levy ML, et al. The ADMIT series--issues in inhalation therapy. 2. Improving technique and clinical effectiveness. *Primary care respiratory journal : journal of the General Practice Airways Group* 2009;**18**(2):76-82 doi: 10.4104/pcrj.2009.00025[published Online First: Epub Date].
24. Crompton GK, Barnes PJ, Broeders M, et al. The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. *Respiratory medicine* 2006;**100**(9):1479-94 doi: 10.1016/j.rmed.2006.01.008[published Online First: Epub Date].
25. Allen SC, Jain M, Ragab S, et al. Acquisition and short-term retention of inhaler techniques require intact executive function in elderly subjects. *Age and ageing* 2003;**32**(3):299-302
26. Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. *American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists* 2011;**68**(13):1221-32 doi: 10.2146/ajhp100452[published Online First: Epub Date].
27. Quinet P, Young CA, Heritier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. *Annals of physical and rehabilitation medicine* 2010;**53**(2):69-76 doi: 10.1016/j.j.rehab.2009.11.001[published Online First: Epub Date].
28. Allen SC, Warwick-Sanders M, Baxter M. A comparison of four tests of cognition as predictors of inability to learn to use a metered dose inhaler in old age. *Int J Clin Pract* 2009;**63**(8):1150-3 doi: 10.1111/j.1742-1241.2009.02060.x[published Online First: Epub Date].
29. Blasi F, Canonica GW, Centanni S, et al. Genuair(R) Usability Test: Results of a National Public Survey of the Elderly. *Copd* 2016;**13**(3):367-71 doi: 10.3109/15412555.2015.1067675[published Online First: Epub Date].
30. Rootmensen GN, van Keimpema AR, Looyen EE, et al. The effects of additional care by a pulmonary nurse for asthma and COPD patients at a respiratory outpatient clinic: results from a double blind, randomized clinical trial. *Patient education and counseling* 2008;**70**(2):179-86 doi: 10.1016/j.pec.2007.09.021[published Online First: Epub Date].
31. Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. *Arch Intern Med* 2003;**163**(5):585-91
32. Khmour MR, Kidney JC, Smyth BM, et al. Clinical pharmacy-led disease and medicine management programme for patients with COPD. *British journal of clinical pharmacology* 2009;**68**(4):588-98 doi: 10.1111/j.1365-2125.2009.03493.x[published Online First: Epub Date].
33. Strayhorn-Smith V, Tolley E, Demirkan K, et al. Metered dose inhaler - spacer technique in hospitalized geriatric patients: Effect of patient education by a pharmacist. *Hosp Pharm* 2000;**35**:162-64
34. Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for people with asthma. *The Cochrane database of systematic reviews* 2017;**3**:CD012286 doi: 10.1002/14651858.CD012286.pub2[published Online First: Epub Date].
35. Thomas RM, Locke ER, Woo DM, et al. Inhaler Training Delivered by Internet-Based Home Videoconferencing Improves Technique and Quality of Life. *Respiratory care* 2017;**62**(11):1412

36. Press VG, Kelly CA, Kim JJ, et al. Virtual Teach-To-Goal; Adaptive Learning of Inhaler Technique for Inpatients with Asthma or COPD. *The Journal of Allergy and Clinical Immunology: In Practice* 2017;**5**(4):1032-39.e1 doi: 10.1016/j.jaip.2016.11.018[published Online First: Epub Date].
37. Wu M, Woodrick NM, Arora VM, et al. Developing a Virtual Teach-To-Goal Inhaler Technique Learning Module: A Mixed Methods Approach. *The Journal of Allergy and Clinical Immunology: In Practice* 2017;**5**(6):1728-36 doi: 10.1016/j.jaip.2017.04.032[published Online First: Epub Date].
38. Bosnic-Anticevich SZ, Sinha H, So S, et al. Metered-dose inhaler technique: the effect of two educational interventions delivered in community pharmacy over time. *The Journal of asthma : official journal of the Association for the Care of Asthma* 2010;**47**(3):251-6 doi: 10.3109/02770900903580843[published Online First: Epub Date].
39. Crane MA, Jenkins CR, Goeman DP, et al. Inhaler device technique can be improved in older adults through tailored education: findings from a randomised controlled trial. *NPJ primary care respiratory medicine* 2014;**24**:14034 doi: 10.1038/npjpcrm.2014.34[published Online First: Epub Date].
40. Lavorini F, Levy ML, Corrigan C, et al. The ADMIT series - issues in inhalation therapy. 6) Training tools for inhalation devices. *Primary care respiratory journal : journal of the General Practice Airways Group* 2010;**19**(4):335-41 doi: 10.4104/pcrj.2010.00065[published Online First: Epub Date].
41. Press VG, Arora VM, Shah LM, et al. Misuse of respiratory inhalers in hospitalized patients with asthma or COPD. *Journal of general internal medicine* 2011;**26**(6):635-42 doi: 10.1007/s11606-010-1624-2[published Online First: Epub Date].
42. Paasche-Orlow MK, Riekert KA, Bilderback A, et al. Tailored Education May Reduce Health Literacy Disparities in Asthma Self-Management. *American Journal of Respiratory and Critical Care Medicine* 2005;**172**(8):980-86 doi: 10.1164/rccm.200409-1291OC[published Online First: Epub Date].
43. Self TH, Hoth LM, Bolin JM, et al. Metered-dose inhaler technique per the Global Initiative for Asthma and Expert Panel Report 3. *Annals of Allergy, Asthma & Immunology* 2016;**117**(1):101-02 doi: 10.1016/j.anai.2016.05.002[published Online First: Epub Date].
44. Goris S, Tasci S, Elmali F. The effects of training on inhaler technique and quality of life in patients with COPD. *Journal of aerosol medicine and pulmonary drug delivery* 2013;**26**(6):336-44 doi: 10.1089/jamp.2012.1017[published Online First: Epub Date].
45. GINA. Pocket Guide for Asthma Management and Prevention. Available in: <http://ginasthma.org>, Updated 2015:32.
46. GOLD. Pocket Guide to COPD Diagnosis, Management, and Prevention - A Guide for Health Care Professionals. Available in: <http://www.goldcopd.org>, 2017 report:42.
47. Fonseca JA, Nogueira-Silva L, Morais-Almeida M, et al. Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthma. *Allergy* 2010;**65**(8):1042-8 doi: 10.1111/j.1398-9995.2009.02310.x[published Online First: Epub Date].
48. Roxo JP, Ponte EV, Ramos DC, et al. [Portuguese-language version of the Asthma Control Test]. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisiologia* 2010;**36**(2):159-66
49. Camelier A, Rosa FW, Salim C, et al. Using the Saint George's Respiratory Questionnaire to evaluate quality of life in patients with chronic obstructive pulmonary disease: validating a new version for use in Brazil. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisiologia* 2006;**32**(2):114-22
50. Faria da Silva LS. Validação do Questionário Clínico para a Doença Pulmonar Obstrutiva Crônica (CCQ) para a Língua Portuguesa [Master Thesis]. Escola Superior de Enfermagem do Porto, 2012.
51. Ferreira J, Silveira P, Figueiredo MM, et al. Validation of the Portuguese version of the Asthma Quality of Life Questionnaire [AQLQ-M] by Marks. *Revista portuguesa de pneumologia* 2005;**11**(4):351-66
52. Ben AJ, Neumann CR, Mengue SS. The Brief Medication Questionnaire and Morisky-Green test to evaluate medication adherence. *Revista de saude publica* 2012;**46**(2):279-89

- 1
2
3 53. (ADMIT) TADMIT. Inhalation Protocols. Secondary Inhalation Protocols 2017.
- 4 54. Silva GP, Morano MT, Viana CM, et al. Portuguese-language version of the COPD Assessment
5 Test: validation for use in Brazil. *Jornal brasileiro de pneumologia : publicacao oficial da*
6 *Sociedade Brasileira de Pneumologia e Tisiologia* 2013;**39**(4):402-8 doi: 10.1590/s1806-
7 37132013000400002[published Online First: Epub Date]].
- 8 55. Kovelis D, Segretti NO, Probst VS, et al. Validation of the Modified Pulmonary Functional Status
9 and Dyspnea Questionnaire and the Medical Research Council scale for use in Brazilian patients
10 with chronic obstructive pulmonary disease. *Jornal brasileiro de pneumologia : publicacao oficial*
11 *da Sociedade Brasileira de Pneumologia e Tisiologia* 2008;**34**(12):1008-18
- 12 56. Amaro F. Escala de Graffar, 1990.
- 13 57. Apóstolo JLA, Loureiro LMdJ, Reis IACd, et al. Contribuição para a adaptação da Geriatric
14 Depression Scale -15 para a língua portuguesa. *Revista de Enfermagem Referência* 2014;**serIV**:65-
15 73
- 16 58. Nunes DP, Duarte YAdO, Santos JLF, et al. Screening for frailty in older adults using a self-
17 reported instrument. *Revista de saude publica* 2015;**49**:2 doi: 10.1590/S0034-
18 8910.2015049005516[published Online First: Epub Date]].
- 19 59. Freitas Sandra SMR, Martins Cristina, Vilar Manuela, Santana Isabel. . Estudos de adaptação do
20 Montreal Cognitive Assessment (MoCA) para a população portuguesa. *Aval. psicol.* [online].
21 2010;**9**(3):345-57
- 22 60. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive
23 pulmonary disease. *Am J Respir Crit Care Med* 2006;**173**(8):842-6 doi: 10.1164/rccm.200508-
24 1338PP[published Online First: Epub Date]].
- 25 61. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. *BMJ*
26 1995;**310**(6973):170 doi: 10.1136/bmj.310.6973.170[published Online First: Epub Date]].
- 27 62. Moran C, Doyle F, Sulaiman I, et al. The INCA(TM) (Inhaler Compliance Assessment(TM)): A
28 comparison with established measures of adherence. *Psychology & health* 2017;**32**(10):1266-87
29 doi: 10.1080/08870446.2017.1290243[published Online First: Epub Date]].
- 30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 - Study Design Diagram

APPENDIX I - Informed consent form, according to Portuguese Directorate-General of Health.

Consentimento Informado nos termos da Norma nº 015/2013 da DGS

Estudo “Ensino da técnica inalatória em idosos com Asma e DPOC: impacto nas exacerbações”

A sua unidade de saúde convida-o a participar no estudo “Ensino da técnica inalatória em idosos com Asma e DPOC: impacto nas exacerbações”. Foi convidado para participar neste estudo porque se trata de um doente com uma doença respiratória crónica (como Asma ou DPOC) e está a ser medicado com um dispositivo inalatório diariamente.

Os objetivos deste estudo são:

- Verificar se utiliza corretamente o seu dispositivo inalatório
- Testar se o ensino regular do uso do inalador melhora o controlo da sua doença.
- Testar se o mesmo ensino regular diminui a probabilidade de ter alguma crise de agudização/exacerbação pela sua doença, e que pode ser potencialmente fatal.

Para verificar estes objetivos iremos dividir, de forma aleatória, os utentes convidados a participar em dois grupos diferentes. Ambos os grupos irão ser avaliados regularmente sobre o controlo da sua doença, quer quando aos sintomas, qualidade de vida e quanto à sua capacidade pulmonar/respiratória. Isto será feito através da aplicação de questionários bem como da realização de um exame complementar simples e não invasivo, a espirometria.

A principal diferença entre os dois grupos, é que, um deles irá receber adicionalmente de um investigador, um ensino e treino regular sobre o uso correto dos dispositivos inalatórios, enquanto o outro grupo irá apenas receber os cuidados médicos regulares que necessitar pelo seu próprio Medico de Família.

A sua participação no estudo irá durar 12 meses. Ao aceitar participar neste estudo, será sorteado para um dos dois grupos, e após isso irá ser avaliado nesta Unidade de Saúde passados 3, 6 e 12 meses pelos investigadores. Não irá saber em nenhum momento (nem o seu Medico de Família) a qual dos grupos pertence, pois, o objetivo do estudo é não influenciar a forma como os dois grupos se comportam. Todas as consultas realizadas no âmbito deste estudo serão gratuitas para si, bem como a realização das avaliações pelos investigadores.

O estudo será coordenado pelo Dr. Tiago Maricoto, da USF Aveiro-Aradas, que é o investigador principal. A sua participação no estudo é voluntária. Poderá decidir não participar no estudo a qualquer momento sem prejuízo dos seus cuidados médicos. Todos os dados recolhidos neste estudo permanecerão confidenciais. O seu Medico de Família terá acesso no final do estudo aos resultados dos seus exames e avaliações.

O potencial benefício para a sua Saúde ao participar neste estudo é melhorar o controlo clínico da sua doença respiratória, melhorar a capacidade respiratória dos seus pulmões e diminuir o risco de crises de agudização graves e potencialmente fatais. Não existem riscos significativos para a sua saúde. Ao não participar neste estudo perde ainda a oportunidade de poder melhorar a forma como usa os seus dispositivos inalatórios, o que pode comprometer o bom controlo da sua doença a longo prazo.

[Parte declarativa do profissional]

Confirmo que expliquei à pessoa abaixo indicada, de forma adequada e inteligível, os procedimentos necessários ao ato referido neste documento. Respondi a todas as questões que me foram colocadas e assegurei-me de que houve um período de reflexão suficiente para a tomada da decisão. Também garanti que, em caso de recusa, serão assegurados os melhores cuidados possíveis nesse contexto, no respeito pelos seus direitos.

Nome legível do profissional de saúde: _____

Assinatura, nº de cédula profissional/mecanográfico:

Unidade de Saúde: _____

Contato institucional do profissional de saúde: _____

À Pessoa/representante

Por favor, leia com atenção todo o conteúdo deste documento. Não hesite em solicitar mais informações se não estiver completamente esclarecido/a. Verifique se todas as informações estão corretas. Se tudo estiver conforme, então assine este documento.

[Parte declarativa da pessoa que consente]

*Declaro ter compreendido os objetivos de quanto me foi proposto e explicado pelo profissional de saúde que assina este documento, ter-me sido dada oportunidade de fazer todas as perguntas sobre o assunto e para todas elas ter obtido resposta esclarecedora, ter-me sido garantido que não haverá prejuízo para os meus direitos assistenciais se eu recusar esta solicitação, e ter-me sido dado tempo suficiente para refletir sobre esta proposta. Autorizo/Não autorizo (**riscar o que não interessa**) o ato indicado, bem como os procedimentos diretamente relacionados que sejam necessários no meu próprio interesse e justificados por razões clínicas fundamentadas.*

NOME: _____

Assinatura /...../..... (data)

SE NÃO FOR O PRÓPRIO A ASSINAR POR IDADE OU INCAPACIDADE

(se o menor tiver discernimento deve também assinar em cima)

NOME:

DOC. IDENTIFICAÇÃO N.º DATA OU VALIDADE /..... /.....

GRAU DE PARENTESCO OU TIPO DE REPRESENTAÇÃO:

ASSINATURA.....

O presente documento é emitido em duplicado, ficando um na posse do participante, e outro arquivado pelos investigadores em local próprio

Reporting checklist for protocol of a clinical trial (SPIRIT).

Instructions to authors

Upload this checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	#3	Date and version identifier	1
Funding	#4	Sources and types of financial, material, and other support	12
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	12
Roles and responsibilities: sponsor contact information	#5b	Name and contact information for the trial sponsor	NA
Roles and responsibilities: sponsor and funder	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have	NA

ultimate authority over any of these activities

1				
2				
3	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	10
4	responsibilities:		centre, steering committee, endpoint adjudication	
5	committees		committee, data management team, and other individuals or	
6			groups overseeing the trial, if applicable (see Item 21a for	
7			data monitoring committee)	
8				
9				
10				
11	Background and	#6a	Description of research question and justification for	4
12	rationale		undertaking the trial, including summary of relevant studies	
13			(published and unpublished) examining benefits and harms	
14			for each intervention	
15				
16				
17	Background and	#6b	Explanation for choice of comparators	4
18	rationale: choice of			
19	comparators			
20				
21				
22				
23	Objectives	#7	Specific objectives or hypotheses	5
24				
25	Trial design	#8	Description of trial design including type of trial (eg, parallel	5
26			group, crossover, factorial, single group), allocation ratio,	
27			and framework (eg, superiority, equivalence, non-inferiority,	
28			exploratory)	
29				
30				
31				
32	Study setting	#9	Description of study settings (eg, community clinic,	8
33			academic hospital) and list of countries where data will be	
34			collected. Reference to where list of study sites can be	
35			obtained	
36				
37				
38				
39	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	5
40			eligibility criteria for study centres and individuals who will	
41			perform the interventions (eg, surgeons, psychotherapists)	
42				
43				
44	Interventions:	#11a	Interventions for each group with sufficient detail to allow	6
45	description		replication, including how and when they will be	
46			administered	
47				
48				
49	Interventions:	#11b	Criteria for discontinuing or modifying allocated	6
50	modifications		interventions for a given trial participant (eg, drug dose	
51			change in response to harms, participant request, or	
52			improving / worsening disease)	
53				
54				
55				
56	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	9
57	adherence		and any procedures for monitoring adherence (eg, drug	
58				
59				
60				

tablet return; laboratory tests)

1				
2				
3	Interventions:	#11d	Relevant concomitant care and interventions that are	6
4	concomitant care		permitted or prohibited during the trial	
5				
6	Outcomes	#12	Primary, secondary, and other outcomes, including the	6
7			specific measurement variable (eg, systolic blood pressure),	
8			analysis metric (eg, change from baseline, final value, time	
9			to event), method of aggregation (eg, median, proportion),	
10			and time point for each outcome. Explanation of the clinical	
11			relevance of chosen efficacy and harm outcomes is strongly	
12			recommended	
13				
14				
15				
16				
17	Participant timeline	#13	Time schedule of enrolment, interventions (including any	6
18			run-ins and washouts), assessments, and visits for	
19			participants. A schematic diagram is highly recommended	
20			(see Figure)	
21				
22				
23				
24	Sample size	#14	Estimated number of participants needed to achieve study	5
25			objectives and how it was determined, including clinical and	
26			statistical assumptions supporting any sample size	
27			calculations	
28				
29				
30				
31	Recruitment	#15	Strategies for achieving adequate participant enrolment to	5,9
32			reach target sample size	
33				
34				
35	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	5,8
36	generation		computer-generated random numbers), and list of any	
37			factors for stratification. To reduce predictability of a random	
38			sequence, details of any planned restriction (eg, blocking)	
39			should be provided in a separate document that is	
40			unavailable to those who enrol participants or assign	
41			interventions	
42				
43				
44				
45				
46	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	5,8
47	concealment		central telephone; sequentially numbered, opaque, sealed	
48	mechanism		envelopes), describing any steps to conceal the sequence	
49			until interventions are assigned	
50				
51				
52				
53	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	5,8
54	implementation		participants, and who will assign participants to	
55			interventions	
56				
57				
58	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	6,9
59				
60				

1			trial participants, care providers, outcome assessors, data	
2			analysts), and how	
3				
4	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	6,9
5	emergency		permissible, and procedure for revealing a participant's	
6	unblinding		allocated intervention during the trial	
7				
8				
9	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	7,8
10			and other trial data, including any related processes to	
11			promote data quality (eg, duplicate measurements, training	
12			of assessors) and a description of study instruments (eg,	
13			questionnaires, laboratory tests) along with their reliability	
14			and validity, if known. Reference to where data collection	
15			forms can be found, if not in the protocol	
16				
17				
18				
19				
20	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	7,8
21	retention		up, including list of any outcome data to be collected for	
22			participants who discontinue or deviate from intervention	
23			protocols	
24				
25				
26				
27	Data management	#19	Plans for data entry, coding, security, and storage, including	7,8
28			any related processes to promote data quality (eg, double	
29			data entry; range checks for data values). Reference to	
30			where details of data management procedures can be	
31			found, if not in the protocol	
32				
33				
34				
35				
36	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	8
37			outcomes. Reference to where other details of the statistical	
38			analysis plan can be found, if not in the protocol	
39				
40				
41	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	8
42	analyses		adjusted analyses)	
43				
44				
45	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	8
46	population and		adherence (eg, as randomised analysis), and any statistical	
47	missing data		methods to handle missing data (eg, multiple imputation)	
48				
49				
50	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	10
51	formal committee		of its role and reporting structure; statement of whether it is	
52			independent from the sponsor and competing interests; and	
53			reference to where further details about its charter can be	
54			found, if not in the protocol. Alternatively, an explanation of	
55			why a DMC is not needed	
56				
57				
58				
59				
60				

1	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	10
2	interim analysis		including who will have access to these interim results and	
3			make the final decision to terminate the trial	
4				
5				
6	Harms	#22	Plans for collecting, assessing, reporting, and managing	10
7			solicited and spontaneously reported adverse events and	
8			other unintended effects of trial interventions or trial conduct	
9				
10				
11	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	10
12			and whether the process will be independent from	
13			investigators and the sponsor	
14				
15				
16				
17	Research ethics	#24	Plans for seeking research ethics committee / institutional	10
18	approval		review board (REC / IRB) approval	
19				
20				
21	Protocol	#25	Plans for communicating important protocol modifications	10
22	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
23			relevant parties (eg, investigators, REC / IRBs, trial	
24			participants, trial registries, journals, regulators)	
25				
26				
27	Consent or assent	#26a	Who will obtain informed consent or assent from potential	10
28			trial participants or authorised surrogates, and how (see	
29			Item 32)	
30				
31				
32				
33	Consent or assent:	#26b	Additional consent provisions for collection and use of	10
34	ancillary studies		participant data and biological specimens in ancillary	
35			studies, if applicable	
36				
37				
38	Confidentiality	#27	How personal information about potential and enrolled	10
39			participants will be collected, shared, and maintained in	
40			order to protect confidentiality before, during, and after the	
41			trial	
42				
43				
44				
45	Declaration of	#28	Financial and other competing interests for principal	12
46	interests		investigators for the overall trial and each study site	
47				
48				
49	Data access	#29	Statement of who will have access to the final trial dataset,	12
50			and disclosure of contractual agreements that limit such	
51			access for investigators	
52				
53				
54	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for	12
55	trial care		compensation to those who suffer harm from trial	
56			participation	
57				
58				
59				
60				

1	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	10,11
2	trial results		results to participants, healthcare professionals, the public,	
3			and other relevant groups (eg, via publication, reporting in	
4			results databases, or other data sharing arrangements),	
5			including any publication restrictions	
6				
7				
8				
9	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use of	10,11
10	authorship		professional writers	
11				
12				
13	Dissemination policy:	#31c	Plans, if any, for granting public access to the full protocol,	10,11
14	reproducible		participant-level dataset, and statistical code	
15	research			
16				
17				
18	Informed consent	#32	Model consent form and other related documentation given	Apx.
19	materials		to participants and authorised surrogates	
20				
21				
22	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of	NA
23			biological specimens for genetic or molecular analysis in the	
24			current trial and for future use in ancillary studies, if	
25			applicable	
26				
27				
28				

29 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 30 BY-ND 3.0. This checklist was completed on 05. February 2018 using <http://www.goodreports.org/>, a
 31 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Inhaler technique education in elderly patients with Asthma or COPD: impact on disease exacerbations – a protocol for a single-blinded randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022685.R3
Article Type:	Protocol
Date Submitted by the Author:	03-Sep-2018
Complete List of Authors:	Maricoto, Tiago; Aveiro-Aradas Family Health Unit, ACeS Baixo Vouga; Faculty of Health Sciences, University of Beira Interior Correia-de-Sousa, Jaime; Life and Health Sciences Research Institute (ICVS)/3B's – PT Government Associate Laboratory, University of Minho; Horizonte Family Health Unit, Taborda-Barata, Luís; CICS - Health Sciences Research Centre; NuESA – Environment & Health Study Group, Faculty of Health Sciences, University of Beira Interior; Department of Allergy & Clinical Immunology, Cova da Beira University Hospital Centre
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	General practice / Family practice
Keywords:	Chronic Obstructive Pulmonary Disease, Asthma < THORACIC MEDICINE, Nebulizers and Vaporizers

SCHOLARONE™
Manuscripts

Inhaler technique education in elderly patients with Asthma or COPD: impact on disease exacerbations – a protocol for a single-blinded randomised controlled trial

AUTHORS

Tiago Maricoto^{1,2}; Jaime Correia-de-Sousa^{3,4}; Luís Taborda-Barata^{5,6}

(1) Aveiro-Aradas Family Health Unit; Aveiro Health Centre; Portugal

(2) Faculty of Health Sciences; University of Beira Interior, Covilhã, Portugal

(3) Life and Health Sciences Research Institute (ICVS)/3B's — PT Government Associate Laboratory, University of Minho, Braga, Portugal

(4) Horizonte Family Health Unit, Matosinhos, Portugal.

(5) CICS - Health Sciences Research Centre & NuESA – Environment & Health Study Group, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal

(6) Department of Allergy & Clinical Immunology, Cova da Beira University Hospital Centre, Covilhã, Portugal

CORRESPONDING AUTHOR

- Tiago Maricoto, MD
Family Doctor
USF Aveiro-Aradas; Praceta Rainha D. Leonor; 3800; Aveiro; Portugal
Tel: +351 234 891 213
PhD Student; Faculty of Health Sciences; University of Beira Interior
tiago.maricoto@gmail.com

WORD COUNT

3186 words

PROTOCOL VERSION

This is the second version of this RCT protocol.

ABSTRACT

Introduction

COPD and Asthma affect more than 10% of the population. Most patients use their inhaler incorrectly, mainly the elderly, thereby becoming more susceptible to poor clinical control and exacerbations. Placebo device training is regarded as one of the best teaching methods, but there is scarce evidence to support it as the most effective one to improve major clinical outcomes. Our objective is to perform a single-blinded RCT to assess the impact of this education tool in these patients.

Methods and Analysis

A multicentre single-blinded RCT will be set up, comparing an inhaler education programme with a teach-to-goal placebo-device training versus usual care, with a one-year follow-up, in patients above 65 years of age with Asthma or COPD. Intervention will be provided at baseline, and after 3 and 6 months, with interim analysis at an intermediate time point. Exacerbation rates were set as primary outcomes, and quality of life, adherence rates, clinical control and respiratory function were chosen as secondary outcomes. A sample size of 146 participants (73 in each arm) was estimated as adequate to detect a 50% reduction in event rates. Two-sample proportions Chi-squared test will be used to study primary outcome and subgroup analysis will be carried out according to major baseline characteristics.

Ethics and dissemination:

Every participant will sign a written consent form. A Data Safety Monitoring Board will be set up to evaluate data throughout the study and to monitor early stopping criteria. Identity of all participants will be protected. This protocol was approved on the 22th November 2017 by the local Ethics Committee of University of Beira Interior, with the reference number CE-UBI-Pj-2017-025. Results will be presented in scientific meeting and published in peer-reviewed journals.

KEYWORDS

Chronic Obstructive Pulmonary Disease; Asthma; Nebulizers and Vaporizers

REGISTRY

This RCT protocol is registered in clinicaltrials.gov, with the number NCT03449316.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This is the first study to address a specific placebo device education programme alone, without any other aspects, in elderly patients with Asthma or COPD.
- No previous study has addressed this teaching method in these patients, as it seems to be the most efficient one.
- Our study has a randomised design, which has been a major limitation in previous studies.
- The one-year follow up period, with two interim evaluations, allow this study to comprehensively address the real impact of a regular education programme.
- The main limitation of this study is the single blinded design, due to the nature of intervention itself, which may introduce some performance bias.

INTRODUCTION

Epidemiology

Asthma and COPD affect about 10% of the population, but many patients have uncontrolled symptoms [1]. In Asthma, in particular, it should be highlighted that only 57% of all patients were shown to have their symptoms controlled [2 3], and the elderly population is particularly vulnerable to this condition [3]. In fact, late onset asthma may be frequently misdiagnosed and mistreated, and the risk of drug interactions also requires close monitoring [4]. Hospitalisation rates due to Asthma and COPD are reported to reach 27% among non-adherent patients, and could be up to 53% in community treated cases, and this may be even more apparent in elderly patients. It should also be stressed that good adherence to inhaler treatment may, in contrast, be associated with a lower rate of severe exacerbations, with reductions observed in up to half of the cases [5-7].

Inhaler technique

Inhaled therapy is the most widely used way to treat asthma and COPD patients [8], but up to 90% of them do not use their inhalers correctly [9 10]. Performance errors have been described with almost every type of device, and over the past decades this problem has not improved, which highlights the need to better understand on the specificities of different inhaler use as well as the impact of different inhaler teaching methods [11]. Several inhaler devices are available on the market and it seems that differences either in device type or in patient characteristics may significantly influence performance [12]. However, all inhalers, when properly used, show no significant differences in terms of treatment efficacy [13 14], but it is well established that poor inhaler technique leads to poor clinical control [15 16] and also to an increased health costs [17]. In addition, some type of specific errors seem to have a higher impact on clinical control, but there is no consensus yet on which errors are critical and non-critical [18 19].

Patients in controlled trials receive more training in inhaler performance and more counselling on adherence than patients who are seen as part of routine clinical practice, but few studies have addressed these variables as separate outcomes [20]. Some studies show that teaching inhaler technique may lower the risk of exacerbations and death [6 21 22]. However, its impact is quickly lost as time elapses, suggesting this is a practice that should be rechecked and regularly applied to patients [23 24]. Nevertheless, how often the review should be carried out has not been established yet, since most studies have not addressed this issue in an isolated manner.

Significant evidence has shown that inhaler technique performance is regarded as particularly complex by older patients [25 26]. These patients also present lower adherence rates [9] and are more resistant to correct performance [27 28]. Furthermore, other major characteristics may influence inhaler use, such as educational level, previous teaching, or even age itself (i.e. age above 75 years) [29]. However, the significance of these observations still has to be fully ascertained since elderly patients are frequently excluded from major clinical trials. Randomised studies with elderly patients are scarce, and most of them did not address these aspects. Some of these studies have shown significant reductions in exacerbation risk, but most of them addressed several aspects of intervention besides inhaler technique education itself, namely self-management plans, disease knowledge, management of exacerbations and their triggers. None has yet addressed inhaler review alone or in a regular education programme [21 30-33].

Inhaler technique may be taught using many tools, such as step-by-step flyer schemes, video demonstrations, videoconferencing and face-to-face demonstrations or even using web-based platforms, but there is insufficient evidence about which is the best education method to improve inhaler performance or its impact upon major outcomes [34-37]. Nevertheless, some studies including adult patients as well, suggest that the most efficient method seems to be using a teach-to-goal

1
2
3 approach with placebo device demonstration and training provided in person [38-42]. In addition,
4 manufacturers' recommendations often differ from clinical guidelines, which makes it difficult for
5 patients to fully understand all the necessary steps of inhaler use [43]. This highlights the importance
6 of watching patients using their inhalers, which can be achieved with a placebo device training set.
7 This study will focus upon elderly patients and aims at testing the effect of a structured and regular
8 placebo device training approach upon disease exacerbation rates.
9

10 11 12 **SPECIFIC AIMS AND HYPOTHESES**

13
14 Our objective is to test the impact of an inhaler technique education programme on the risk of
15 exacerbations in elderly patients with Asthma or COPD.

16 The main hypothesis is that, among elderly patients with Asthma or COPD, regular education of
17 inhaler technique using a teach-to-goal placebo device-based approach, and delivered by family
18 doctors at baseline, 3 and 6 months, can reduce the exacerbation risk by 50% after a one-year follow-
19 up, when compared to usual care.
20
21
22
23
24

25 **RESEARCH DESIGN AND METHODOLOGY**

26 27 **Study Design**

28 Two arms single blinded randomised controlled trial with a 1 year follow up (fig.1). Participants will
29 be allocated to each group on a random basis, which is defined by a computerised generator and is
30 independent of the control of the principal investigator. The allocation sequence of the 146
31 participants will be defined through a computer generator prior to the start of the study. After the
32 generation of this sequence, 146 envelopes will be created, numbered in the appropriate order, and will
33 contain the result of the allocation. The order of the envelopes' number will define the order of
34 participants' enrolment. The principal investigator will not be aware of the information contained
35 within the envelopes, thereby maintaining a minimisation randomisation process. To ensure the
36 accuracy of the use of the envelopes, the documents inside the envelope will be signed by the Data
37 Safety Monitoring Board and must be returned by the researchers after the allocation of the
38 participants.
39
40
41
42

43 **Sample size calculation**

44 Sample size was estimated using the *Chi square independent group proportions* approach of *STATA*
45 *Statistical Package*®, considering the event proportion in control group of 50% (0.5 annual rate) as
46 reported in other previous studies [21 22 44] and estimating a reduction of event rate in the
47 intervention group to 25% (0.25 annual rate) as reported in similar studies. A 95% confidence interval,
48 with β value (power) of 80%, an alpha level of 5% and a ratio of cases/controls of 1:1 were
49 established. Finally, the sample size was readjusted upward, considering an estimated proportion of
50 full compliance of the study of 80% (20% losses). The estimated sample size was 116, readjusted to a
51 total of 146 individuals (73 in each arm).
52
53

54 **Inclusion Criteria**

55 Patients with a diagnosis of COPD or Asthma, prescribed any kind of inhaler device (pressurised
56 Metered Dose Inhaler (pMDI) with or without Spacer, Dry Powder Inhaler (DPI) or Soft Mist), aged
57
58

1
2
3 ≥65 years and being a regular user of primary health care services (defined as having had at least one
4 appointment in the last two years with his/her own Family Doctor). In order to minimise diagnostic
5 inaccuracy, Asthma and COPD diagnosis will be reviewed in every participant at baseline prior to
6 enrolment and in accordance with GINA and GOLD strategies [45 46].
7

8 **Exclusion Criteria**

9 Severe or acute illness (such as unstable cardiovascular status, unstable angina, recent myocardial
10 infarction (within one month) or pulmonary embolism, haemoptysis of unknown origin, recent
11 pneumothorax (within one month), recent thoracic, abdominal or eye surgery (within one month),
12 acute nausea or vomiting, severe respiratory distress, dementia).

13 We will exclude patients who do not need inhaler medication on a daily basis, since these patients are
14 less susceptible to the full impact of the intervention. In addition, these are mostly patients with
15 intermittent asthma, as well as COPD patients with mild obstruction (GOLD stage I), and tend to have
16 a low frequency of disease exacerbations, which would hamper our ability to detect a true outcome
17 effect.
18
19

20 **Predictors/Intervention**

21 Intervention Group – This group will receive a structured and regular follow-up plan, with education
22 on inhaler technique. Patients will be trained by a Family Doctor (the primary investigator) in terms of
23 the inhaler technique using placebo devices similar to their own devices. We will start by evaluating
24 their baseline technique, and then, a teach-to-goal approach will be used with correction of identified
25 errors. Then we will ask patients to demonstrate the inhaler technique, and again, committed errors
26 will be corrected by demonstration. We will repeat all correct steps as many times as needed in order
27 for patients to perform them correctly. This intervention will be performed at baseline, 3 and 6
28 months. Outcomes will be assessed at baseline and after 3, 6 and 12 months, since there is dissenting
29 evidence about the best timeline to achieve significant exacerbation risk reductions [21 30 32]. In each
30 visit, and prior to the main intervention with the primary investigator, assessment of the inhaler
31 technique and application of all questionnaires (clinical control, treatment adherence and quality of
32 life) will be performed by a secondary blinded investigator.
33

34 Control Group – This group will receive usual care from their own Family doctors, with no specific
35 intervention. Each doctor will perform the necessary clinical appointments according to his/her real
36 life judgment. Besides this, this group will have visits at baseline and after 3, 6 and 12 months to
37 assess secondary outcomes. At each visit, assessment of the inhaler technique and application of all
38 questionnaires (clinical control, treatment adherence and quality of life) will be performed by a
39 secondary blinded investigator. At any appointment, if the patient asks for or if the clinician decides to
40 teach inhaler technique, that will be recorded, since it will be important to analyse and control for the
41 true effect size of intervention.
42

43 If any adjustments are made in drug classes or device types in any participant, this information will be
44 recorded.
45
46
47

48 **Outcomes of interest**

49 Primary Outcome: Adverse events (continuous, time to event).

50 For Asthma, an event will be defined as increased respiratory clinical symptoms leading the patient to
51 search for medical care, and resulting in any of the following:
52

- 53 • Need for increased inhaled corticosteroid dose of at least 4x the regular dose
- 54 • Need for increase of short-acting β_2 agonists on a daily basis
- 55 • Need for oral corticosteroids
- 56 • Need for oral antibiotics
- 57

1
2
3 • Hospitalisation or Emergency Room (ER) visit with increased respiratory clinical symptoms.
4 For COPD, an event will be defined as increased respiratory clinical symptoms prompting the patient
5 to search for medical care, and resulting in any of the following:

- 6
7 • Need for increase of long-acting β_2 agonists on a daily basis
8 • Need for oral corticosteroids
9 • Need for oral antibiotics
10 • Hospitalisation or ER visit with increased respiratory clinical symptoms.

11 Respiratory-related mortality and all-cause mortality will also be considered an adverse event.

12 All adverse events and mortality causes will be carefully analysed in order to assess their eligibility by
13 two independent and external investigators, who will constitute a Data Safety Monitoring Board. This
14 will be performed using different platforms of clinical records, from the ER of the regional reference
15 hospital, from the Primary Health Care facilities (such as PEM© for prescribed drugs, SCLINICO©
16 for clinical records and PDS© for ER records) and even by asking the participant for additional
17 information. After any event, and if necessary for ethical reasons, inhaler technique and adherence
18 improvement will be addressed by the primary investigator regardless of the participant allocation, and
19 in accordance with the recommendation of the Data Safety Monitoring Board.
20
21

22 Secondary Outcomes:

- 23 • Clinical assessment using COPD Assessment Tools (CAT) and modified Medical Research
24 Council (mMRC) for COPD; Control of Allergic Rhinitis and Asthma Test (CARAT) [47]
25 and Asthma Control Test (ACT) for Asthma [48].
26 • Quality of Life using St. George's Respiratory Questionnaire [49] and Clinical COPD
27 Questionnaire (CCQ) [50] for COPD and Asthma Quality of Life Questionnaire (AQLQ) [51].
28 • Functional control using Forced Expiratory Volume in 1st second (FEV1), Forced Vital
29 Capacity (FVC), Peak Expiratory Flow (PEF) and Maximum Expiratory Flows of 25-75% of
30 FVC (MEF25-75) as a % of predicted value; and FEV1/FVC ratio.
31 • Adherence rate using the Brief Medication Questionnaire (this will also evaluate the frequency
32 of using the devices) [52].
33 • Number of errors in inhaler technique (that will be standardised to a score up to 100% scale)
34 [To evaluate inhaler technique performance with each device, the Aerosol Drug Management
35 Improvement Team (ADMIT) protocols and guidelines will be used [53], evaluating all the
36 recommended steps for inhaler use in each one of them (pMDI with or without chamber, Qvar
37 Autohaler, Turbohaler, Diskus, Aerolizer, Handihaler, Breezhaler, Novolizer, Genuair,
38 Twisthaler and Easyhaler). For those devices that do not have any protocol from the ADMIT
39 group we will use the recommendations from the manufacture's Summary of Product
40 Characteristics (Soft Mist Inhaler, Budesonide from *Farmoz*[®], Ellipta, Spiromax and
41 Forspiro)].
42

43 All questionnaires will be used in validated Portuguese versions [47-52 54 55]. All participants
44 will perform spirometry with bronchodilation test at baseline visit for diagnostic confirmation, as
45 well as a baseline spirometry without bronchodilation for functional control at subsequent visits. A
46 certified provider will perform spirometry.
47
48
49
50

51 **Other variables collected at baseline**

- 52 • Demographics (Body Mass Index, Age, Sex)
53 • Classification of clinical status, according to:
54 ○ Exacerbation history.
55 ○ Years of diagnosis.
56
57
58
59
60

- Asthma classification/stage according to GINA guidelines (clinically as well controlled, partially controlled or uncontrolled; and therapeutically as in STEP 1, 2, 3, 4 or 5)[45]
- COPD stage according to 2017 GOLD guidelines (combined assessment stages A,B,C and D; and severity of airflow limitation GOLD 1, 2, 3 and 4)[46].
- Social class according to Graffar classification (Portuguese version)[56].
- Co-morbidities (such as concomitant allergic rhinitis, cancer, cardiac heart failure, alcohol or drug abuse, current smoking and smoking pack years, diabetes mellitus, previous stroke or acute myocardial infarction, thoracic, abdominal or cerebral aneurysms, severe osteoarthritis in hands and upper limbs).
- Depression using Geriatric Depression Scale in Portuguese[57].
- Frailty state in elderly, using a self-reported instrument in Portuguese [58].
- Cognitive function using Montreal Cognitive Assessment (MOCA)in Portuguese [59]
- Influenza and pneumococcal vaccination status
- Previous teaching of inhaler technique, specifying the education type (placebo device, video, leaflet, multimedia, etc.)..
- Years of use with current device.

The principal investigator will collect all baseline data prior to allocation and randomisation, and this will be recorded in a proper form.

Statistical Analysis

The hypothesis testing approach will be the following:

Null hypothesis: Teaching inhalation technique performance with a placebo device approach does not reduce the exacerbation risk in elderly patients with Asthma or COPD after a one-year follow-up.

Alternative hypothesis: Teaching inhaler technique performance with a placebo device approach reduces the exacerbation risk in elderly patients with Asthma or COPD after a one-year follow-up.

Dichotomous Predictor: Usual Care VS Regular teach-to-goal education with placebo device.

Dichotomous Outcome: Exacerbation Yes/No

Data will be analysed using the *STATA Statistical Package*® software.

Test statistic for primary outcome: Dichotomous data will be analysed with a two-sample proportions Chi-square test and a COX proportional hazard time-to-event analysis, and both arms will be compared using the measures of association: risk ratio; risk difference; hazard ratio and Number Needed to Treat (NNT) analyses.

Test statistic for secondary outcomes: Continuous data will be analysed using parametric tests, such as T test for comparison of mean values and dichotomous data will be analysed using Chi-square test. In order to test differences between groups in the mean values of continuous analysis, mixed effects models for repeated measures will be used. For binary outcomes, linear regression models with group-time interactions will also be adapted, and generalised linear models (such as Poisson regression) will be applied for exacerbations, as recommended in the literature [60]. As an alternative approach, generalised estimating equation models will be used to handle unmeasured dependence between outcomes.

In case of cohort losses above 20%, comparative analysis for intention to treat, per-protocol and a multidata imputation will be carried out. Missing data will be treated as missing completely at random. Subgroup analysis will be performed according to secondary variables, such as diagnosis, age (including stratification into the following categories: 65-75, 75-85, and >85 years), sex, years of

1
2
3 diagnosis, disease classification/stage, comorbidities, educational level, previous teaching of inhaler
4 technique, device type, as well as the specific types of detected errors (in order to identify the most
5 critical ones). This will be performed using regression models to multivariate analyses.

6 An interim analysis will be performed midway through the follow-up, namely at 6 months, defining a
7 significance level adjusted by the Bonferroni technique of 0.025 [61].
8

9 10 **Study Setting**

11 The study will be conducted in a multicentre network that will include two or three primary care
12 centres, which will be coordinated by a team of experts in the field. All of them will be in urban or
13 suburban areas. A Portuguese primary care centre usually accounts approximately for more than
14 10,000 patients, and about 30% of them are aged above 65 years. Considering an approximate
15 prevalence of Asthma and COPD of 8% in this population, there is a potential target population of
16 almost 250 patients in each health care facility. Recruiting patients at more than one site will improve
17 the feasibility, reproducibility and credibility of the study, but will increase all the logistic issues.

18 All invited participants will have a first contact with the primary investigator to confirm the diagnosis
19 and all the eligibility criteria, and to carefully explain all the study procedures before their inclusion
20 and subsequent randomisation. Diagnosis will be confirmed according to state of the art and the
21 previously mentioned updated guidelines, and with spirometry. The number of patients screened and
22 deemed ineligible as well as the number of patients who are considered eligible but decline
23 participation will be also recorded.
24
25

26 27 **Timeline**

28 Study protocol final version: August 2017

29 Ethics consent and scientific academic authorisation: December 2017

30 Clinical administrative authorisations: first semester of 2018

31 Multicentre team gathering: first semester of 2018

32 Beginning of recruitment: second semester of 2018

33 End of recruitment: second semester of 2019

34 Data analysis and dissemination: during 2020
35

36 37 **Patient and Public Involvement**

38 No patient or public were involved in the design of this protocol, or in the establishment of the
39 intervention and the outcome measures. Results from all participants will be given to their own family
40 doctors in order to be used if deemed necessary to clinical practice.
41
42
43
44

45 **DISCUSSION**

46
47 This is the first study designed to test this specific intervention in inhaler performance in elderly
48 patients with a regular education programme, and it was designed to detect a significant reduction on
49 disease exacerbation rate. It is expected to detect approximately 55 adverse events, 18 in the
50 intervention group and 37 in the control group. In addition, it is expected to find a more significant
51 improvement in the intervention group, in all clinical and functional parameters during the follow-up.

52 This study has some limitations, mainly in selection bias due to the risk of missing data and follow-up
53 losses. To overcome this problem, different strategies will be applied, such as an increase in estimated
54 sample size, readjusted for an estimation of 20% losses; and sending a reminder prior to each visit
55 using SMS/Email/Call to contact the participant.
56
57

1
2
3 Another aspect that could bias our study is the Hawthorne effect throughout the study (ie. behaviour
4 change in participants due to their involvement in the study). However, we believe that by establishing
5 a cohort time of one year this effect will not be sustained. On the other hand, the control group (“usual
6 care”) will maintain their usual care at their own family doctors, who are completely free from any
7 influence of the study design. For this reason, the control group (“usual care”) participants will not
8 receive any intervention from the primary investigator. They will only contact with the secondary
9 investigator in order to collect endpoints and outcome data, and the latter is completely blinded to
10 randomisation. With this approach, the Hawthorne effect will not contaminate the control group, and
11 will represent a real life usual care. On the other hand, the Data Safety Monitoring Board will be
12 composed of two external investigators, who will, together with the statistician, be blinded to the
13 endpoints and outcomes (PROBE setting). Using usual care as the comparator arm also brings some
14 limitations to consider, because it is not a perfect comparator due to its nature. It is not sufficient for
15 good patient outcomes and it is not standardized. This aspect is due, for instance, to the fact that
16 patients on usual care can receive interventions on inhaler education and self-management tools from
17 other uncontrolled sources. To overcome that we will retrospectively query patients in this arm and
18 their own family doctor for any type of interventions that may have been delivered during the study
19 period.
20

21
22 Another possible limitation of our study is that we will not use electronic measures of adherence and
23 inhalation techniques. These are a very useful approach to monitoring real world adherence to inhaler
24 therapy. In fact, these electronic measures overcome the bias seen with self-report and other problems
25 observed with objective medication checks such as prescription refill rates. However, most electronic
26 measures of adherence do not measure timing of device activation but rather the overall number of
27 activations performed, and, in addition, this measure does not mean that medication was taken on a
28 regular basis (patients may just activate the inhaler several times, prior to handing over the device). It
29 is not until recently that a new device has been studied, which seems to overcome this problem, and
30 which also analyses inhaler technique, but it is not widely available – INCA device[62]. Nevertheless,
31 these devices are expensive and their use could not be implemented in our study. We therefore decided
32 to use the adherence questionnaire (BMQ), which is a well-validated tool in several languages
33 worldwide, and also in Portuguese [52]. Furthermore, it is a very simple and easy method to detect
34 non-adherence, which also allows separating sub-domains of adherence. Thus, it is a good tool for
35 assessing adherence in our study involving the general population of asthma and COPD patients.
36 Regarding inhalation technique, we decided to use regular checklists, since they are the most widely
37 method used in other studies, thereby allowing further comparisons. They are also easy to use and
38 allow detection of critical errors in each device.
39

40
41 The standardisation of the protocol intervention is another issue to be considered. In order to overcome
42 different approaches among different investigators from different multicentre sites, a protocol with
43 detailed instructions will be created to guide them during the intervention (investigators) and
44 assessment visits (secondary investigators). This protocol will explain all the steps and procedures for
45 training inhaler technique as well as for assessing it, and all the procedures to follow in each visit for
46 assessing the outcomes.
47

48 Primary investigators will be trained in communication techniques related to inhaler education of
49 different devices and all of them will have a kit of placebo devices for use with participants. Such
50 training will allow the standardization of all procedures of intervention and it will be provided ahead
51 by the coordination team of the study.
52

53 54 55 **ETHICS AND DISSEMINATION** 56 57

1
2
3 The study protocol has already been analysed by the local Ethics Committee of University of Beira
4 Interior, with the reference number CE-UBI-Pj-2017-025, and was approved on 22th, November 2017.
5 Every participant will sign a written consent form (Appendix I). We decided to use “usual care” as the
6 main comparator instead of another intervention method, since all interventional methods have shown
7 some degree of efficacy in clinically relevant outcomes, as previously mentioned. We thus believe that
8 comparing with other education methods would minimise the effect detection of our teach-to-goal
9 placebo-device intervention. Moreover, all of the randomised studies that included mostly elderly
10 patients also used “usual care” as a comparator, which will be important when comparing them with
11 our results. However, we highlight the fact that those studies did not use the same age criteria as we
12 are using, since they also included non-elderly adult patients in their samples. In addition, they did not
13 just focus on inhaler teaching, since they provided additional sessions with other program elements,
14 such as self-management care. There is, thus, insufficient evidence about the efficacy of inhaler
15 education as an isolated intervention, and for that reason, our approach will be novel and will
16 significantly contribute towards clarifying those issues.

17
18 A Data Safety Monitoring Board will be set up, composed of two external investigators with a board
19 expertise in this clinical field and in academic and scientific activities, to evaluate data obtained
20 throughout the study. Evaluations will occur every 6 months, whatever the number of participants
21 enrolled or the follow-up time reached at that point. The stop earlier criteria will be defined as any
22 moment on follow-up in which the collected data show statistically significant differences in the
23 primary outcomes. The study may be suspended earlier if sufficient data are obtained for at least 6
24 months of follow-up, or if significant evidence of intervention effectiveness is obtained, providing that
25 statistical significance values are met by the Bonferroni adaptation.

26
27 Invited participants who refuse to participate will be evaluated at baseline, according to previously
28 mentioned characteristics, in order to compare them with the included cohort. They will also be
29 invited to sign a written informed consent form that will allow investigators to collect such data. The
30 documents used to collect the data of the participants will contain only an identification code of each
31 participant, in order to protect their identity. The code of each participant must be composed of the
32 initials of the first two names, followed by the last two digits of the National Health Care Service
33 Number (eg. *Name FirstSurname SecondSurname*, 123456789 -----> code "NF89").

34
35 The number of participants considered ineligible will be recorded, as well as the number of eligible
36 participants who refuse to participate in the study.

37
38 The results obtained from this study will be published in peer-reviewed journals and presented at
39 scientific meetings of primary health care and respiratory fields. All data recorded during the study
40 will be stored for a period of 5 years, in accordance with the Portuguese Clinical Research Law, in a
41 safe and proper place in the primary investigator's health centre. After this period, all data that contain
42 participants' codes will be destroyed.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AUTHORS' CONTRIBUTIONS

All authors have equally contributed to the elaboration of this protocol in every stage of its design and writing. TM elaborated the first draft of the study, JCS and LTB gave inputs to all necessary design adjustments, and all authors have carried out final revisions of the manuscript.

COMPETING INTERESTS STATEMENT

Dr. Correia-de-Sousa reports competing interests from Harvard Medical School, during the conduct of the study, as scientific support. He also reports from Boheringer Ingelheim and from AstraZeneca outside the submitted work, and all these fees were received by a non-profit organisation to be used in CME and research.

The remaining authors declare only from Harvard Medical School, during the conduct of the study, as scientific support.

FUNDING

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

This work was developed without any funding support or financial source. The academic affiliation of this protocol is the Life and Health Sciences Research Institute (ICVS)/3B's at University of Minho and the Faculty of Health Sciences at the University of Beira Interior in Portugal.

This work was prepared with scientific support from Harvard Medical School, in accordance with the Portuguese Clinical Scholarship Research Training Program.

ACKNOWLEDGMENTS

The authors endorse acknowledgment to Prof. Jonh Groarke, from the Harvard Medical School, for his important scientific support and input in reviewing the final version of this manuscript.

DATA ACCESS

All data from the trial will be kept in a safe place of the principal investigator's institutional facilities and by the Data Safety Monitoring Board, in accordance with the national and international clinical research policies.

FIGURE LEGENDS

Figure 1 – Study design diagram.

REFERENCES

1. World Health Organization. The global burden of disease: 2004 update. Available from: <http://www.who.int>, 2008:160.
2. Sa-Sousa A, Morais-Almeida M, Azevedo LF, et al. Prevalence of asthma in Portugal - The Portuguese National Asthma Survey. *Clinical and translational allergy* 2012;**2**(1):15 doi: 10.1186/2045-7022-2-15[published Online First: Epub Date].
3. de Sousa JC, Santo ME, Colaço T, et al. Asthma in an Urban Population in Portugal: A prevalence study. *BMC Public Health* 2011;**11**:347-47 doi: 10.1186/1471-2458-11-347[published Online First: Epub Date].
4. Reddel H, Battersman E, Becker A, et al. Global Strategy for Asthma Management and Prevention. Available from: <http://www.ginasthma.org>: Global initiative for asthma, 2015 update:149.
5. van Boven JF, Tommelein E, Boussery K, et al. Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. *Respiratory research* 2014;**15**:66 doi: 10.1186/1465-9921-15-66[published Online First: Epub Date].
6. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. *Thorax* 2009;**64**(11):939-43 doi: 10.1136/thx.2009.113662[published Online First: Epub Date].
7. Engelkes M, Janssens HM, de Jongste JC, et al. Medication adherence and the risk of severe asthma exacerbations: a systematic review. *The European respiratory journal* 2015;**45**(2):396-407 doi: 10.1183/09031936.00075614[published Online First: Epub Date].
8. Rees J. Methods of delivering drugs. *BMJ : British Medical Journal* 2005;**331**(7515):504-06
9. Cochrane MG, Bala MV, Downs KE, et al. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. *Chest* 2000;**117**(2):542-50
10. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. *Respiratory medicine* 2008;**102**(4):593-604 doi: 10.1016/j.rmed.2007.11.003[published Online First: Epub Date].
11. Sanchis J, Gich I, Pedersen S. Systematic Review of Errors in Inhaler Use. *Chest* 2016;**150**(2):394-406 doi: 10.1016/j.chest.2016.03.041[published Online First: Epub Date].
12. Broeders ME, Molema J, Hop WC, et al. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. *Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine* 2003;**16**(2):131-41 doi: 10.1089/089426803321919898[published Online First: Epub Date].
13. Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. *Health technology assessment (Winchester, England)* 2001;**5**(26):1-149
14. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest* 2005;**127**(1):335-71 doi: 10.1378/chest.127.1.335[published Online First: Epub Date].
15. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. *The European respiratory journal* 2002;**19**(2):246-51
16. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. *Respiratory medicine* 2011;**105**(6):930-8 doi: 10.1016/j.rmed.2011.01.005[published Online First: Epub Date].
17. Roggeri A, Micheletto C, Roggeri DP. Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues. *International journal of chronic obstructive pulmonary disease* 2016;**11**:597-602 doi: 10.2147/copd.s103335[published Online First: Epub Date].
18. Price DB, Román-Rodríguez M, McQueen RB, et al. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. *The Journal of Allergy and Clinical Immunology: In Practice* 2017 doi: <http://dx.doi.org/10.1016/j.jaip.2017.01.004>[published Online First: Epub Date].

19. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. *Respiratory research* 2018;**19**(1):10 doi: 10.1186/s12931-017-0710-y[published Online First: Epub Date].
20. Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. *The European respiratory journal* 2011;**37**(6):1308-31 doi: 10.1183/09031936.00166410[published Online First: Epub Date].
21. Tommelein E, Mehuys E, Van Hees T, et al. Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. *British journal of clinical pharmacology* 2014;**77**(5):756-66 doi: 10.1111/bcp.12242[published Online First: Epub Date].
22. Takemura M, Mitsui K, Ido M, et al. Effect of a network system for providing proper inhalation technique by community pharmacists on clinical outcomes in COPD patients. *International journal of chronic obstructive pulmonary disease* 2013;**8**:239-44 doi: 10.2147/copd.s44022[published Online First: Epub Date].
23. Broeders ME, Sanchis J, Levy ML, et al. The ADMIT series--issues in inhalation therapy. 2. Improving technique and clinical effectiveness. *Primary care respiratory journal : journal of the General Practice Airways Group* 2009;**18**(2):76-82 doi: 10.4104/pcrj.2009.00025[published Online First: Epub Date].
24. Crompton GK, Barnes PJ, Broeders M, et al. The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. *Respiratory medicine* 2006;**100**(9):1479-94 doi: 10.1016/j.rmed.2006.01.008[published Online First: Epub Date].
25. Allen SC, Jain M, Ragab S, et al. Acquisition and short-term retention of inhaler techniques require intact executive function in elderly subjects. *Age and ageing* 2003;**32**(3):299-302
26. Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. *American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists* 2011;**68**(13):1221-32 doi: 10.2146/ajhp100452[published Online First: Epub Date].
27. Quinet P, Young CA, Heritier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. *Annals of physical and rehabilitation medicine* 2010;**53**(2):69-76 doi: 10.1016/j.rehab.2009.11.001[published Online First: Epub Date].
28. Allen SC, Warwick-Sanders M, Baxter M. A comparison of four tests of cognition as predictors of inability to learn to use a metered dose inhaler in old age. *Int J Clin Pract* 2009;**63**(8):1150-3 doi: 10.1111/j.1742-1241.2009.02060.x[published Online First: Epub Date].
29. Blasi F, Canonica GW, Centanni S, et al. Genuair(R) Usability Test: Results of a National Public Survey of the Elderly. *Copd* 2016;**13**(3):367-71 doi: 10.3109/15412555.2015.1067675[published Online First: Epub Date].
30. Rootmensen GN, van Keimpema AR, Looyen EE, et al. The effects of additional care by a pulmonary nurse for asthma and COPD patients at a respiratory outpatient clinic: results from a double blind, randomized clinical trial. *Patient education and counseling* 2008;**70**(2):179-86 doi: 10.1016/j.pec.2007.09.021[published Online First: Epub Date].
31. Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. *Arch Intern Med* 2003;**163**(5):585-91
32. Khmour MR, Kidney JC, Smyth BM, et al. Clinical pharmacy-led disease and medicine management programme for patients with COPD. *British journal of clinical pharmacology* 2009;**68**(4):588-98 doi: 10.1111/j.1365-2125.2009.03493.x[published Online First: Epub Date].
33. Strayhorn-Smith V, Tolley E, Demirkan K, et al. Metered dose inhaler - spacer technique in hospitalized geriatric patients: Effect of patient education by a pharmacist. *Hosp Pharm* 2000;**35**:162-64
34. Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for people with asthma. *The Cochrane database of systematic reviews* 2017;**3**:CD012286 doi: 10.1002/14651858.CD012286.pub2[published Online First: Epub Date].
35. Thomas RM, Locke ER, Woo DM, et al. Inhaler Training Delivered by Internet-Based Home Videoconferencing Improves Technique and Quality of Life. *Respiratory care* 2017;**62**(11):1412

36. Press VG, Kelly CA, Kim JJ, et al. Virtual Teach-To-Goal; Adaptive Learning of Inhaler Technique for Inpatients with Asthma or COPD. *The Journal of Allergy and Clinical Immunology: In Practice* 2017;**5**(4):1032-39.e1 doi: 10.1016/j.jaip.2016.11.018[published Online First: Epub Date].
37. Wu M, Woodrick NM, Arora VM, et al. Developing a Virtual Teach-To-Goal Inhaler Technique Learning Module: A Mixed Methods Approach. *The Journal of Allergy and Clinical Immunology: In Practice* 2017;**5**(6):1728-36 doi: 10.1016/j.jaip.2017.04.032[published Online First: Epub Date].
38. Bosnic-Anticevich SZ, Sinha H, So S, et al. Metered-dose inhaler technique: the effect of two educational interventions delivered in community pharmacy over time. *The Journal of asthma : official journal of the Association for the Care of Asthma* 2010;**47**(3):251-6 doi: 10.3109/02770900903580843[published Online First: Epub Date].
39. Crane MA, Jenkins CR, Goeman DP, et al. Inhaler device technique can be improved in older adults through tailored education: findings from a randomised controlled trial. *NPJ primary care respiratory medicine* 2014;**24**:14034 doi: 10.1038/npjpcrm.2014.34[published Online First: Epub Date].
40. Lavorini F, Levy ML, Corrigan C, et al. The ADMIT series - issues in inhalation therapy. 6) Training tools for inhalation devices. *Primary care respiratory journal : journal of the General Practice Airways Group* 2010;**19**(4):335-41 doi: 10.4104/pcrj.2010.00065[published Online First: Epub Date].
41. Press VG, Arora VM, Shah LM, et al. Misuse of respiratory inhalers in hospitalized patients with asthma or COPD. *Journal of general internal medicine* 2011;**26**(6):635-42 doi: 10.1007/s11606-010-1624-2[published Online First: Epub Date].
42. Paasche-Orlow MK, Riekert KA, Bilderback A, et al. Tailored Education May Reduce Health Literacy Disparities in Asthma Self-Management. *American Journal of Respiratory and Critical Care Medicine* 2005;**172**(8):980-86 doi: 10.1164/rccm.200409-1291OC[published Online First: Epub Date].
43. Self TH, Hoth LM, Bolin JM, et al. Metered-dose inhaler technique per the Global Initiative for Asthma and Expert Panel Report 3. *Annals of Allergy, Asthma & Immunology* 2016;**117**(1):101-02 doi: 10.1016/j.anai.2016.05.002[published Online First: Epub Date].
44. Goris S, Tasci S, Elmali F. The effects of training on inhaler technique and quality of life in patients with COPD. *Journal of aerosol medicine and pulmonary drug delivery* 2013;**26**(6):336-44 doi: 10.1089/jamp.2012.1017[published Online First: Epub Date].
45. GINA. Pocket Guide for Asthma Management and Prevention. Available in: <http://ginasthma.org>, Updated 2015:32.
46. GOLD. Pocket Guide to COPD Diagnosis, Management, and Prevention - A Guide for Health Care Professionals. Available in: <http://www.goldcopd.org>, 2017 report:42.
47. Fonseca JA, Nogueira-Silva L, Morais-Almeida M, et al. Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthma. *Allergy* 2010;**65**(8):1042-8 doi: 10.1111/j.1398-9995.2009.02310.x[published Online First: Epub Date].
48. Roxo JP, Ponte EV, Ramos DC, et al. [Portuguese-language version of the Asthma Control Test]. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisiologia* 2010;**36**(2):159-66
49. Camelier A, Rosa FW, Salim C, et al. Using the Saint George's Respiratory Questionnaire to evaluate quality of life in patients with chronic obstructive pulmonary disease: validating a new version for use in Brazil. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisiologia* 2006;**32**(2):114-22
50. Faria da Silva LS. Validação do Questionário Clínico para a Doença Pulmonar Obstrutiva Crônica (CCQ) para a Língua Portuguesa [Master Thesis]. Escola Superior de Enfermagem do Porto, 2012.
51. Ferreira J, Silveira P, Figueiredo MM, et al. Validation of the Portuguese version of the Asthma Quality of Life Questionnaire [AQLQ-M] by Marks. *Revista portuguesa de pneumologia* 2005;**11**(4):351-66
52. Ben AJ, Neumann CR, Mengue SS. The Brief Medication Questionnaire and Morisky-Green test to evaluate medication adherence. *Revista de saude publica* 2012;**46**(2):279-89

- 1
2
3 53. (ADMIT) TADMIT. Inhalation Protocols. Secondary Inhalation Protocols 2017.
- 4 54. Silva GP, Morano MT, Viana CM, et al. Portuguese-language version of the COPD Assessment
5 Test: validation for use in Brazil. *Jornal brasileiro de pneumologia : publicacao oficial da*
6 *Sociedade Brasileira de Pneumologia e Tisiologia* 2013;**39**(4):402-8 doi: 10.1590/s1806-
7 37132013000400002[published Online First: Epub Date]].
- 8 55. Kovelis D, Segretti NO, Probst VS, et al. Validation of the Modified Pulmonary Functional Status
9 and Dyspnea Questionnaire and the Medical Research Council scale for use in Brazilian patients
10 with chronic obstructive pulmonary disease. *Jornal brasileiro de pneumologia : publicacao oficial*
11 *da Sociedade Brasileira de Pneumologia e Tisiologia* 2008;**34**(12):1008-18
- 12 56. Amaro F. Escala de Graffar, 1990.
- 13 57. Apóstolo JLA, Loureiro LMdJ, Reis IACd, et al. Contribuição para a adaptação da Geriatric
14 Depression Scale -15 para a língua portuguesa. *Revista de Enfermagem Referência* 2014;**serIV**:65-
15 73
- 16 58. Nunes DP, Duarte YAdO, Santos JLF, et al. Screening for frailty in older adults using a self-
17 reported instrument. *Revista de saude publica* 2015;**49**:2 doi: 10.1590/S0034-
18 8910.2015049005516[published Online First: Epub Date]].
- 19 59. Freitas Sandra SMR, Martins Cristina, Vilar Manuela, Santana Isabel. . Estudos de adaptação do
20 Montreal Cognitive Assessment (MoCA) para a população portuguesa. *Aval. psicol.* [online].
21 2010;**9**(3):345-57
- 22 60. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive
23 pulmonary disease. *Am J Respir Crit Care Med* 2006;**173**(8):842-6 doi: 10.1164/rccm.200508-
24 1338PP[published Online First: Epub Date]].
- 25 61. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. *BMJ*
26 1995;**310**(6973):170 doi: 10.1136/bmj.310.6973.170[published Online First: Epub Date]].
- 27 62. Moran C, Doyle F, Sulaiman I, et al. The INCA(TM) (Inhaler Compliance Assessment(TM)): A
28 comparison with established measures of adherence. *Psychology & health* 2017;**32**(10):1266-87
29 doi: 10.1080/08870446.2017.1290243[published Online First: Epub Date]].
- 30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 - Study Design Diagram

APPENDIX I - Informed consent form, according to Portuguese Directorate-General of Health.

Consentimento Informado nos termos da Norma nº 015/2013 da DGS

Estudo “Ensino da técnica inalatória em idosos com Asma e DPOC: impacto nas exacerbações”

A sua unidade de saúde convida-o a participar no estudo “Ensino da técnica inalatória em idosos com Asma e DPOC: impacto nas exacerbações”. Foi convidado para participar neste estudo porque se trata de um doente com uma doença respiratória crónica (como Asma ou DPOC) e está a ser medicado com um dispositivo inalatório diariamente.

Os objetivos deste estudo são:

- Verificar se utiliza corretamente o seu dispositivo inalatório
- Testar se o ensino regular do uso do inalador melhora o controlo da sua doença.
- Testar se o mesmo ensino regular diminui a probabilidade de ter alguma crise de agudização/exacerbação pela sua doença, e que pode ser potencialmente fatal.

Para verificar estes objetivos iremos dividir, de forma aleatória, os utentes convidados a participar em dois grupos diferentes. Ambos os grupos irão ser avaliados regularmente sobre o controlo da sua doença, quer quando aos sintomas, qualidade de vida e quanto à sua capacidade pulmonar/respiratória. Isto será feito através da aplicação de questionários bem como da realização de um exame complementar simples e não invasivo, a espirometria.

A principal diferença entre os dois grupos, é que, um deles irá receber adicionalmente de um investigador, um ensino e treino regular sobre o uso correto dos dispositivos inalatórios, enquanto o outro grupo irá apenas receber os cuidados médicos regulares que necessitar pelo seu próprio Medico de Família.

A sua participação no estudo irá durar 12 meses. Ao aceitar participar neste estudo, será sorteado para um dos dois grupos, e após isso irá ser avaliado nesta Unidade de Saúde passados 3, 6 e 12 meses pelos investigadores. Não irá saber em nenhum momento (nem o seu Medico de Família) a qual dos grupos pertence, pois, o objetivo do estudo é não influenciar a forma como os dois grupos se comportam. Todas as consultas realizadas no âmbito deste estudo serão gratuitas para si, bem como a realização das avaliações pelos investigadores.

O estudo será coordenado pelo Dr. Tiago Maricoto, da USF Aveiro-Aradas, que é o investigador principal. A sua participação no estudo é voluntária. Poderá decidir não participar no estudo a qualquer momento sem prejuízo dos seus cuidados médicos. Todos os dados recolhidos neste estudo permanecerão confidenciais. O seu Medico de Família terá acesso no final do estudo aos resultados dos seus exames e avaliações.

O potencial benefício para a sua Saúde ao participar neste estudo é melhorar o controlo clínico da sua doença respiratória, melhorar a capacidade respiratória dos seus pulmões e diminuir o risco de crises de agudização graves e potencialmente fatais. Não existem riscos significativos para a sua saúde. Ao não participar neste estudo perde ainda a oportunidade de poder melhorar a forma como usa os seus dispositivos inalatórios, o que pode comprometer o bom controlo da sua doença a longo prazo.

[Parte declarativa do profissional]

Confirmo que expliquei à pessoa abaixo indicada, de forma adequada e inteligível, os procedimentos necessários ao ato referido neste documento. Respondi a todas as questões que me foram colocadas e assegurei-me de que houve um período de reflexão suficiente para a tomada da decisão. Também garanti que, em caso de recusa, serão assegurados os melhores cuidados possíveis nesse contexto, no respeito pelos seus direitos.

Nome legível do profissional de saúde: _____

Assinatura, nº de cédula profissional/mecanográfico:

Unidade de Saúde: _____

Contato institucional do profissional de saúde: _____

À Pessoa/representante

Por favor, leia com atenção todo o conteúdo deste documento. Não hesite em solicitar mais informações se não estiver completamente esclarecido/a. Verifique se todas as informações estão corretas. Se tudo estiver conforme, então assine este documento.

[Parte declarativa da pessoa que consente]

*Declaro ter compreendido os objetivos de quanto me foi proposto e explicado pelo profissional de saúde que assina este documento, ter-me sido dada oportunidade de fazer todas as perguntas sobre o assunto e para todas elas ter obtido resposta esclarecedora, ter-me sido garantido que não haverá prejuízo para os meus direitos assistenciais se eu recusar esta solicitação, e ter-me sido dado tempo suficiente para refletir sobre esta proposta. Autorizo/Não autorizo (**riscar o que não interessa**) o ato indicado, bem como os procedimentos diretamente relacionados que sejam necessários no meu próprio interesse e justificados por razões clínicas fundamentadas.*

NOME: _____

Assinatura /...../..... (data)

SE NÃO FOR O PRÓPRIO A ASSINAR POR IDADE OU INCAPACIDADE

(se o menor tiver discernimento deve também assinar em cima)

NOME:

DOC. IDENTIFICAÇÃO N.º DATA OU VALIDADE /..... /.....

GRAU DE PARENTESCO OU TIPO DE REPRESENTAÇÃO:

ASSINATURA.....

O presente documento é emitido em duplicado, ficando um na posse do participante, e outro arquivado pelos investigadores em local próprio

Reporting checklist for protocol of a clinical trial (SPIRIT).

Instructions to authors

Upload this checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	#3	Date and version identifier	1
Funding	#4	Sources and types of financial, material, and other support	12
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	12
Roles and responsibilities: sponsor contact information	#5b	Name and contact information for the trial sponsor	NA
Roles and responsibilities: sponsor and funder	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have	NA

ultimate authority over any of these activities

1				
2				
3	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	10
4	responsibilities:		centre, steering committee, endpoint adjudication	
5	committees		committee, data management team, and other individuals or	
6			groups overseeing the trial, if applicable (see Item 21a for	
7			data monitoring committee)	
8				
9				
10				
11	Background and	#6a	Description of research question and justification for	4
12	rationale		undertaking the trial, including summary of relevant studies	
13			(published and unpublished) examining benefits and harms	
14			for each intervention	
15				
16				
17	Background and	#6b	Explanation for choice of comparators	4
18	rationale: choice of			
19	comparators			
20				
21				
22				
23	Objectives	#7	Specific objectives or hypotheses	5
24				
25	Trial design	#8	Description of trial design including type of trial (eg, parallel	5
26			group, crossover, factorial, single group), allocation ratio,	
27			and framework (eg, superiority, equivalence, non-inferiority,	
28			exploratory)	
29				
30				
31				
32	Study setting	#9	Description of study settings (eg, community clinic,	8
33			academic hospital) and list of countries where data will be	
34			collected. Reference to where list of study sites can be	
35			obtained	
36				
37				
38				
39	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	5
40			eligibility criteria for study centres and individuals who will	
41			perform the interventions (eg, surgeons, psychotherapists)	
42				
43				
44	Interventions:	#11a	Interventions for each group with sufficient detail to allow	6
45	description		replication, including how and when they will be	
46			administered	
47				
48				
49	Interventions:	#11b	Criteria for discontinuing or modifying allocated	6
50	modifications		interventions for a given trial participant (eg, drug dose	
51			change in response to harms, participant request, or	
52			improving / worsening disease)	
53				
54				
55				
56	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	9
57	adherence		and any procedures for monitoring adherence (eg, drug	
58				
59				
60				

tablet return; laboratory tests)

1				
2				
3	Interventions:	#11d	Relevant concomitant care and interventions that are	6
4	concomitant care		permitted or prohibited during the trial	
5				
6	Outcomes	#12	Primary, secondary, and other outcomes, including the	6
7			specific measurement variable (eg, systolic blood pressure),	
8			analysis metric (eg, change from baseline, final value, time	
9			to event), method of aggregation (eg, median, proportion),	
10			and time point for each outcome. Explanation of the clinical	
11			relevance of chosen efficacy and harm outcomes is strongly	
12			recommended	
13				
14				
15				
16				
17	Participant timeline	#13	Time schedule of enrolment, interventions (including any	6
18			run-ins and washouts), assessments, and visits for	
19			participants. A schematic diagram is highly recommended	
20			(see Figure)	
21				
22				
23				
24	Sample size	#14	Estimated number of participants needed to achieve study	5
25			objectives and how it was determined, including clinical and	
26			statistical assumptions supporting any sample size	
27			calculations	
28				
29				
30				
31	Recruitment	#15	Strategies for achieving adequate participant enrolment to	5,9
32			reach target sample size	
33				
34				
35	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	5,8
36	generation		computer-generated random numbers), and list of any	
37			factors for stratification. To reduce predictability of a random	
38			sequence, details of any planned restriction (eg, blocking)	
39			should be provided in a separate document that is	
40			unavailable to those who enrol participants or assign	
41			interventions	
42				
43				
44				
45				
46	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	5,8
47	concealment		central telephone; sequentially numbered, opaque, sealed	
48	mechanism		envelopes), describing any steps to conceal the sequence	
49			until interventions are assigned	
50				
51				
52				
53	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	5,8
54	implementation		participants, and who will assign participants to	
55			interventions	
56				
57				
58	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	6,9
59				
60				

1			trial participants, care providers, outcome assessors, data	
2			analysts), and how	
3				
4	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	6,9
5	emergency		permissible, and procedure for revealing a participant's	
6	unblinding		allocated intervention during the trial	
7				
8				
9	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	7,8
10			and other trial data, including any related processes to	
11			promote data quality (eg, duplicate measurements, training	
12			of assessors) and a description of study instruments (eg,	
13			questionnaires, laboratory tests) along with their reliability	
14			and validity, if known. Reference to where data collection	
15			forms can be found, if not in the protocol	
16				
17				
18				
19				
20	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	7,8
21	retention		up, including list of any outcome data to be collected for	
22			participants who discontinue or deviate from intervention	
23			protocols	
24				
25				
26				
27	Data management	#19	Plans for data entry, coding, security, and storage, including	7,8
28			any related processes to promote data quality (eg, double	
29			data entry; range checks for data values). Reference to	
30			where details of data management procedures can be	
31			found, if not in the protocol	
32				
33				
34				
35				
36	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	8
37			outcomes. Reference to where other details of the statistical	
38			analysis plan can be found, if not in the protocol	
39				
40				
41	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	8
42	analyses		adjusted analyses)	
43				
44				
45	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	8
46	population and		adherence (eg, as randomised analysis), and any statistical	
47	missing data		methods to handle missing data (eg, multiple imputation)	
48				
49				
50	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	10
51	formal committee		of its role and reporting structure; statement of whether it is	
52			independent from the sponsor and competing interests; and	
53			reference to where further details about its charter can be	
54			found, if not in the protocol. Alternatively, an explanation of	
55			why a DMC is not needed	
56				
57				
58				
59				
60				

1	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	10
2	interim analysis		including who will have access to these interim results and	
3			make the final decision to terminate the trial	
4				
5				
6	Harms	#22	Plans for collecting, assessing, reporting, and managing	10
7			solicited and spontaneously reported adverse events and	
8			other unintended effects of trial interventions or trial conduct	
9				
10				
11	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	10
12			and whether the process will be independent from	
13			investigators and the sponsor	
14				
15				
16				
17	Research ethics	#24	Plans for seeking research ethics committee / institutional	10
18	approval		review board (REC / IRB) approval	
19				
20				
21	Protocol	#25	Plans for communicating important protocol modifications	10
22	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
23			relevant parties (eg, investigators, REC / IRBs, trial	
24			participants, trial registries, journals, regulators)	
25				
26				
27	Consent or assent	#26a	Who will obtain informed consent or assent from potential	10
28			trial participants or authorised surrogates, and how (see	
29			Item 32)	
30				
31				
32				
33	Consent or assent:	#26b	Additional consent provisions for collection and use of	10
34	ancillary studies		participant data and biological specimens in ancillary	
35			studies, if applicable	
36				
37				
38	Confidentiality	#27	How personal information about potential and enrolled	10
39			participants will be collected, shared, and maintained in	
40			order to protect confidentiality before, during, and after the	
41			trial	
42				
43				
44				
45	Declaration of	#28	Financial and other competing interests for principal	12
46	interests		investigators for the overall trial and each study site	
47				
48				
49	Data access	#29	Statement of who will have access to the final trial dataset,	12
50			and disclosure of contractual agreements that limit such	
51			access for investigators	
52				
53				
54	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for	12
55	trial care		compensation to those who suffer harm from trial	
56			participation	
57				
58				
59				
60				

1	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	10,11
2	trial results		results to participants, healthcare professionals, the public,	
3			and other relevant groups (eg, via publication, reporting in	
4			results databases, or other data sharing arrangements),	
5			including any publication restrictions	
6				
7				
8				
9	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use of	10,11
10	authorship		professional writers	
11				
12				
13	Dissemination policy:	#31c	Plans, if any, for granting public access to the full protocol,	10,11
14	reproducible		participant-level dataset, and statistical code	
15	research			
16				
17				
18	Informed consent	#32	Model consent form and other related documentation given	Apx.
19	materials		to participants and authorised surrogates	
20				
21				
22	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of	NA
23			biological specimens for genetic or molecular analysis in the	
24			current trial and for future use in ancillary studies, if	
25			applicable	
26				
27				
28				

29 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 30 BY-ND 3.0. This checklist was completed on 05. February 2018 using <http://www.goodreports.org/>, a
 31 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Inhaler technique education in elderly patients with Asthma or COPD: impact on disease exacerbations – a protocol for a single-blinded randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022685.R4
Article Type:	Protocol
Date Submitted by the Author:	10-Nov-2018
Complete List of Authors:	Maricoto, Tiago; Aveiro-Aradas Family Health Unit, ACeS Baixo Vouga; Faculty of Health Sciences, University of Beira Interior Correia-de-Sousa, Jaime; Life and Health Sciences Research Institute (ICVS)/3B's – PT Government Associate Laboratory, University of Minho; Horizonte Family Health Unit, Taborda-Barata, Luís; CICS - Health Sciences Research Centre; NuESA – Environment & Health Study Group, Faculty of Health Sciences, University of Beira Interior; Department of Allergy & Clinical Immunology, Cova da Beira University Hospital Centre
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	General practice / Family practice
Keywords:	Chronic Obstructive Pulmonary Disease, Asthma < THORACIC MEDICINE, Nebulizers and Vaporizers

SCHOLARONE™
Manuscripts

1
2
3 **Inhaler technique education in elderly patients with Asthma or COPD: impact on disease**
4 **exacerbations – a protocol for a single-blinded randomised controlled trial**
5

6
7
8 **AUTHORS**
9

10 Tiago Maricoto^{1,2}; Jaime Correia-de-Sousa^{3,4}; Luís Taborda-Barata^{5,6}

11
12 (1) Aveiro-Aradas Family Health Unit; Aveiro Health Centre; Portugal

13 (2) Faculty of Health Sciences; University of Beira Interior, Covilhã, Portugal

14 (3) Life and Health Sciences Research Institute (ICVS)/3B's — PT Government Associate
15 Laboratory, University of Minho, Braga, Portugal

16 (4) Horizonte Family Health Unit, Matosinhos, Portugal.

17 (5) CICS - Health Sciences Research Centre & NuESA – Environment & Health Study Group,
18 Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal

19 (6) Department of Allergy & Clinical Immunology, Cova da Beira University Hospital Centre,
20 Covilhã, Portugal
21
22
23
24
25

26 **CORRESPONDING AUTHOR**
27

- 28
29 • Tiago Maricoto, MD
30 Family Doctor
31 USF Aveiro-Aradas; Praceta Rainha D. Leonor; 3800; Aveiro; Portugal
32 Tel: +351 234 891 213
33 PhD Student; Faculty of Health Sciences; University of Beira Interior
34 tiago.maricoto@gmail.com
35
36
37
38
39

40 **WORD COUNT**
41

42 3186 words
43
44
45
46

47 **PROTOCOL VERSION**
48

49 This is the second version of this RCT protocol.
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction

COPD and Asthma affect more than 10% of the population. Most patients use their inhaler incorrectly, mainly the elderly, thereby becoming more susceptible to poor clinical control and exacerbations. Placebo device training is regarded as one of the best teaching methods, but there is scarce evidence to support it as the most effective one to improve major clinical outcomes. Our objective is to perform a single-blinded RCT to assess the impact of this education tool in these patients.

Methods and Analysis

A multicentre single-blinded RCT will be set up, comparing an inhaler education programme with a teach-to-goal placebo-device training versus usual care, with a one-year follow-up, in patients above 65 years of age with Asthma or COPD. Intervention will be provided at baseline, and after 3 and 6 months, with interim analysis at an intermediate time point. Exacerbation rates were set as primary outcomes, and quality of life, adherence rates, clinical control and respiratory function were chosen as secondary outcomes. A sample size of 146 participants (73 in each arm) was estimated as adequate to detect a 50% reduction in event rates. Two-sample proportions Chi-squared test will be used to study primary outcome and subgroup analysis will be carried out according to major baseline characteristics.

Ethics and dissemination:

Every participant will sign a written consent form. A Data Safety Monitoring Board will be set up to evaluate data throughout the study and to monitor early stopping criteria. Identity of all participants will be protected. This protocol was approved on the 22th November 2017 by the local Ethics Committee of University of Beira Interior, with the reference number CE-UBI-Pj-2017-025. Results will be presented in scientific meeting and published in peer-reviewed journals.

KEYWORDS

Chronic Obstructive Pulmonary Disease; Asthma; Nebulizers and Vaporizers

REGISTRY

This RCT protocol is registered in clinicaltrials.gov, with the number NCT03449316.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This study is innovative because it includes exclusively elderly patients with Asthma or COPD, addressing, in a one-year follow-up, a specific placebo device education programme, alone, without any other aspects.
- No previous study has addressed this teaching method in these patients, as it seems to be the most efficient one.
- Our study has a randomised design, which has been a major limitation in previous studies.
- The one-year follow up period, with two interim evaluations, allow this study to comprehensively address the real impact of a regular education programme.
- The main limitation of this study is the single blinded design, due to the nature of intervention itself, which may introduce some performance bias.

INTRODUCTION

Epidemiology

Asthma and COPD affect about 10% of the population, but many patients have uncontrolled symptoms [1]. In Asthma, in particular, it should be highlighted that only 57% of all patients were shown to have their symptoms controlled [2 3], and the elderly population is particularly vulnerable to this condition [3]. In fact, late onset asthma may be frequently misdiagnosed and mistreated, and the risk of drug interactions also requires close monitoring [4]. Hospitalisation rates due to Asthma and COPD are reported to reach 27% among non-adherent patients, and could be up to 53% in community treated cases, and this may be even more apparent in elderly patients. It should also be stressed that good adherence to inhaler treatment may, in contrast, be associated with a lower rate of severe exacerbations, with reductions observed in up to half of the cases [5-7].

Inhaler technique

Inhaled therapy is the most widely used way to treat asthma and COPD patients [8], but up to 90% of them do not use their inhalers correctly [9 10]. Performance errors have been described with almost every type of device, and over the past decades this problem has not improved, which highlights the need to better understand on the specificities of different inhaler use as well as the impact of different inhaler teaching methods [11]. Several inhaler devices are available on the market and it seems that differences either in device type or in patient characteristics may significantly influence performance [12]. However, all inhalers, when properly used, show no significant differences in terms of treatment efficacy [13 14], but it is well established that poor inhaler technique leads to poor clinical control [15 16] and also to an increased health costs [17]. In addition, some type of specific errors seem to have a higher impact on clinical control, but there is no consensus yet on which errors are critical and non-critical [18 19].

Patients in controlled trials receive more training in inhaler performance and more counselling on adherence than patients who are seen as part of routine clinical practice, but few studies have addressed these variables as separate outcomes [20]. Some studies show that teaching inhaler technique may lower the risk of exacerbations and death [6 21 22]. However, its impact is quickly lost as time elapses, suggesting this is a practice that should be rechecked and regularly applied to patients [23 24]. Nevertheless, how often the review should be carried out has not been established yet, since most studies have not addressed this issue in an isolated manner.

Significant evidence has shown that inhaler technique performance is regarded as particularly complex by older patients [25 26]. These patients also present lower adherence rates [9] and are more resistant to correct performance [27 28]. Furthermore, other major characteristics may influence inhaler use, such as educational level, previous teaching, or even age itself (i.e. age above 75 years) [29]. However, the significance of these observations still has to be fully ascertained since elderly patients are frequently excluded from major clinical trials. Randomised studies with elderly patients are scarce, and most of them did not address these aspects. Some of these studies have shown significant reductions in exacerbation risk, but most of them addressed several aspects of intervention besides inhaler technique education itself, namely self-management plans, disease knowledge, management of exacerbations and their triggers. None has yet addressed inhaler review alone or in a regular education programme [21 30-33].

Inhaler technique may be taught using many tools, such as step-by-step flyer schemes, video demonstrations, videoconferencing and face-to-face demonstrations or even using web-based platforms, but there is insufficient evidence about which is the best education method to improve inhaler performance or its impact upon major outcomes [34-37]. Nevertheless, some studies including adult patients as well, suggest that the most efficient method seems to be using a teach-to-goal approach with

1
2
3 placebo device demonstration and training provided in person [38-42]. In addition, manufacturers'
4 recommendations often differ from clinical guidelines, which makes it difficult for patients to fully
5 understand all the necessary steps of inhaler use [43]. This highlights the importance of watching
6 patients using their inhalers, which can be achieved with a placebo device training set.

7
8 This study will focus upon elderly patients and aims at testing the effect of a structured and regular
9 placebo device training approach upon disease exacerbation rates.
10
11

12 13 **SPECIFIC AIMS AND HYPOTHESES**

14
15 Our objective is to test the impact of an inhaler technique education programme on the risk of
16 exacerbations in elderly patients with Asthma or COPD.

17 The main hypothesis is that, among elderly patients with Asthma or COPD, regular education of inhaler
18 technique using a teach-to-goal placebo device-based approach, and delivered by family doctors at
19 baseline, 3 and 6 months, can reduce the exacerbation risk by 50% after a one-year follow-up, when
20 compared to usual care.
21
22

23 24 25 26 27 **RESEARCH DESIGN AND METHODOLOGY**

28 29 **Study Design**

30
31 Two arms single blinded randomised controlled trial with a 1 year follow up (fig.1). Participants will be
32 allocated to each group on a random basis, which is defined by a computerised generator and is
33 independent of the control of the principal investigator. The allocation sequence of the 146 participants
34 will be defined through a computer generator prior to the start of the study. After the generation of this
35 sequence, 146 envelopes will be created, numbered in the appropriate order, and will contain the result
36 of the allocation. The order of the envelopes' number will define the order of participants' enrolment.
37 The principal investigator will not be aware of the information contained within the envelopes, thereby
38 maintaining a minimisation randomisation process. To ensure the accuracy of the use of the envelopes,
39 the documents inside the envelope will be signed by the Data Safety Monitoring Board and must be
40 returned by the researchers after the allocation of the participants.
41
42
43

44 45 **Sample size calculation**

46 Sample size was estimated using the *Chi square independent group proportions* approach of *STATA*
47 *Statistical Package*©, considering the event proportion in control group of 50% (0.5 annual rate) as
48 reported in other previous studies [21 22 44] and estimating a reduction of event rate in the intervention
49 group to 25% (0.25 annual rate) as reported in similar studies. A 95% confidence interval, with β value
50 (power) of 80%, an alpha level of 5% and a ratio of cases/controls of 1:1 were established. Finally, the
51 sample size was readjusted upward, considering an estimated proportion of full compliance of the study
52 of 80% (20% losses). The estimated sample size was 116, readjusted to a total of 146 individuals (73 in
53 each arm).
54
55

56 57 **Inclusion Criteria**

58 Patients with a diagnosis of COPD or Asthma, prescribed any kind of inhaler device (pressurised
59 Metered Dose Inhaler (pMDI) with or without Spacer, Dry Powder Inhaler (DPI) or Soft Mist), aged
60 ≥ 65 years and being a regular user of primary health care services (defined as having had at least one

1
2
3 appointment in the last two years with his/her own Family Doctor). In order to minimise diagnostic
4 inaccuracy, Asthma and COPD diagnosis will be reviewed in every participant at baseline prior to
5 enrolment and in accordance with GINA and GOLD strategies [45 46].
6
7

8 **Exclusion Criteria**

9 Severe or acute illness (such as unstable cardiovascular status, unstable angina, recent myocardial
10 infarction (within one month) or pulmonary embolism, haemoptysis of unknown origin, recent
11 pneumothorax (within one month), recent thoracic, abdominal or eye surgery (within one month), acute
12 nausea or vomiting, severe respiratory distress, dementia).

13 We will exclude patients who do not need inhaler medication on a daily basis, since these patients are
14 less susceptible to the full impact of the intervention. In addition, these are mostly patients with
15 intermittent asthma, as well as COPD patients with mild obstruction (GOLD stage I), and tend to have
16 a low frequency of disease exacerbations, which would hamper our ability to detect a true outcome
17 effect.
18
19

20 **Predictors/Intervention**

21 Intervention Group – This group will receive a structured and regular follow-up plan, with education on
22 inhaler technique. Patients will be trained by a Family Doctor (the primary investigator) in terms of the
23 inhaler technique using placebo devices similar to their own devices. We will start by evaluating their
24 baseline technique, and then, a teach-to-goal approach will be used with correction of identified errors.
25 Then we will ask patients to demonstrate the inhaler technique, and again, committed errors will be
26 corrected by demonstration. We will repeat all correct steps as many times as needed in order for patients
27 to perform them correctly. This intervention will be performed at baseline, 3 and 6 months. Outcomes
28 will be assessed at baseline and after 3, 6 and 12 months, since there is dissenting evidence about the
29 best timeline to achieve significant exacerbation risk reductions [21 30 32]. In each visit, and prior to
30 the main intervention with the primary investigator, assessment of the inhaler technique and application
31 of all questionnaires (clinical control, treatment adherence and quality of life) will be performed by a
32 secondary blinded investigator.
33
34

35 Control Group – This group will receive usual care from their own Family doctors, with no specific
36 intervention. Each doctor will perform the necessary clinical appointments according to his/her real life
37 judgment. Besides this, this group will have visits at baseline and after 3, 6 and 12 months to assess
38 secondary outcomes. At each visit, assessment of the inhaler technique and application of all
39 questionnaires (clinical control, treatment adherence and quality of life) will be performed by a
40 secondary blinded investigator. At any appointment, if the patient asks for or if the clinician decides to
41 teach inhaler technique, that will be recorded, since it will be important to analyse and control for the
42 true effect size of intervention.
43
44

45 If any adjustments are made in drug classes or device types in any participant, this information will be
46 recorded.
47
48
49

50 **Outcomes of interest**

51 Primary Outcome: Adverse events (continuous, time to event).

52 For Asthma, an event will be defined as increased respiratory clinical symptoms leading the patient to
53 search for medical care, and resulting in any of the following:

- 54 • Need for increased inhaled corticosteroid dose of at least 4x the regular dose
- 55 • Need for increase of short-acting β_2 agonists on a daily basis
- 56 • Need for oral corticosteroids
- 57 • Need for oral antibiotics
- 58
- 59
- 60

1
2
3
4 • Hospitalisation or Emergency Room (ER) visit with increased respiratory clinical symptoms.
5 For COPD, an event will be defined as increased respiratory clinical symptoms prompting the patient to
6 search for medical care, and resulting in any of the following:

- 7
8
9
10
11
- Need for increase of long-acting β_2 agonists on a daily basis
 - Need for oral corticosteroids
 - Need for oral antibiotics
 - Hospitalisation or ER visit with increased respiratory clinical symptoms.

12 Respiratory-related mortality and all-cause mortality will also be considered an adverse event.

13 All adverse events and mortality causes will be carefully analysed in order to assess their eligibility by
14 two independent and external investigators, who will constitute a Data Safety Monitoring Board. This
15 will be performed using different platforms of clinical records, from the ER of the regional reference
16 hospital, from the Primary Health Care facilities (such as PEM© for prescribed drugs, SCLINICO© for
17 clinical records and PDS© for ER records) and even by asking the participant for additional information.
18 After any event, and if necessary for ethical reasons, inhaler technique and adherence improvement will
19 be addressed by the primary investigator regardless of the participant allocation, and in accordance with
20 the recommendation of the Data Safety Monitoring Board.
21
22
23

24 Secondary Outcomes:

- 25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
- Clinical assessment using COPD Assessment Tools (CAT) and modified Medical Research Council (mMRC) for COPD; Control of Allergic Rhinitis and Asthma Test (CARAT) [47] and Asthma Control Test (ACT) for Asthma [48].
 - Quality of Life using St. George's Respiratory Questionnaire [49] and Clinical COPD Questionnaire (CCQ) [50] for COPD and Asthma Quality of Life Questionnaire (AQLQ) [51].
 - Functional control using Forced Expiratory Volume in 1st second (FEV₁), Forced Vital Capacity (FVC), Peak Expiratory Flow (PEF) and Maximum Expiratory Flows of 25-75% of FVC (MEF₂₅₋₇₅) as a % of predicted value; and FEV₁/FVC ratio.
 - Adherence rate using the Brief Medication Questionnaire (this will also evaluate the frequency of using the devices) [52].
 - Number of errors in inhaler technique (that will be standardised to a score up to 100% scale) [To evaluate inhaler technique performance with each device, the Aerosol Drug Management Improvement Team (ADMIT) protocols and guidelines will be used [53], evaluating all the recommended steps for inhaler use in each one of them (pMDI with or without chamber, Qvar Autohaler, Turbohaler, Diskus, Aerolizer, Handihaler, Breezhaler, Novolizer, Genuair, Twisthaler and Easyhaler). For those devices that do not have any protocol from the ADMIT group we will use the recommendations from the manufacture's Summary of Product Characteristics (Soft Mist Inhaler, Budesonide from *Farmoz*[®], Ellipta, Spiromax and Forspiro)].

48 All questionnaires will be used in validated Portuguese versions [47-52 54 55]. All participants will
49 perform spirometry with bronchodilation test at baseline visit for diagnostic confirmation, as well
50 as a baseline spirometry without bronchodilation for functional control at subsequent visits. A
51 certified provider will perform spirometry.
52
53

54 **Other variables collected at baseline**

- 55
56
57
58
59
60
- Demographics (Body Mass Index, Age, Sex)
 - Classification of clinical status, according to:
 - Exacerbation history.
 - Years of diagnosis.

- Asthma classification/stage according to GINA guidelines (clinically as well controlled, partially controlled or uncontrolled; and therapeutically as in STEP 1, 2, 3, 4 or 5)[45]
- COPD stage according to 2017 GOLD guidelines (combined assessment stages A,B,C and D; and severity of airflow limitation GOLD 1, 2, 3 and 4)[46].
- Social class according to Graffar classification (Portuguese version)[56].
- Co-morbidities (such as concomitant allergic rhinitis, cancer, cardiac heart failure, alcohol or drug abuse, current smoking and smoking pack years, diabetes mellitus, previous stroke or acute myocardial infarction, thoracic, abdominal or cerebral aneurysms, severe osteoarthritis in hands and upper limbs).
- Depression using Geriatric Depression Scale in Portuguese[57].
- Frailty state in elderly, using a self-reported instrument in Portuguese [58].
- Cognitive function using Montreal Cognitive Assessment (MOCA)in Portuguese [59]
- Influenza and pneumococcal vaccination status
- Previous teaching of inhaler technique, specifying the education type (placebo device, video, leaflet, multimedia, etc.)..
- Years of use with current device.

The principal investigator will collect all baseline data prior to allocation and randomisation, and this will be recorded in a proper form.

Statistical Analysis

The hypothesis testing approach will be the following:

Null hypothesis: Teaching inhalation technique performance with a placebo device approach does not reduce the exacerbation risk in elderly patients with Asthma or COPD after a one-year follow-up.

Alternative hypothesis: Teaching inhaler technique performance with a placebo device approach reduces the exacerbation risk in elderly patients with Asthma or COPD after a one-year follow-up.

Dichotomous Predictor: Usual Care VS Regular teach-to-goal education with placebo device.

Dichotomous Outcome: Exacerbation Yes/No

Data will be analysed using the *STATA Statistical Package*® software.

Test statistic for primary outcome: Dichotomous data will be analysed with a two-sample proportions Chi-square test and a COX proportional hazard time-to-event analysis, and both arms will be compared using the measures of association: risk ratio; risk difference; hazard ratio and Number Needed to Treat (NNT) analyses.

Test statistic for secondary outcomes: Continuous data will be analysed using parametric tests, such as T test for comparison of mean values and dichotomous data will be analysed using Chi-square test. In order to test differences between groups in the mean values of continuous analysis, mixed effects models for repeated measures will be used. For binary outcomes, linear regression models with group-time interactions will also be adapted, and generalised linear models (such as Poisson regression) will be applied for exacerbations, as recommended in the literature [60]. As an alternative approach, generalised estimating equation models will be used to handle unmeasured dependence between outcomes.

In case of cohort losses above 20%, comparative analysis for intention to treat, per-protocol and a multidata imputation will be carried out. Missing data will be treated as missing completely at random. Subgroup analysis will be performed according to secondary variables, such as diagnosis, age (including stratification into the following categories: 65-75, 75-85, and >85 years), sex, years of diagnosis, disease classification/stage, comorbidities, educational level, previous teaching of inhaler technique, device

1
2
3 type, as well as the specific types of detected errors (in order to identify the most critical ones). This will
4 be performed using regression models to multivariate analyses.

5 An interim analysis will be performed midway through the follow-up, namely at 6 months, defining a
6 significance level adjusted by the Bonferroni technique of 0.025 [61].
7

8 9 **Study Setting**

10 The study will be conducted in a multicentre network that will include two or three primary care centres,
11 which will be coordinated by a team of experts in the field. All of them will be in urban or suburban
12 areas. A Portuguese primary care centre usually accounts approximately for more than 10,000 patients,
13 and about 30% of them are aged above 65 years. Considering an approximate prevalence of Asthma and
14 COPD of 8% in this population, there is a potential target population of almost 250 patients in each
15 health care facility. Recruiting patients at more than one site will improve the feasibility, reproducibility
16 and credibility of the study, but will increase all the logistic issues.

17 All invited participants will have a first contact with the primary investigator to confirm the diagnosis
18 and all the eligibility criteria, and to carefully explain all the study procedures before their inclusion and
19 subsequent randomisation. Diagnosis will be confirmed according to state of the art and the previously
20 mentioned updated guidelines, and with spirometry. The number of patients screened and deemed
21 ineligible as well as the number of patients who are considered eligible but decline participation will be
22 also recorded.
23
24
25
26

27 **Timeline**

28 Study protocol final version: August 2017

29 Ethics consent and scientific academic authorisation: December 2017

30 Clinical administrative authorisations: first semester of 2018

31 Multicentre team gathering: first semester of 2018

32 Beginning of recruitment: second semester of 2018

33 End of recruitment: second semester of 2019

34 Data analysis and dissemination: during 2020
35
36
37

38 **Patient and Public Involvement**

39 No patient or public were involved in the design of this protocol, or in the establishment of the
40 intervention and the outcome measures. Results from all participants will be given to their own family
41 doctors in order to be used if deemed necessary to clinical practice.
42
43
44
45
46

47 **DISCUSSION**

48
49 This study is innovative because it includes exclusively elderly patients with Asthma or COPD,
50 addressing a specific placebo device education programme, alone, without any other aspects, and it was
51 designed to detect a significant reduction on disease exacerbation rate. It is expected to detect
52 approximately 55 adverse events, 18 in the intervention group and 37 in the control group. In addition,
53 it is expected to find a more significant improvement in the intervention group, in all clinical and
54 functional parameters during the follow-up.
55

56 This study has some limitations, mainly in selection bias due to the risk of missing data and follow-up
57 losses. To overcome this problem, different strategies will be applied, such as an increase in estimated
58 sample size, readjusted for an estimation of 20% losses; and sending a reminder prior to each visit using
59 SMS/Email/Call to contact the participant.
60

1
2
3 Another aspect that could bias our study is the Hawthorne effect throughout the study (ie. behaviour
4 change in participants due to their involvement in the study). However, we believe that by establishing
5 a cohort time of one year this effect will not be sustained. On the other hand, the control group (“usual
6 care”) will maintain their usual care at their own family doctors, who are completely free from any
7 influence of the study design. For this reason, the control group (“usual care”) participants will not
8 receive any intervention from the primary investigator. They will only contact with the secondary
9 investigator in order to collect endpoints and outcome data, and the latter is completely blinded to
10 randomisation. With this approach, the Hawthorne effect will not contaminate the control group, and
11 will represent a real life usual care. On the other hand, the Data Safety Monitoring Board will be
12 composed of two external investigators, who will, together with the statistician, be blinded to the
13 endpoints and outcomes (PROBE setting). Using usual care as the comparator arm also brings some
14 limitations to consider, because it is not a perfect comparator due to its nature. It is not sufficient for
15 good patient outcomes and it is not standardized. This aspect is due, for instance, to the fact that patients
16 on usual care can receive interventions on inhaler education and self-management tools from other
17 uncontrolled sources. To overcome that we will retrospectively query patients in this arm and their own
18 family doctor for any type of interventions that may have been delivered during the study period.

19
20 Another possible limitation of our study is that we will not use electronic measures of adherence and
21 inhalation techniques. These are a very useful approach to monitoring real world adherence to inhaler
22 therapy. In fact, these electronic measures overcome the bias seen with self-report and other problems
23 observed with objective medication checks such as prescription refill rates. However, most electronic
24 measures of adherence do not measure timing of device activation but rather the overall number of
25 activations performed, and, in addition, this measure does not mean that medication was taken on a
26 regular basis (patients may just activate the inhaler several times, prior to handing over the device). It is
27 not until recently that a new device has been studied, which seems to overcome this problem, and which
28 also analyses inhaler technique, but it is not widely available – INCA device[62]. Nevertheless, these
29 devices are expensive and their use could not be implemented in our study. We therefore decided to use
30 the adherence questionnaire (BMQ), which is a well-validated tool in several languages worldwide, and
31 also in Portuguese [52]. Furthermore, it is a very simple and easy method to detect non-adherence, which
32 also allows separating sub-domains of adherence. Thus, it is a good tool for assessing adherence in our
33 study involving the general population of asthma and COPD patients. Regarding inhalation technique,
34 we decided to use regular checklists, since they are the most widely method used in other studies, thereby
35 allowing further comparisons. They are also easy to use and allow detection of critical errors in each
36 device.

37
38 The standardisation of the protocol intervention is another issue to be considered. In order to overcome
39 different approaches among different investigators from different multicentre sites, a protocol with
40 detailed instructions will be created to guide them during the intervention (investigators) and assessment
41 visits (secondary investigators). This protocol will explain all the steps and procedures for training
42 inhaler technique as well as for assessing it, and all the procedures to follow in each visit for assessing
43 the outcomes.

44
45 Primary investigators will be trained in communication techniques related to inhaler education of
46 different devices and all of them will have a kit of placebo devices for use with participants. Such
47 training will allow the standardization of all procedures of intervention and it will be provided ahead by
48 the coordination team of the study.

49 50 51 52 53 54 55 56 57 **ETHICS AND DISSEMINATION** 58 59 60

1
2
3 The study protocol has already been analysed by the local Ethics Committee of University of Beira
4 Interior, with the reference number CE-UBI-Pj-2017-025, and was approved on 22th, November 2017.
5 Every participant will sign a written consent form (Appendix I). We decided to use “usual care” as the
6 main comparator instead of another intervention method, since all interventional methods have shown
7 some degree of efficacy in clinically relevant outcomes, as previously mentioned. We thus believe that
8 comparing with other education methods would minimise the effect detection of our teach-to-goal
9 placebo-device intervention. Moreover, all of the randomised studies that included mostly elderly
10 patients also used “usual care” as a comparator, which will be important when comparing them with our
11 results. However, we highlight the fact that those studies did not use the same age criteria as we are
12 using, since they also included non-elderly adult patients in their samples. In addition, they did not just
13 focus on inhaler teaching, since they provided additional sessions with other program elements, such as
14 self-management care. There is, thus, insufficient evidence about the efficacy of inhaler education as an
15 isolated intervention, and for that reason, our approach will be novel and will significantly contribute
16 towards clarifying those issues.
17
18
19

20 A Data Safety Monitoring Board will be set up, composed of two external investigators with a board
21 expertise in this clinical field and in academic and scientific activities, to evaluate data obtained
22 throughout the study. Evaluations will occur every 6 months, whatever the number of participants
23 enrolled or the follow-up time reached at that point. The stop earlier criteria will be defined as any
24 moment on follow-up in which the collected data show statistically significant differences in the primary
25 outcomes. The study may be suspended earlier if sufficient data are obtained for at least 6 months of
26 follow-up, or if significant evidence of intervention effectiveness is obtained, providing that statistical
27 significance values are met by the Bonferroni adaptation.
28
29

30 Invited participants who refuse to participate will be evaluated at baseline, according to previously
31 mentioned characteristics, in order to compare them with the included cohort. They will also be invited
32 to sign a written informed consent form that will allow investigators to collect such data. The documents
33 used to collect the data of the participants will contain only an identification code of each participant, in
34 order to protect their identity. The code of each participant must be composed of the initials of the first
35 two names, followed by the last two digits of the National Health Care Service Number (eg. *Name*
36 *FirstSurname SecondSurname*, 123456789 -----> code "NF89").
37
38

39 The number of participants considered ineligible will be recorded, as well as the number of eligible
40 participants who refuse to participate in the study.

41 The results obtained from this study will be published in peer-reviewed journals and presented at
42 scientific meetings of primary health care and respiratory fields. All data recorded during the study will
43 be stored for a period of 5 years, in accordance with the Portuguese Clinical Research Law, in a safe
44 and proper place in the primary investigator's health centre. After this period, all data that contain
45 participants' codes will be destroyed.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AUTHORS' CONTRIBUTIONS

All authors have equally contributed to the elaboration of this protocol in every stage of its design and writing. TM elaborated the first draft of the study, JCS and LTB gave inputs to all necessary design adjustments, and all authors have carried out final revisions of the manuscript.

COMPETING INTERESTS STATEMENT

Dr. Correia-de-Sousa reports competing interests from Harvard Medical School, during the conduct of the study, as scientific support. He also reports from Boheringer Ingelheim and from AstraZeneca outside the submitted work, and all these fees were received by a non-profit organisation to be used in CME and research.

The remaining authors declare only from Harvard Medical School, during the conduct of the study, as scientific support.

FUNDING

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

This work was developed without any funding support or financial source. The academic affiliation of this protocol is the Life and Health Sciences Research Institute (ICVS)/3B's at University of Minho and the Faculty of Health Sciences at the University of Beira Interior in Portugal.

This work was prepared with scientific support from Harvard Medical School, in accordance with the Portuguese Clinical Scholarship Research Training Program.

ACKNOWLEDGMENTS

The authors endorse acknowledgment to Prof. Jonh Groarke, from the Harvard Medical School, for his important scientific support and input in reviewing the final version of this manuscript.

DATA ACESS

All data from the trial will be kept in a safe place of the principal investigator's institutional facilities and by the Data Safety Monitoring Board, in accordance with the national and international clinical research policies.

FIGURE LEGENDS

Figure 1 – Study design diagram.

REFERENCES

1. World Health Organization. The global burden of disease: 2004 update. Available from: <http://www.who.int>, 2008:160.
2. Sa-Sousa A, Morais-Almeida M, Azevedo LF, et al. Prevalence of asthma in Portugal - The Portuguese National Asthma Survey. *Clinical and translational allergy* 2012;**2**(1):15 doi: 10.1186/2045-7022-2-15[published Online First: Epub Date].
3. de Sousa JC, Santo ME, Colaço T, et al. Asthma in an Urban Population in Portugal: A prevalence study. *BMC Public Health* 2011;**11**:347-47 doi: 10.1186/1471-2458-11-347[published Online First: Epub Date].
4. Reddel H, Battersman E, Becker A, et al. Global Strategy for Asthma Management and Prevention. Available from: <http://www.ginasthma.org>: Global initiative for asthma, 2015 update:149.
5. van Boven JF, Tommelein E, Boussery K, et al. Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. *Respiratory research* 2014;**15**:66 doi: 10.1186/1465-9921-15-66[published Online First: Epub Date].
6. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. *Thorax* 2009;**64**(11):939-43 doi: 10.1136/thx.2009.113662[published Online First: Epub Date].
7. Engelkes M, Janssens HM, de Jongste JC, et al. Medication adherence and the risk of severe asthma exacerbations: a systematic review. *The European respiratory journal* 2015;**45**(2):396-407 doi: 10.1183/09031936.00075614[published Online First: Epub Date].
8. Rees J. Methods of delivering drugs. *BMJ : British Medical Journal* 2005;**331**(7515):504-06
9. Cochrane MG, Bala MV, Downs KE, et al. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. *Chest* 2000;**117**(2):542-50
10. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. *Respiratory medicine* 2008;**102**(4):593-604 doi: 10.1016/j.rmed.2007.11.003[published Online First: Epub Date].
11. Sanchis J, Gich I, Pedersen S. Systematic Review of Errors in Inhaler Use. *Chest* 2016;**150**(2):394-406 doi: 10.1016/j.chest.2016.03.041[published Online First: Epub Date].
12. Broeders ME, Molema J, Hop WC, et al. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. *Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine* 2003;**16**(2):131-41 doi: 10.1089/089426803321919898[published Online First: Epub Date].
13. Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. *Health technology assessment (Winchester, England)* 2001;**5**(26):1-149
14. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest* 2005;**127**(1):335-71 doi: 10.1378/chest.127.1.335[published Online First: Epub Date].
15. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. *The European respiratory journal* 2002;**19**(2):246-51
16. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. *Respiratory medicine* 2011;**105**(6):930-8 doi: 10.1016/j.rmed.2011.01.005[published Online First: Epub Date].
17. Roggeri A, Micheletto C, Roggeri DP. Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues. *International journal of chronic obstructive pulmonary disease* 2016;**11**:597-602 doi: 10.2147/copd.s103335[published Online First: Epub Date].
18. Price DB, Román-Rodríguez M, McQueen RB, et al. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. *The Journal of Allergy and Clinical Immunology: In Practice* 2017 doi: <http://dx.doi.org/10.1016/j.jaip.2017.01.004>[published Online First: Epub Date].

19. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. *Respiratory research* 2018;**19**(1):10 doi: 10.1186/s12931-017-0710-y[published Online First: Epub Date]].
20. Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. *The European respiratory journal* 2011;**37**(6):1308-31 doi: 10.1183/09031936.00166410[published Online First: Epub Date]].
21. Tommelein E, Mehuys E, Van Hees T, et al. Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. *British journal of clinical pharmacology* 2014;**77**(5):756-66 doi: 10.1111/bcp.12242[published Online First: Epub Date]].
22. Takemura M, Mitsui K, Ido M, et al. Effect of a network system for providing proper inhalation technique by community pharmacists on clinical outcomes in COPD patients. *International journal of chronic obstructive pulmonary disease* 2013;**8**:239-44 doi: 10.2147/copd.s44022[published Online First: Epub Date]].
23. Broeders ME, Sanchis J, Levy ML, et al. The ADMIT series--issues in inhalation therapy. 2. Improving technique and clinical effectiveness. *Primary care respiratory journal : journal of the General Practice Airways Group* 2009;**18**(2):76-82 doi: 10.4104/pcrj.2009.00025[published Online First: Epub Date]].
24. Crompton GK, Barnes PJ, Broeders M, et al. The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. *Respiratory medicine* 2006;**100**(9):1479-94 doi: 10.1016/j.rmed.2006.01.008[published Online First: Epub Date]].
25. Allen SC, Jain M, Ragab S, et al. Acquisition and short-term retention of inhaler techniques require intact executive function in elderly subjects. *Age and ageing* 2003;**32**(3):299-302
26. Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. *American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists* 2011;**68**(13):1221-32 doi: 10.2146/ajhp100452[published Online First: Epub Date]].
27. Quinet P, Young CA, Heritier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. *Annals of physical and rehabilitation medicine* 2010;**53**(2):69-76 doi: 10.1016/j.rehab.2009.11.001[published Online First: Epub Date]].
28. Allen SC, Warwick-Sanders M, Baxter M. A comparison of four tests of cognition as predictors of inability to learn to use a metered dose inhaler in old age. *Int J Clin Pract* 2009;**63**(8):1150-3 doi: 10.1111/j.1742-1241.2009.02060.x[published Online First: Epub Date]].
29. Blasi F, Canonica GW, Centanni S, et al. Genuair(R) Usability Test: Results of a National Public Survey of the Elderly. *Copd* 2016;**13**(3):367-71 doi: 10.3109/15412555.2015.1067675[published Online First: Epub Date]].
30. Rootmensen GN, van Keimpema AR, Looyen EE, et al. The effects of additional care by a pulmonary nurse for asthma and COPD patients at a respiratory outpatient clinic: results from a double blind, randomized clinical trial. *Patient education and counseling* 2008;**70**(2):179-86 doi: 10.1016/j.pec.2007.09.021[published Online First: Epub Date]].
31. Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. *Arch Intern Med* 2003;**163**(5):585-91
32. Khdour MR, Kidney JC, Smyth BM, et al. Clinical pharmacy-led disease and medicine management programme for patients with COPD. *British journal of clinical pharmacology* 2009;**68**(4):588-98 doi: 10.1111/j.1365-2125.2009.03493.x[published Online First: Epub Date]].
33. Strayhorn-Smith V, Tolley E, Demirkan K, et al. Metered dose inhaler - spacer technique in hospitalized geriatric patients: Effect of patient education by a pharmacist. *Hosp Pharm* 2000;**35**:162-64
34. Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for people with asthma. *The Cochrane database of systematic reviews* 2017;**3**:CD012286 doi: 10.1002/14651858.CD012286.pub2[published Online First: Epub Date]].
35. Thomas RM, Locke ER, Woo DM, et al. Inhaler Training Delivered by Internet-Based Home Videoconferencing Improves Technique and Quality of Life. *Respiratory care* 2017;**62**(11):1412

36. Press VG, Kelly CA, Kim JJ, et al. Virtual Teach-To-Goal; Adaptive Learning of Inhaler Technique for Inpatients with Asthma or COPD. *The Journal of Allergy and Clinical Immunology: In Practice* 2017;**5**(4):1032-39.e1 doi: 10.1016/j.jaip.2016.11.018[published Online First: Epub Date].
37. Wu M, Woodrick NM, Arora VM, et al. Developing a Virtual Teach-To-Goal Inhaler Technique Learning Module: A Mixed Methods Approach. *The Journal of Allergy and Clinical Immunology: In Practice* 2017;**5**(6):1728-36 doi: 10.1016/j.jaip.2017.04.032[published Online First: Epub Date].
38. Bosnic-Anticevich SZ, Sinha H, So S, et al. Metered-dose inhaler technique: the effect of two educational interventions delivered in community pharmacy over time. *The Journal of asthma : official journal of the Association for the Care of Asthma* 2010;**47**(3):251-6 doi: 10.3109/02770900903580843[published Online First: Epub Date].
39. Crane MA, Jenkins CR, Goeman DP, et al. Inhaler device technique can be improved in older adults through tailored education: findings from a randomised controlled trial. *NPJ primary care respiratory medicine* 2014;**24**:14034 doi: 10.1038/npjpcrm.2014.34[published Online First: Epub Date].
40. Lavorini F, Levy ML, Corrigan C, et al. The ADMIT series - issues in inhalation therapy. 6) Training tools for inhalation devices. *Primary care respiratory journal : journal of the General Practice Airways Group* 2010;**19**(4):335-41 doi: 10.4104/pcrj.2010.00065[published Online First: Epub Date].
41. Press VG, Arora VM, Shah LM, et al. Misuse of respiratory inhalers in hospitalized patients with asthma or COPD. *Journal of general internal medicine* 2011;**26**(6):635-42 doi: 10.1007/s11606-010-1624-2[published Online First: Epub Date].
42. Paasche-Orlow MK, Riekert KA, Bilderback A, et al. Tailored Education May Reduce Health Literacy Disparities in Asthma Self-Management. *American Journal of Respiratory and Critical Care Medicine* 2005;**172**(8):980-86 doi: 10.1164/rccm.200409-1291OC[published Online First: Epub Date].
43. Self TH, Hoth LM, Bolin JM, et al. Metered-dose inhaler technique per the Global Initiative for Asthma and Expert Panel Report 3. *Annals of Allergy, Asthma & Immunology* 2016;**117**(1):101-02 doi: 10.1016/j.anai.2016.05.002[published Online First: Epub Date].
44. Goris S, Tasci S, Elmali F. The effects of training on inhaler technique and quality of life in patients with COPD. *Journal of aerosol medicine and pulmonary drug delivery* 2013;**26**(6):336-44 doi: 10.1089/jamp.2012.1017[published Online First: Epub Date].
45. GINA. Pocket Guide for Asthma Management and Prevention. Available in: <http://ginasthma.org>, Updated 2015:32.
46. GOLD. Pocket Guide to COPD Diagnosis, Management, and Prevention - A Guide for Health Care Professionals. Available in: <http://www.goldcopd.org>, 2017 report:42.
47. Fonseca JA, Nogueira-Silva L, Morais-Almeida M, et al. Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthma. *Allergy* 2010;**65**(8):1042-8 doi: 10.1111/j.1398-9995.2009.02310.x[published Online First: Epub Date].
48. Roxo JP, Ponte EV, Ramos DC, et al. [Portuguese-language version of the Asthma Control Test]. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisiologia* 2010;**36**(2):159-66
49. Camelier A, Rosa FW, Salim C, et al. Using the Saint George's Respiratory Questionnaire to evaluate quality of life in patients with chronic obstructive pulmonary disease: validating a new version for use in Brazil. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisiologia* 2006;**32**(2):114-22
50. Faria da Silva LS. Validação do Questionário Clínico para a Doença Pulmonar Obstrutiva Crónica (CCQ) para a Língua Portuguesa [Master Thesis]. Escola Superior de Enfermagem do Porto, 2012.
51. Ferreira J, Silveira P, Figueiredo MM, et al. Validation of the Portuguese version of the Asthma Quality of Life Questionnaire [AQLQ-M] by Marks. *Revista portuguesa de pneumologia* 2005;**11**(4):351-66
52. Ben AJ, Neumann CR, Mengue SS. The Brief Medication Questionnaire and Morisky-Green test to evaluate medication adherence. *Revista de saude publica* 2012;**46**(2):279-89
53. (ADMIT) TADMIT. Inhalation Protocols. Secondary Inhalation Protocols 2017.

- 1
2
3 54. Silva GP, Morano MT, Viana CM, et al. Portuguese-language version of the COPD Assessment
4 Test: validation for use in Brazil. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade*
5 *Brasileira de Pneumologia e Tisiologia* 2013;**39**(4):402-8 doi: 10.1590/s1806-
6 37132013000400002[published Online First: Epub Date]].
- 7 55. Kovelis D, Segretti NO, Probst VS, et al. Validation of the Modified Pulmonary Functional Status
8 and Dyspnea Questionnaire and the Medical Research Council scale for use in Brazilian patients
9 with chronic obstructive pulmonary disease. *Jornal brasileiro de pneumologia : publicacao oficial da*
10 *Sociedade Brasileira de Pneumologia e Tisiologia* 2008;**34**(12):1008-18
- 11 56. Amaro F. Escala de Graffar, 1990.
- 12 57. Apóstolo JLA, Loureiro LMdJ, Reis IACd, et al. Contribuição para a adaptação da Geriatric
13 Depression Scale -15 para a língua portuguesa. *Revista de Enfermagem Referência* 2014;**serIV**:65-
14 73
- 15 58. Nunes DP, Duarte YAdO, Santos JLF, et al. Screening for frailty in older adults using a self-reported
16 instrument. *Revista de saude publica* 2015;**49**:2 doi: 10.1590/S0034-
17 8910.2015049005516[published Online First: Epub Date]].
- 18 59. Freitas Sandra SMR, Martins Cristina, Vilar Manuela, Santana Isabel. . Estudos de adaptação do
19 Montreal Cognitive Assessment (MoCA) para a população portuguesa. *Aval. psicol.* [online].
20 2010;**9**(3):345-57
- 21 60. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary
22 disease. *Am J Respir Crit Care Med* 2006;**173**(8):842-6 doi: 10.1164/rccm.200508-
23 1338PP[published Online First: Epub Date]].
- 24 61. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. *BMJ*
25 1995;**310**(6973):170 doi: 10.1136/bmj.310.6973.170[published Online First: Epub Date]].
- 26 62. Moran C, Doyle F, Sulaiman I, et al. The INCA(TM) (Inhaler Compliance Assessment(TM)): A
27 comparison with established measures of adherence. *Psychology & health* 2017;**32**(10):1266-87 doi:
28 10.1080/08870446.2017.1290243[published Online First: Epub Date]].
- 29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 - Study Design Diagram

APPENDIX I - Informed consent form, according to Portuguese Directorate-General of Health.

Consentimento Informado nos termos da Norma nº 015/2013 da DGS

Estudo “Ensino da técnica inalatória em idosos com Asma e DPOC: impacto nas exacerbações”

A sua unidade de saúde convida-o a participar no estudo “Ensino da técnica inalatória em idosos com Asma e DPOC: impacto nas exacerbações”. Foi convidado para participar neste estudo porque se trata de um doente com uma doença respiratória crónica (como Asma ou DPOC) e está a ser medicado com um dispositivo inalatório diariamente.

Os objetivos deste estudo são:

- Verificar se utiliza corretamente o seu dispositivo inalatório
- Testar se o ensino regular do uso do inalador melhora o controlo da sua doença.
- Testar se o mesmo ensino regular diminui a probabilidade de ter alguma crise de agudização/exacerbação pela sua doença, e que pode ser potencialmente fatal.

Para verificar estes objetivos iremos dividir, de forma aleatória, os utentes convidados a participar em dois grupos diferentes. Ambos os grupos irão ser avaliados regularmente sobre o controlo da sua doença, quer quando aos sintomas, qualidade de vida e quanto à sua capacidade pulmonar/respiratória. Isto será feito através da aplicação de questionários bem como da realização de um exame complementar simples e não invasivo, a espirometria.

A principal diferença entre os dois grupos, é que, um deles irá receber adicionalmente de um investigador, um ensino e treino regular sobre o uso correto dos dispositivos inalatórios, enquanto o outro grupo irá apenas receber os cuidados médicos regulares que necessitar pelo seu próprio Medico de Família.

A sua participação no estudo irá durar 12 meses. Ao aceitar participar neste estudo, será sorteado para um dos dois grupos, e após isso irá ser avaliado nesta Unidade de Saúde passados 3, 6 e 12 meses pelos investigadores. Não irá saber em nenhum momento (nem o seu Medico de Família) a qual dos grupos pertence, pois, o objetivo do estudo é não influenciar a forma como os dois grupos se comportam. Todas as consultas realizadas no âmbito deste estudo serão gratuitas para si, bem como a realização das avaliações pelos investigadores.

O estudo será coordenado pelo Dr. Tiago Maricoto, da USF Aveiro-Aradas, que é o investigador principal. A sua participação no estudo é voluntária. Poderá decidir não participar no estudo a qualquer momento sem prejuízo dos seus cuidados médicos. Todos os dados recolhidos neste estudo permanecerão confidenciais. O seu Medico de Família terá acesso no final do estudo aos resultados dos seus exames e avaliações.

O potencial benefício para a sua Saúde ao participar neste estudo é melhorar o controlo clínico da sua doença respiratória, melhorar a capacidade respiratória dos seus pulmões e diminuir o risco de crises de agudização graves e potencialmente fatais. Não existem riscos significativos para a sua saúde. Ao não participar neste estudo perde ainda a oportunidade de poder melhorar a forma como usa os seus dispositivos inalatórios, o que pode comprometer o bom controlo da sua doença a longo prazo.

[Parte declarativa do profissional]

Confirmo que expliquei à pessoa abaixo indicada, de forma adequada e inteligível, os procedimentos necessários ao ato referido neste documento. Respondi a todas as questões que me foram colocadas e assegurei-me de que houve um período de reflexão suficiente para a tomada da decisão. Também garanti que, em caso de recusa, serão assegurados os melhores cuidados possíveis nesse contexto, no respeito pelos seus direitos.

Nome legível do profissional de saúde: _____

Assinatura, nº de cédula profissional/mecanográfico:

Unidade de Saúde: _____

Contato institucional do profissional de saúde: _____

À Pessoa/representante

Por favor, leia com atenção todo o conteúdo deste documento. Não hesite em solicitar mais informações se não estiver completamente esclarecido/a. Verifique se todas as informações estão corretas. Se tudo estiver conforme, então assine este documento.

[Parte declarativa da pessoa que consente]

*Declaro ter compreendido os objetivos de quanto me foi proposto e explicado pelo profissional de saúde que assina este documento, ter-me sido dada oportunidade de fazer todas as perguntas sobre o assunto e para todas elas ter obtido resposta esclarecedora, ter-me sido garantido que não haverá prejuízo para os meus direitos assistenciais se eu recusar esta solicitação, e ter-me sido dado tempo suficiente para refletir sobre esta proposta. Autorizo/Não autorizo (**riscar o que não interessa**) o ato indicado, bem como os procedimentos diretamente relacionados que sejam necessários no meu próprio interesse e justificados por razões clínicas fundamentadas.*

NOME: _____

Assinatura /...../..... (data)

SE NÃO FOR O PRÓPRIO A ASSINAR POR IDADE OU INCAPACIDADE

(se o menor tiver discernimento deve também assinar em cima)

NOME:

DOC. IDENTIFICAÇÃO N.º DATA OU VALIDADE /..... /.....

GRAU DE PARENTESCO OU TIPO DE REPRESENTAÇÃO:

ASSINATURA.....

O presente documento é emitido em duplicado, ficando um na posse do participante, e outro arquivado pelos investigadores em local próprio

Reporting checklist for protocol of a clinical trial (SPIRIT).

Instructions to authors

Upload this checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	#3	Date and version identifier	1
Funding	#4	Sources and types of financial, material, and other support	12
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	12
Roles and responsibilities: sponsor contact information	#5b	Name and contact information for the trial sponsor	NA
Roles and responsibilities: sponsor and funder	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have	NA

		ultimate authority over any of these activities	
1			
2			
3	Roles and	#5d	10
4	responsibilities:	Composition, roles, and responsibilities of the coordinating	
5	committees	centre, steering committee, endpoint adjudication	
6		committee, data management team, and other individuals or	
7		groups overseeing the trial, if applicable (see Item 21a for	
8		data monitoring committee)	
9			
10			
11	Background and	#6a	4
12	rationale	Description of research question and justification for	
13		undertaking the trial, including summary of relevant studies	
14		(published and unpublished) examining benefits and harms	
15		for each intervention	
16			
17	Background and	#6b	4
18	rationale: choice of	Explanation for choice of comparators	
19	comparators		
20			
21			
22			
23	Objectives	#7	5
24		Specific objectives or hypotheses	
25			
26	Trial design	#8	5
27		Description of trial design including type of trial (eg, parallel	
28		group, crossover, factorial, single group), allocation ratio,	
29		and framework (eg, superiority, equivalence, non-inferiority,	
30		exploratory)	
31			
32	Study setting	#9	8
33		Description of study settings (eg, community clinic,	
34		academic hospital) and list of countries where data will be	
35		collected. Reference to where list of study sites can be	
36		obtained	
37			
38			
39	Eligibility criteria	#10	5
40		Inclusion and exclusion criteria for participants. If applicable,	
41		eligibility criteria for study centres and individuals who will	
42		perform the interventions (eg, surgeons, psychotherapists)	
43			
44	Interventions:	#11a	6
45	description	Interventions for each group with sufficient detail to allow	
46		replication, including how and when they will be	
47		administered	
48			
49	Interventions:	#11b	6
50	modifications	Criteria for discontinuing or modifying allocated	
51		interventions for a given trial participant (eg, drug dose	
52		change in response to harms, participant request, or	
53		improving / worsening disease)	
54			
55			
56	Interventions:	#11c	9
57	adherence	Strategies to improve adherence to intervention protocols,	
58		and any procedures for monitoring adherence (eg, drug	
59			
60			

tablet return; laboratory tests)

1				
2				
3	Interventions:	#11d	Relevant concomitant care and interventions that are	6
4	concomitant care		permitted or prohibited during the trial	
5				
6	Outcomes	#12	Primary, secondary, and other outcomes, including the	6
7			specific measurement variable (eg, systolic blood pressure),	
8			analysis metric (eg, change from baseline, final value, time	
9			to event), method of aggregation (eg, median, proportion),	
10			and time point for each outcome. Explanation of the clinical	
11			relevance of chosen efficacy and harm outcomes is strongly	
12			recommended	
13				
14				
15				
16				
17	Participant timeline	#13	Time schedule of enrolment, interventions (including any	6
18			run-ins and washouts), assessments, and visits for	
19			participants. A schematic diagram is highly recommended	
20			(see Figure)	
21				
22				
23				
24	Sample size	#14	Estimated number of participants needed to achieve study	5
25			objectives and how it was determined, including clinical and	
26			statistical assumptions supporting any sample size	
27			calculations	
28				
29				
30				
31	Recruitment	#15	Strategies for achieving adequate participant enrolment to	5,9
32			reach target sample size	
33				
34				
35	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	5,8
36	generation		computer-generated random numbers), and list of any	
37			factors for stratification. To reduce predictability of a random	
38			sequence, details of any planned restriction (eg, blocking)	
39			should be provided in a separate document that is	
40			unavailable to those who enrol participants or assign	
41			interventions	
42				
43				
44				
45				
46	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	5,8
47	concealment		central telephone; sequentially numbered, opaque, sealed	
48	mechanism		envelopes), describing any steps to conceal the sequence	
49			until interventions are assigned	
50				
51				
52				
53	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	5,8
54	implementation		participants, and who will assign participants to	
55			interventions	
56				
57				
58	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	6,9
59				
60				

1			trial participants, care providers, outcome assessors, data	
2			analysts), and how	
3				
4	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	6,9
5	emergency		permissible, and procedure for revealing a participant's	
6	unblinding		allocated intervention during the trial	
7				
8				
9	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	7,8
10			and other trial data, including any related processes to	
11			promote data quality (eg, duplicate measurements, training	
12			of assessors) and a description of study instruments (eg,	
13			questionnaires, laboratory tests) along with their reliability	
14			and validity, if known. Reference to where data collection	
15			forms can be found, if not in the protocol	
16				
17				
18				
19				
20	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	7,8
21	retention		up, including list of any outcome data to be collected for	
22			participants who discontinue or deviate from intervention	
23			protocols	
24				
25				
26				
27	Data management	#19	Plans for data entry, coding, security, and storage, including	7,8
28			any related processes to promote data quality (eg, double	
29			data entry; range checks for data values). Reference to	
30			where details of data management procedures can be	
31			found, if not in the protocol	
32				
33				
34				
35				
36	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	8
37			outcomes. Reference to where other details of the statistical	
38			analysis plan can be found, if not in the protocol	
39				
40				
41	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	8
42	analyses		adjusted analyses)	
43				
44				
45	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	8
46	population and		adherence (eg, as randomised analysis), and any statistical	
47	missing data		methods to handle missing data (eg, multiple imputation)	
48				
49				
50	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	10
51	formal committee		of its role and reporting structure; statement of whether it is	
52			independent from the sponsor and competing interests; and	
53			reference to where further details about its charter can be	
54			found, if not in the protocol. Alternatively, an explanation of	
55			why a DMC is not needed	
56				
57				
58				
59				
60				

1	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	10
2	interim analysis		including who will have access to these interim results and	
3			make the final decision to terminate the trial	
4				
5				
6	Harms	#22	Plans for collecting, assessing, reporting, and managing	10
7			solicited and spontaneously reported adverse events and	
8			other unintended effects of trial interventions or trial conduct	
9				
10				
11	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	10
12			and whether the process will be independent from	
13			investigators and the sponsor	
14				
15				
16				
17	Research ethics	#24	Plans for seeking research ethics committee / institutional	10
18	approval		review board (REC / IRB) approval	
19				
20				
21	Protocol	#25	Plans for communicating important protocol modifications	10
22	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
23			relevant parties (eg, investigators, REC / IRBs, trial	
24			participants, trial registries, journals, regulators)	
25				
26				
27	Consent or assent	#26a	Who will obtain informed consent or assent from potential	10
28			trial participants or authorised surrogates, and how (see	
29			Item 32)	
30				
31				
32				
33	Consent or assent:	#26b	Additional consent provisions for collection and use of	10
34	ancillary studies		participant data and biological specimens in ancillary	
35			studies, if applicable	
36				
37				
38	Confidentiality	#27	How personal information about potential and enrolled	10
39			participants will be collected, shared, and maintained in	
40			order to protect confidentiality before, during, and after the	
41			trial	
42				
43				
44				
45	Declaration of	#28	Financial and other competing interests for principal	12
46	interests		investigators for the overall trial and each study site	
47				
48				
49	Data access	#29	Statement of who will have access to the final trial dataset,	12
50			and disclosure of contractual agreements that limit such	
51			access for investigators	
52				
53				
54	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for	12
55	trial care		compensation to those who suffer harm from trial	
56			participation	
57				
58				
59				
60				

1	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	10,11
2	trial results		results to participants, healthcare professionals, the public,	
3			and other relevant groups (eg, via publication, reporting in	
4			results databases, or other data sharing arrangements),	
5			including any publication restrictions	
6				
7				
8				
9	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use of	10,11
10	authorship		professional writers	
11				
12				
13	Dissemination policy:	#31c	Plans, if any, for granting public access to the full protocol,	10,11
14	reproducible		participant-level dataset, and statistical code	
15	research			
16				
17				
18	Informed consent	#32	Model consent form and other related documentation given	Apx.
19	materials		to participants and authorised surrogates	
20				
21				
22	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of	NA
23			biological specimens for genetic or molecular analysis in the	
24			current trial and for future use in ancillary studies, if	
25			applicable	
26				
27				
28				

29 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 30 BY-ND 3.0. This checklist was completed on 05. February 2018 using <http://www.goodreports.org/>, a
 31 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60